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Glioblastoma multiforme (GBM) is the most prevalent adult malignant 
brain tumor and has been shown to arise from stem-like glioma-propagating cells 
(GPCs). Previous literature highlights the role of cell surface carbohydrate 
moieties (sialylation) in promoting tumor malignancy and invasiveness. Using 
patient-derived GPCs, we found that the cellular fraction corresponding to high 
sialylation status (increased ST3GAL1) possessed greater invasive and self-
renewal potential. Genetic depletion of ST3GAL1 abrogated cell surface 
sialylation with concomitant loss of GPC viability and invasiveness. Consistently, 
ST3Gal1 loss resulted in prolonged survival of an orthotopic mouse model. We 
also observed that increasing grades of patient glioma tumors demonstrated a 
similar marked, increased intensity of ST3GAL1 staining, thus validating its role 
as a potential prognostic marker. To further substantiate the clinical relevance of 
ST3Gal1, we interrogated patient databases for relatedness to ST3GAL1 
signaling programs. We observed that ST3GAL1-over-expressed patient cohorts 
correlated with high tumor grades of the mesenchymal molecular profile, typifying 
highly aggressive and recurrent gliomas. 
To explore the molecular mechanism triggering ST3Gal1 activation, we 
used a bioinformatical approach to analyze ST3GAL1-co-expressed gene 
modules. We focused on one top-ranking pathway, TGFβ, and validated its ability 
to activate ST3Gal1 signaling in vitro. This is impactful as TGFβ is frequently 
associated with mesenchymal tumors of poor prognosis. To define downstream 
events of ST3Gal1, we molecularly profiled GPCs with perturbations of the gene 
and examined core activation programs. We provide evidence that ST3Gal1 
regulates FoxM1, a key stem cell self-renewal and tumor-propagating gene. 
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Our work is unique because we show for the first time how cell surface 
sialylation, a well-known cancer invasiveness factor, is triggered by a key glioma 
pathway, TGFβ. Furthermore, we are now able to link this upstream activation to 
a stem cell-related pathway, FoxM1, highlighting that the sustenance of tumor 
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CHAPTER 1 – INTRODUCTION 
1.1 Glioma classification 
Gliomas, a major variant of brain tumors, make up  approximately 30% of 
all central nervous system (CNS) tumors and 80% of all malignant brain tumors 
(Goodenberger & Jenkins, 2012). These tumors are notorious for their highly 
infiltrative and recurrent nature despite advanced surgical intervention and 
adjuvant chemotherapy and radiation treatment. Gliomas present heterogeneous 
cellular morphologies and patients often display variable prognosis. Grade IV 
glioblastoma multiforme (GBM) presents a dismal prognosis with a mean survival 
period of 15 months after diagnosis (Louis et al, 2007). Currently, patients are 
diagnosed and treated according to their histological analyses, relying solely on a 
morphology-based classification system, that of the World Health Organization 
(WHO) criteria (Louis et al, 2007).                                         
The WHO system divides diffuse gliomas into astrocytic tumors, 
oligodendrogliomas, and oligoastrocytomas. These are then graded into 
histological degrees of malignancy (WHO grade I-IV), which are based on the 
presence of specific criteria such as nuclear atypia, mitotic activity, microvascular 
proliferation and necrosis.  Two major classes of gliomas are astrocytomas and 
oligodendrogliomas, named according to their presumed cells-of-origin, the 
astrocyte and oligodendrocyte progenitor cell (OPC) respectively.  Astrocytic 
tumors are further subdivided into grades I (pilocytic astrocytomas, PA), II (low 
grade), III (anaplastic), and IV (GBM) (Table 1.1). Oligodendrocytic tumors are 
classified into grades II (low grade) and III (anaplastic). The WHO Grade I 
classification scheme applies to lesions with low proliferative potential and the 
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possibility of cure following surgical resection. WHO Grade II tumors are 
infiltrative in nature and, despite low-level proliferative activity, often recur. WHO 
grade III refers to lesions with histological evidence of malignancy, including 
nuclear atypia and brisk mitotic activity. In most cases, patients with grade III 
tumors receive adjuvant radiation and/or chemotherapy. Finally, WHO grade IV is 
reserved for cytologically malignant, mitotically active and necrosis-prone 
neoplasms typically associated with poor prognosis.  
 
Table 1.1 WHO grading of glial tumors is based on histology. WHO grading of 
astrocytic glial tumors into grades I-IV is based upon the presence of 4 criteria; namely 
nuclear atypia, mitoses, microvasucular proliferation, and necrosis. Adapted from 




While the WHO grading system is widely used, it is recognized to have 
limitations. The classification schemes based on visual criteria alone are 
subjective and allow considerable inter-observer variations (Coons et al, 1997). 
4 
 
Moreover, gliomas are often morphologically diverse and it is sometimes difficult 
to assign specific WHO grading categories. Since treatment protocols often 
depend on the reported histology, accuracy in diagnosis is crucial for optimal 
patient treatment and care (Murphy et al, 2002). Noteworthy is the frequent 
observation that patients with identical histologies often respond differently to 
common therapies, highlighting the limitation of relying solely on histology to 
diagnose and subsequently treat patients. 
1.1.1 Molecular classification  
In 2006, the National Cancer Institute (NCI) in Bethesda, U.S.A. initiated 
a multi-consortial effort to deep-profile a collection of tumors, with initial focus on 
those cancers with greatest impact to healthcare (The Cancer Genome Atlas, 
TCGA) (Research, 2008). Glioblastoma was chosen as the first cancer to profile 
because of its dismal survival outcome and lack of effective therapies. This effort 
was predicated on the belief and well-established observations that histologically 
identical tumors can be molecularly heterogeneous, and that these molecular 
traits prognosticate patient survival independently of current clinical indicators. By 
inference, the signaling pathways predicted by such molecular heterogeneity 
could possibly constitute viable targets for therapeutic intervention. This 
hypothesis thus highlights the limitation of relying solely on morphology-based 
criteria to diagnose and subsequently treat patients. The information gathered 
from these tumors include gene expression, miRNA, microarray-based 
comparative genomic hybridization (aCGH), methylation data and clinical profiles 
such as age, sex, tumor diagnosis, treatment and survival patterns. Indeed, 
TCGA published a sequence of studies that have since proven the existence of 4 
molecular subgroups (Proneural, Neural, Classical, Mesenchymal), each with 
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distinct genomic aberrations, gene expression and survival profiles (Verhaak et al, 
2010). The Proneural class represents the patient cohort receiving no treatment 
benefit from current therapy, while the Mesenchymal cohort represents patients 
with highly aggressive and recurrent GBM. Most importantly, this study illustrated 
that based on gene expression alone, patients could be stratified into molecular 
subclasses with genomic and clinical correlation. This indicates that gene 
expression drives brain tumor disease progression and clinical outcome. We 
have provided a summary of the types of genomic aberrations associated with 
each molecular subtype (Verhaak et al, 2010) (Table 1.2). Briefly, 3 main 
signaling pathways are able to subgroup GBM tumors: Receptor Tyrosine Kinase 
(RTK), Retinoblastoma (Rb) and TP53 mutations. The presence of mutations that 
activate oncogenic pathways suggest their therapeutic targeting. In support, 
Wiedemeyer et al. demonstrated that patient-derived glioma cells displaying 
inactivating mutations of the Rb pathway dictated their response to anti-cyclin 
dependent kinase (CDK4/6) small molecule inhibitors (Wiedemeyer et al, 2010) . 
They further identified patient cohorts most likely to receive treatment benefit 
from this class of therapeutic molecules. Another recent study by TCGA defined 
promoter hypermethylation profiles (Noushmehr et al, 2010). The authors found 
that a distinct subset of GBM samples displays concerted hypermethylation at a 
large number of loci, indicating the existence of a glioma-CpG island methylator 
phenotype (G-CIMP). They then validated G-CIMP in a set of non-TCGA 
glioblastomas and low-grade gliomas. G-CIMP tumors belong to the Proneural 
subgroup, are more prevalent among lower-grade gliomas, display distinct copy-
number alterations, and are tightly associated with isocitrate dehydrogenase 1 
(IDH1) somatic mutations. Patients with G-CIMP tumors are younger at the time 
of diagnosis and experience significantly improved outcome. These findings 
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identify G-CIMP as a distinct subset of human gliomas on molecular and clinical 
grounds. 
Table 1.2. Distribution of frequently mutated genes across GBM subtypes. 
 
Separately, while TCGA is focused on solely grade IV GBM tumors and 
represents the first detailed analysis of brain tumor signaling pathways, another 
effort by NCI has established the Repository for Molecular Brain Neoplasia Data 
(REMBRANDT), which provides similar deep-sequencing information of all 
grades of gliomas (Madhavan et al, 2009). Other efforts include the Phillips et al. 
classification scheme on high-grade malignant gliomas (Phillips et al, 2006), the 
Gravendeel et al. classification scheme for mainly oligodendrogliomas 
(Gravendeel et al, 2009), and the Li et al. classification scheme for all grades of 
gliomas (Li et al, 2009). In the latter case, the authors have applied 2 
unsupervised machine learning methods to genome-wide gene expression 
profiles of 159 gliomas, thereby establishing a robust glioma classification model 
relying only on the molecular data. The model predicts for 2 major groups of 
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gliomas (oligodendroglioma-rich and glioblastoma-rich groups) separable into 6 
hierarchically nested subtypes. Application of the classification system to the 
external glioma datasets allowed them to identify previously unrecognized 
prognostic groups within previously published data and within TCGA 
glioblastoma samples and the different biological pathways associated with the 
different glioma subtypes, offering a potential clue to the pathogenesis and 
possibly therapeutic targets for tumors within each subtype. While future work 
remains to distinguish the various gene signatures in these studies, one common 
theme emphasizes the importance of molecularly predicted pathways and their 
possible utility as therapeutic targets.  
Collectively, these studies strongly suggest that the molecular 
heterogeneity of brain tumors contributes to the disease progression and survival 
outcome of glioma patients. This molecular heterogeneity could thus account for 
the frequently observed inter-patient variability to treatment response. The 
purpose of molecular sub-classiﬁcation of gliomas is to delineate the biology of 
tumorigenesis and determine the genetic lesions that lead to oncogenesis and 
sustenance of tumor growth. Using the molecular classification scheme, GBM 
patients can now potentially be treated according to their molecular subclasses 
and pathway activation. Indeed, a recent report has shown that co-expression of 
the epidermal growth factor receptor variant III (EGFRvIII) and the tumor 
suppressor phosphatase and tensin homolog (PTEN) associates with clinical 
response to EGFR kinase inhibitors in a recent clinical trial (Mellinghoff et al, 
2005). Noticeably, molecular classification has paved the way for more rational 




1.2 Mouse models of glioma 
Over the last few decades, molecular genetic analyses have convincingly 
shown biological heterogeneity within human gliomas. While sophisticated 
bioinformatics analyses provide clues to the genetics of tumor initiation and 
progression, experimental mouse models are required to definitively implicate 
these mutational events. The development of appropriate mouse models 
provides the opportunity to interrogate the contribution of specific pathway 
abnormalities to gliomagenesis. Furthermore, mouse models offer a 
physiologically relevant platform to gain insight into basic tumor biology as tumor 
development de novo is usually accompanied by other complex processes such 
as angiogenesis, invasion metastasis and bidirectional communication between 
tumor and micro-environment. More importantly, mouse models provide a 
genetically controlled environment for studying isolated tumorigenic mechanisms 
and treatment response. Some of the genetically engineered mouse models 
(GEMMs) that faithfully recapitulate the process of gliomagenesis will be 
discussed in this section.  
 
1.2.1 Xenograft mouse model 
Xenograft mouse models are typically used in preclinical trials to test the 
efficacy of novel therapeutic agents as well as study the tumorigenic capacity of 
induced mutational events in implanted cells. In these mouse models, clinical 
material or glioma cells are usually injected under the skin in flank regions 
(subcutaneous engraftment) or into the brains (intracranial implantation) of 
immune-compromised mice such as the non-obese diabetic severe combined 
immunodeficient (NOD-SCID) strains. Historically, drug development research 
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has relied on the subcutaneous model for assessment of small molecule efficacy. 
While this model provides a straightforward in vivo approach for preclinical 
testing, there are major drawbacks, including the absence of an appropriate 
microenvironment for tumor development, and the fact that the blood brain 
barrier is not present, which contributes significantly to measuring efficacy of 
drug penetration. For this and other reasons discussed below, the orthotopic or 
intracranial implantation model is rapidly gaining popularity as use in glioma 
studies. 
Patient-derived glioma cells have been shown to re-establish orthotopic 
xenografts that recapitulate the molecular heterogeneity spectrum defined by 
TCGA efforts (Verhaak et al, 2010). In particular, their serially propagated tumors 
maintain gene expression and karyotypic hallmarks characteristic of the original 
primary tumors. Specifically, Galli et al. demonstrated that patient-derived glioma 
cells or gliomaspheres (from culture in serum-free medium supplemented with 
growth factors) could only form tumors in orthotopic and not flank models (Galli et 
al, 2004). Furthermore, subcutaneous tumors yielded gene expression profiles 
very different from orthotopically formed tumors, illustrating the significance of an 
appropriate microenvironment. These reasons make the orthotopic mouse 
glioma model a very attractive tool in assessing drug efficacy and tumorigenic 
potential of implanted material. 
1.2.2 Genetically engineered mouse models (GEMMs) 
Genetically engineered mouse models (GEMMs) are often used to study 
isolated gene events causative of brain tumor development. They however often 
do not provide an accurate recapitulation of the clinical situation where multiple 
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genetic mutations and external factors contribute to disease progression. 
Nevertheless, such models shed light on the importance of tumor-initiating/driver 
versus passenger mutations in the disease. The first brain tumor GEMMs were 
murine models that over-expressed the viral oncogene, SV40 T antigen (Brinster 
et al, 1984). Subsequently, transgenic strategies involving knock-out or knock-in 
genetic manipulations to study the loss-of-function and gain-of-function of 
specific cellular genes were developed. Some of these GEMMs may result in 
predisposition towards tumor formation; however, the global disruption of 
ubiquitous signaling pathways controlled by oncogenes or tumor suppressor 
genes can cause profound developmental abnormalities, thereby confounding 
data interpretation. For instance, homozygous deletion of PTEN, one of the most 
frequently mutated genes in glioma, proved to be embryonically lethal  and 
heterozygous loss was sufficient to induce pre-neoplastic changes in other 
organs, but not in the brain (Di Cristofano et al, 1998). Continuous evolution of 
genetic modification techniques now permit conditional targeting of genetic 
aberrations in specific cell types, giving rise to highly sophisticated lineage-
tracing models that reveal the cell type-of-origin, otherwise not possible in studies 
using patient-derived glioma cells. Such techniques have been elegantly 
demonstrated in intestinal cancers (Barker et al, 2009; Barker et al, 2007) and 
basal cell carcinoma (Lapouge et al, 2011). 
The relationship between alterations in platelet-derived growth factor 
(PDGF) signaling and glioma formation in the Proneural patient group was 
investigated by ectopic expression of PDGFB in mice brains (Assanah et al, 2006; 
Dai et al, 2001; Uhrbom et al, 1998). Indeed, tumor formation was observed and 
expression proﬁling revealed a parallel expression pattern to human Proneural 
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GBM (Lei et al, 2011). In addition, a mouse model with constitutively active 
EGFR expression, in combination with deletion of INK4a/ARF and PTEN, 
developed high-penetrance tumors that histologically resembled human GBMs 
with the Classical molecular subtype (Zhu et al, 2009).  On the other hand, the 
human Mesenchymal GBM subtype was recapitulated by a mouse model 
harboring TP53, PTEN and NF1 deletions (Alcantara Llaguno et al, 2009; Zhu et 
al, 2005). Taken together, the faithful recapitulation of patients’ genetic 
abnormalities in GEMMs allows direct verification of genes effecting oncogenic 
transformation.  
  
1.3  Cell-of-origin in gliomas 
 Lineage–tracing mouse analysis allows us to determine which cell 
compartments are crucial for tumor-initiating, genetic events. Such an approach 
assumes that there are reasonable gene markers that can distinguish various cell 
types, as would not be possible in the mammary system for example. Thus, the 
most elegant lineage-tracing studies have been demonstrated in cancers of the 
brain (Alcantara Llaguno et al, 2009; Zheng et al, 2008), intestinal system 
(Barker et al, 2009; Barker et al, 2007) and skin (Lapouge et al, 2011). Such 
models shed light on the cell-of-origin which is otherwise not possible in studies 
involving patient-derived material. In central nervous system disorders, the 
significance of TP53 and PTEN  deletions in the oncogenic transformation 
process was highlighted when neural stem cells (NSCs), and not the more 
lineage-committed progenitors propagated the astrocytoma phenotype (Jacques 
et al, 2009). Another recent study explored deletions of TP53, PTEN and 
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neurofibromatosis type 1 (NF1) genes (Alcantara Llaguno et al, 2009). The 
authors showed that mutations initiated in neural stem cells and astrocytic 
precursors developed fully penetrant GBM tumors that recapitulated the 
Mesenchymal molecular subtype found in patients. 
 Although several studies have shown that NSCs and/or multipotential 
neural progenitor cells are likely the cells-of-origin for high-grade gliomas, more 
restricted progenitor cells have also been demonstrated to initiate tumor 
development (Bachoo et al, 2002; Uhrbom et al, 2005). The cancer cell-of-origin 
is difficult to identify by analyzing cells within terminal stage tumors as above, 
whose identity could be concealed by the acquired plasticity. Thus, an ideal 
approach to identify the cell-of-origin is to analyze proliferative abnormalities in 
distinct lineages prior to malignancy. By using the mosaic analysis with double 
markers (MADM) technique, Liu et al. demonstrated that initiating mutations of 
TP53 and NF1 in the NSC compartment resulted in aberrant expansion of the 
OPC pool prior to malignancy, and this expansion did not occur in NSCs or their 
derived lineages (Liu et al, 2011). However, both nestin and glial fibrillary acidic 
protein (GFAP) markers used in the mouse model to mark NSCs and astrocytes 
respectively, are dynamically regulated, and can drive expression in more than 
one cell type (Doetsch et al, 1999). Furthermore, the OPC marker PDGFRA is 
also expressed in NSCs (Jackson et al, 2006). Such studies indicate that 
identifying the cell-of-origin is not trivial and clearly, more sophisticated lineage-




1.4 Glioma-propagating cells (GPCs) 
Cancer stem cells or cancer-initiating cells were originally defined as cells 
which when implanted in immune-compromised mice, initiated tumors with 
resulting morphologies very similar to the original primary tumors (Rich & Eyler, 
2008). Cancer stem cells of the hematopoietic system (Bonnet & Dick, 1997), 
intestine (O'Brien et al, 2007), skin (Boiko et al, 2010), brain (Singh et al, 2003) 
and breast (Al-Hajj et al, 2003) have been identified in this manner. Quintana et 
al. recently showed that such a definition could be erroneous, depending on how 
one manipulated experimental conditions (Quintana et al, 2008). For example, 
the addition of an extracellular matrix protein (Matrigel), or using a more immune-
compromised mouse strain, or varying the time to formation of tumor, could alter 
the frequency and appearance of the cancer stem cell, thereby suggesting that 
its definition could merely be an artefactual consequence of experimental 
conditions. While more conclusive evidence regarding the cell-of-origin has come 
from lineage-tracing mouse studies (Alcantara Llaguno et al, 2009; Zheng et al, 
2008), the use of patient-derived glioma stem cells, or now more appropriately 
termed “glioma-propagating cells” (GPCs), presents another complementary 
approach to explore the oncogenic process. For instance, GPC-established 
xenografts are able to recapitulate the patient molecular heterogeneity spectrum 
(Verhaak et al, 2010), thereby offering an important tumor “replica” resource to 
prospectively test therapeutic agents, yet have retrospective clinical information 
for correlative studies. Furthermore, such patient-derived glioma xenografts 
demonstrate gene expression and karyotypic hallmarks found in the original 
primary tumor (Lee et al, 2006). Galli et al. showed that serially propagated 
glioma xenografts maintain GPCs with their original genomic information, 
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highlighting the importance of orthotopically passaging GPCs in mice, and using 
low passage cells for in vitro analyses (Figure 1.1) (Galli et al, 2004). 
Perhaps the most interesting validation of the relevance of using patient-
derived cancer stem-like cells comes from studies where gene expression data 
established from these cells prognosticated patient outcome. This provides the 
most direct link between information residing in these cells and disease 
progression, and strongly suggests that stem-like traits are clinically relevant in 
the advancement of the disease. Several studies have indicated that gene 
expression data contained in the tumor-propagating cell fraction, and not the 
non-tumor propagating fraction, stratified patient survival in cancers of the blood 
(Eppert et al, 2011), brain (Yan et al, 2011) and breast (Liu et al, 2007; Shats et 
al, 2011). Our recent effort has also shown that transcriptomic programs residing 
in patient-derived GPCs dictate the primary tumor phenotype (Ng et al, 2012). 
Accordingly, we examined genes differentially regulated between 2 major glioma 
variants: GBM and oligodendroglial tumors . This gene signature correlated with 
the up-regulation of the transforming growth factor beta (TGFβ) pathway in GBM 
tumors, and the up-regulation of the Notch and Wnt signaling pathways in 
oligodendroglial tumors. We then validated these predictions biochemically in an 
independent set of primary tumors, as well as in our collection of GPCs. Our data 
provide evidence that patient-derived GPCs contain gene expression programs 
that determine disease progression and patient survival outcome, and that they 




Figure 1.1. Isolation of glioma-propagating cells (GPCs) from brain tumor. Fresh 
tumor specimen was dissociated and plated in serum-free media supplemented with 
growth factors. The growth factor-responsive GPCs proliferate to form floating clusters of 
cells. These can be further dissociated into single-cell suspensions and then re-plated 
into fresh medium. This process can be repeated, resulting in geometric expansion of the 
number of cells that are generated at each passage. Tumor xenograft that recapitulates 
the pathophysiology of parental tumor can be generated by implanting the derived GPC 
lines into immunocompromised mice. 
 
1.4.1  Identification of GPCs 
Several cell surface markers have been shown to enrich for GPC traits 
and tumor formation in immune-compromised mice: CD133 (Singh et al, 2003), 
CD15 (Son et al, 2009), aldehyde dehydrogenase (ALDH) (Rasper et al, 2010), 
side population (Bleau et al, 2009), cell adhesion molecule L1CAM (Bao et al, 
2008) and integrin α6 (Lathia et al, 2010). While the definition of the tumor-
initiating cell is controversial for reasons discussed above, there is convincing 
evidence that transcriptomic information contained in such cellular fractions 
contributes to disease progression and clinical outcome (Verhaak et al, 2010). A 
less clear definition of the brain tumor-initiating cell is also complicated by the 
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fact that gliomas can arise from, for instance, CD133-negative cells in a subset of 
brain tumors (Beier et al, 2007). Such studies can be reconciled by the fact that 
surface marker expression can represent overlapping subsets, and that it can 
also change with disease progression. Indeed, the melanoma-initiating cell 
frequency is increased with higher tumor grades (Boiko et al, 2010), 
consequently affecting the interpretation of rarity of the subpopulation. 
Noteworthy is also the observation that bona fide cancer stem cells can be 
quiescent and rarely dividing, thus any studies relying on proliferation-based 
assays cannot possibly accurately detect such cells. Indeed, in acute myeloid 
leukemia, the CD34+ CD38- leukemia stem cell (LSC) has been shown to reside 
in the endosteal region, and its quiescent cell cycle state allows it to escape the 
effects of chemotherapeutic drug agents (Saito et al, 2010). Consequently, 
induction of cell cycle re-entry can be a therapeutic strategy to exhaust the LSC 
pool. With such limitations in the use of cell surface markers, current studies are 
moving towards re-defining the GPC, with focus on functional properties.  
1.4.2  Functional identification of GPCs 
Several criteria demonstrate the true self-renewal potential of GPCs, 
including their extensive in vitro passage capability and ability to serially form 
tumors in immune-compromised mice, recapitulating the primary tumor 
phenotype (Table 1.3). A common method used to determine the in vitro GPC 
frequency relies on an adaptation of the neurosphere assay, first developed by 
Reynolds et al. to expand mouse neural stem cells (Reynolds & Weiss, 1992). 
Over the years, emphasis has been made to improve the accuracy of this assay, 
mainly confounded by the fact that the neurosphere is a heterogeneous mix of 
cell types. This includes determining GPC sphere number and size over at least 
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3-4 generations to detect the more slowly-dividing, self-renewing population, and 
seeding cells for the assay at clonal density, usually at no more than 2,500-5,000 
cells per cm2  (Gritti et al, 1996; Rietze et al, 2001). Sphere number reflects GPC 
frequency, while sphere size represents the proliferation of specifically GPCs 
versus other transient-amplifying progenitors. A defined clonal density is 
important to rule out cellular aggregation as opposed to the desired bona fide 
sphere formation resulting from self-renewal of single GPCs. Such refinements 
have allowed accurate measurements of the efficacies of drug agents on GPCs 
in vitro (Diamandis et al, 2007), as well as translate to meaningful in vivo survival 
analyses (Penuelas et al, 2009). More importantly, GPCs must form serially 
transplantable tumors that reflect the extensive self-renewal potential, and 
display xenograft morphologies resembling the original primary tumor 
pathophysiology (Lee et al, 2006). We will utilize these assays to determine 
effects on our GPCs in the subsequent chapters. 
Table 1.3. GPCs are defined by functional characteristics. GPCs are defined by their 
capacity for extensive self-renewal ability, sustained proliferation and tumor propagation 
in mouse model. Characteristics that are common but not necessarily associated with 






1.5 Cell surface glycans  
 Glycobiology is the study of the structure, biosynthesis, and biology of 
sugar chains or glycans (Varki & Sharon, 2009). Glycans decorate the surface of 
all mammalian cells by a process termed as “glycosylation”, in which 
carbohydrate moieties (oligosaccharide chains) are linked to lipids and proteins. 
These glycans play crucial roles in many biological processes such as cell-cell 
recognition, adhesion, cell-cell interaction and fine tuning of receptor-mediated 
signal transduction (Fukuda, 1995; Haltiwanger & Lowe, 2004).  
Notably, the combinatorial possibilities of glycan structures far exceed 
that of peptide-based structural diversity, mainly due to the greater number of 
sugar building blocks existing in nature. Early clues of glycan-based complexity 
were revealed from a study of red blood cells (Morgan & Watkins, 1953). With 
the use of lectins, sugar-binding proteins that are highly specific to their unique 
carbohydrate moieties, together with biochemical approaches, the 
monosaccharide-dependent variation among ABO blood groups was defined. 
Importantly, this study demonstrated that the specificity of antigens of different 
blood groups reside in carbohydrate patterns and revealed the immune-dominant 
sugars in the antigenic structures (Morgan & Watkins, 2000). This work further 
established that the glycan-based ABO blood group antigens are expressed in a 
dynamic and lineage-specific manner during human embryogenesis. The 
modulation of glycan diversity during the process of development and 
differentiation were further supported by an effort to use monoclonal antibodies to 
identify important cell surface molecules whose expressions were restricted to 
early stages of embryogenesis but not in adult cell types (Solter & Knowles, 
1979). This work generated a series of stage-specific embryonic antigen (SSEAs) 
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antibodies that bind to specific glycan epitopes which are stage- and lineage-
specific. The findings further implicate the specificity of glycan presentation in the 
process of development and differentiation.  
Given the structural diversity of glycans and their ability to mark stage-
specific cells, we sought to explore glycan presentation in stem-like, patient-
derived GPCs. We anticipate the vast repertoire of sugar moieties and their 
linkages are likely to confer unique immunogenic profiles to GPCs. Moreover, 
various aberrant glycosylation patterns have also been implicated in the 
progression of brain tumors (Moskal et al, 2009).  
 
1.6 Altered glycosylation in brain tumors 
 Glycosylation is one of the most common protein post-translational 
modifications. Altered glycosylation patterns and the presence of aberrant 
glycosyl molecules have been documented in various types of human cancers. In 
addition, numerous studies have provided evidence that these carbohydrates 
play critical functional roles in major pathophysiological events during early 
stages of tumor progression, metastasis and formation of secondary tumors at 
distant sites from the primary tumor (Fuster & Esko, 2005). In brain tumors, 
significant altered expression of oligosaccharides have been found in 
gangliosides, differing in extent depending on tumor grade (Shinoura et al, 1992; 
Traylor & Hogan, 1980). In addition, adhesion molecules such as CD44, neural 
adhesion molecule (NCAM), cadherin and galectins that play critical roles in the 
invasiveness of brain tumor cells are found to be highly glycosylated (Moskal et 
al, 2009). In oncogenic transformation, one of the most commonly observed 
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glycosylation aberration is sialylation, a process involving capping sialic acid 
molecule(s) to the tips of glycan structures.  
 1.6.1 Sialylation in cancer 
Sialic acid is a generic term for neuraminic acid, a monosaccharide with a 
9-carbon backbone that is widely distributed at the terminal positions of 
oligosaccharide structures (Varki & Schauer, 2009). The presence of sialic acids 
on the tips of oligosaccharide chains attached to proteins enables them to play 
critical roles in modulating the interaction of protein with its environment, 
influencing its solubility, activity and biological fate. In human beings, sialyl 
residues are usually linked to the inner sugar residues of galactose (Gal) via α2,6 
or α2,3-linkage, or linked to galactosamine or N-acetylgalactosamine (GalNAc) 
via α2,6-linkage. Besides, sialic acids are also found to be α2,8-linked  to other 
sialyl residues, forming polysialic acids (Harduin-Lepers et al, 1995). These 
molecules are catalyzed by enzymes of the sialyltransferase (ST) family, which 
can be classified into 4 groups according to the carbohydrate linkages they 
synthesize: ST3Gal (α2,3-linkage), ST6Gal (α2,6-linkage), ST6GalNAc and 
ST8Sia (α2,8-linkage). 
 Increased sialylation has been implicated in tumor cell invasiveness 
(Collard et al, 1986), metastatic potential (Passaniti & Hart, 1988), resistance to 
T-cell mediated cell death (Werkmeister et al, 1983) and adhesion to endothelial 
cells and the extracellular matrix (Dennis et al, 1982). More importantly, 
sialyltransferase overexpression and over-representation of sialylated antigens 
have been reported to correlate positively with cancer progression and poor 
prognosis in leukemia (Baker et al, 1985), breast (Recchi et al, 1998), colon 
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(Petretti et al, 2000), ovarian cancers (Davidson et al, 2000), gastric (Gretschel et 
al, 2003) and bladder cancers (Videira et al, 2009). In brain tumors, Yamamoto et 
al. showed that α2,3-sialyltransferase (ST3Gal3) and α2,3-linked glycoprotein 
sialylation were markedly over-expressed in human glioma specimens 
(Yamamoto et al, 1997). Follow-up studies showed that ectopic expression of 
sialyltransferase ST6Gal1 in glioma cells by replacing α2,3-linked with α2,6-
linked sialic acids, inhibited glioma formation in vivo. These changes were in part 
attributed to the alteration of sialic acids on integrins at the glioma cell surface 
(Dawson et al, 2004; Yamamoto et al, 2001). These studies further highlight the 
role of sialyltransferases at conferring malignancy and disease progression in 
brain tumors.  Interestingly, we identified α2,3-sialyltransferase (ST3Gal1) in 
mediating GPC survival. ST3Gal1 and its role in normal biology and cancer 
development will be discussed in the next section.  
1.6.2 Physiological role of ST3Gal1  
Galβ1-3GalNAc α2,3-sialyltransferase (ST3Gal1) is a golgi membrane-
bound glycoprotein that catalyzes the transfer of sialic acid residues to Galβ1-
3GalNAc disaccharide structure, resulting in trisaccharide structure Siaα2,3- 
Galβ1-3GalNAc (Figure 1.2) (Kono et al, 1997). The glycoproteins that express 
this disaccharide glycan structure and are targeted by ST3Gal1 have not been 
fully elucidated. Lectin affinity chromatography using Peanut Agglutinin (PNA), 
which recognizes the Galβ1-3GalNAc structure, revealed the potential 
glycoprotein target of ST3Gal1. Using this method, He et al. reported that PNA-
captured glycoproteins were mainly localized in the membrane, endoplasmic 
reticulum, lysosome and extracellular (He et al, 2010; He et al, 2011). The 
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functional validation and importance of ST3Gal1-mediated sialylation on these 
glycoproteins therefore remain to be further investigated.  
Human ST3Gal1 consists of 4 domains: a short N-terminal cytoplasmic 
tail, a single transmembrane domain, a stem region and a large C-terminal 
catalytic domain containing L-, S- and VS-sialyl motifs. The L- and S-sialyl motifs 
are important in recognizing the sialyl residues and acceptor substrates on 
glycoconjugates (Datta & Paulson, 1995; Datta et al, 1998). The exact role of the 
VS-sialyl motif has not been fully elucidated. However, mutagenesis studies in 
the VS-sialyl motif yielded inactive enzymes, thereby suggesting its role in 
catalyzing the transfer of sialyl residues to the acceptor glycoconjugates 
(Jeanneau et al, 2004).  
 
Figure 1.2. Schematic diagram showing enzymatic reaction of sialyltransferase 
ST3Gal1. ST3Gal1 catalyzes transfer of the sialic acid residue to Galβ1,3GalNAc on 
glycoproteins or glycolipids via α2,3-linkage. 
 
Studies of T-lymphocyte activation revealed that the modulation of 
sialylation by ST3Gal1 is required for homeostatic elimination of CD8+ T cells by 
apoptosis and facilitating the formation of viable CD8+ memory T cells (Priatel et 
al, 2000; Van Dyken et al, 2007). In addition, ST3Gal1 has also been associated 
with neoplastic transformation. Over-expression of ST3Gal1 has been implicated 
23 
 
in cancers of the breast, colorectum and bladder (Burchell et al, 1999; Schneider 
et al, 2001; Videira et al, 2009). More recently, the oncogenic role of ST3Gal1 
was confirmed in breast carcinoma. Picco et al. demonstrated that transgenic 
over-expression of ST3Gal1 in a mammary cancer mouse model significantly 
decreased the latency of tumor formation, and correlated with poorer survival 
(Picco et al, 2010). However, the molecular mechanism of ST3Gal1 remains 
unclear.   
Despite the well-characterized role of ST3Gal1 at synthesizing specific 
sialylated structures, the mechanism of action and the regulation of ST3Gal1 are 
still unclear. Furthermore, the role of ST3Gal1 in brain tumor formation has not 
been implicated. Here, we provide novel evidence that ST3Gal1 is crucial for 
GPC maintenance, invasiveness and disease progression in glioma patients. We 
further suggest that ST3Gal1 expression is prognostic in glioma disease 
progression. 
1.6.3 ST3Gal1 inhibitor 
Soyasaponin I is the first ST3Gal1 inhibitor discovered via a screening 
strategy (Wu et al, 2001). It acts as a competitive inhibitor affecting the binding of 
sialic acid molecule to ST3Gal1. It effectively attenuates α-2,3-sialylation and 
mitigates metastatic potential of breast cancer cells and murine melanoma cells 
(Chang et al, 2006; Hsu et al, 2005). Recently, more potent ST3Gal1 inhibitors, 
AL10 (Chiang et al, 2010) and Lith-O-Asp (Chen et al, 2011) were developed 
based on the lithocholic acid-based analog of Soyasaponin I. Consistently, both 
inhibitors have been shown to suppress invasion and metastasis in lung cancer 
cells. These studies provide evidence that inhibiting ST3Gal1 could be a potential 
therapeutic intervention for cancer. 
24 
 
1.7 FoxM1 signaling in Glioma  
 Dysregulation of cell cycle in most cancers, including gliomas is an 
essential mechanism for development, progression, and resistance to cancer  
treatments (Hanahan & Weinberg, 2011). The importance of cell cycle control in 
gliomagenesis is highlighted in earlier studies using GEMMs. Interestingly, the 
initial effort to create a mouse glioma model by using single tumor suppressor 
gene knockouts or over-expression of single oncogenes has largely failed (Reilly 
& Jacks, 2001). Subsequently, it was found that only the genetically engineered 
mouse bearing activation of receptor tyrosine kinase (RTK) signaling, along with 
simultaneous loss of genes involved in cell cycle control, develop gliomas with 
high penetrance (Holland et al, 1998; Xiao et al, 2002). These studies 
demonstrate that the significance of cell cycle pathways in glioma formation. 
 Mammalian transcription factor Forkhead Box M1 (FoxM1) belongs to the 
extensive family of Forkhead transcription factors, whose members are 
characterized by a 100-amino acid long, evolutionarily conserved DNA-binding 
domain called Forkhead or winged-helix domain. FoxM1 is an oncogenic 
transcription factor involved in a wide range of biological processes including 
embryogenesis, proliferation, differentiation, apoptosis, transformation, 
tumorigenesis, longevity and metabolic homeostasis (Kalin et al, 2011). The 
transcriptional activity of FoxM1 correlates with its phosphorylation level. Both 
gradually increase as cells progress through the cell cycle, reaching maximum 
levels at the G2-M transition. FoxM1 is initially phosphorylated at G1 and then 
further phosphorylated in a sequential order by multiple protein kinases including 
cyclin-dependent kinase (Cdk)-cyclin complexes and mitogenic kinases at the S- 
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and G2-M phases of the cell cycle, generating the hyperphosphorylated and fully 
active form of FoxM1 by the G2-M phase. 
As FoxM1 is such a critical regulator of the cell cycle, its activity is tightly 
controlled to provide orderly expression of its downstream effectors and to 
prevent uncontrolled cell proliferation. Subsequent phosphorylation of FoxM1 is 
the driving force behind its activity during cell cycle progression and not 
surprisingly, rapid dephosphorylation of FoxM1 occurs when cells are exiting 
mitosis (Major et al, 2004). During G1/S transition, FoxM1 activates the 
transcription of Cdc25A (Wang et al, 2002), JNK1 (Wang et al, 2008a), members 
of the Skp-cullin-F-box (SCF) ubiquitin ligase complex, Skp2 and Cks1 (Wang et 
al, 2005a), thus promoting the Skp2-dependent proteasomal degradation of the 
Cdk inhibitors p21Cip1 and p27Kip1. At the G2/M transition and through mitosis, 
FoxM1 is required for the expression of Cdc25B (Wang et al, 2002), cyclin B1 
(Leung et al, 2001), Aurora B kinase (Wang et al, 2005a), Polo-like kinase-1 (Plk-
1) (Laoukili et al, 2005), centromere protein A, B (Wang et al, 2005a) and F 
(Laoukili et al, 2005) (CENP-A, B, F) and survivin (Wang et al, 2005a) to allow 
mitotic progression, proper assembly of the mitotic spindles, accurate 
chromosome segregation and cytokinesis (Laoukili et al, 2005). FoxM1 protein is 
also targeted for proteasomal degradation by the anaphase-promoting 
complex/cyclosome (APC/C)-Cdh1 complex in late mitosis and early G1-phases 
of the cell cycle (Laoukili et al, 2008). The N-terminal region of FoxM1 contains 
both destruction box (D box) and KEN box sequences that are required for 
targeting by Cdh1. Mutation of either the D box or KEN box sequences stabilizes 
FoxM1 and blocks Cdh1-induced proteolysis (Laoukili et al, 2008).  In addition, its 
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own transcription regulates its activity in a positive feedback loop (Halasi & Gartel, 
2009). 
We were particularly interested in FoxM1 as a downstream mediator of 
ST3Gal1 for several reasons: (1) FoxM1 was identified as the most significantly 
modulated gene upstream of all cell cycle processes through our bioinformatics 
interrogation, (2) FoxM1 has been implicated in human epithelial cancers where 
it promotes tumorigenesis through expansion of the stem/progenitor cell pool, 
thereby suggesting a new role of FoxM1 in self-renewal (Gemenetzidis et al, 
2010; Zhang et al, 2011). Moreover, Zhang et al. recently implicated FoxM1 in 
the maintenance of the GPC state in glioblastoma (Zhang et al, 2008). Briefly, 
the authors showed that FoxM1 binds to β-catenin and regulates its nuclear 
localization and transcriptional activity, both of which are crucial to promote the 
self-renewal of GPCs and their tumorigenic potential. Additionally, genetic 
knockdown of FOXM1 disrupts β-catenin nuclear localization and consequently 
induces cellular differentiation.  Collectively, this study illustrates the importance 
of FoxM1 at promoting the self-renewal of GPCs.  
 
1.8 Gap in knowledge 
Our effort comprises the following: 
1. We sought to validate our patient-derived GPC collection by molecular 
profiling and small molecule drug screening. In the molecularly-based 
approach, we used both unbiased and supervised hierarchical clustering 
methods to determine subgroups of our GPCs, in the context of other 
international GPC collections. Secondly, through our collaboration with Eli 
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Lilly pharmaceutical company, we utilized a panel of small molecules 
targeting several common oncologic pathways. Our findings support that 
our GPCs are clinically relevant and possess oncogenic pathways 
similarly found in international collections. 
 
2. Next, we asked if cell surface carbohydrate patterning could distinguish 
the GPC from its transient progenitors. We utilized a panel of lectins and 
identified Peanut Agglutinin (PNA) to differentially stain the GPC in its 
stem versus differentiated state. Through bioinformatics interrogation 
based on combining PNA-sorted GPC information with patient clinical 
databases, we identified ST3Gal1 as the sialyltransferase responsible for 
conferring the PNA binding pattern. 
 
3. We asked if ST3Gal1 conferred a tumor cell prosurvival role, specifically 
by promoting GPC survival. To address this, we measured in vitro GPC 
formation and invasive capacity after genetic knockdown of ST3GAL1. 
We also determined survival patterns of implanted mice. Finally, to 
validate that ST3Gal1 activation constitutes a clinically relevant scenario, 
we examined the gene expression program arising from ST3GAL1-
knocked down cells, for patterns of similarity with patient individual gene 
expression data. We also determined the correlation of this ST3GAL1 
gene activation program with patient magnetic resonance imaging (MRI) 
scans to document tumor cell invasiveness. Our data support the GPC 




4. Finally, we sought to determine the molecular trigger of ST3Gal1, and its 
downstream effectors. We utilized bioinformatics methods to predict these 
pathways, and subsequently validated them in independent collections of 




























CHAPTER 2 – MATERIALS AND METHODS 
2.1 Tissue collection and primary gliomasphere culture 
Graded brain tumor specimens were obtained with informed consent, as part of a 
study protocol approved by the SingHealth Centralised Institutional Review 
Board A. In this study, NNI-1 was from a patient with recurrent GBM (grade IV) 
who had received radiation therapy, and NNI-2, 4, 11 were from patients with 
primary GBM who were treatment naïve. NNI-8 is a GPC line derived from 
patients with primary anaplastic oligoastrocytoma who was treatment naïve. 
Tumors were processed according to Gritti et al. (Gritti et al, 1996). Cells were 
seeded as free-floating spheres at a density of 2,500 cells per cm2 in chemically 
defined serum-free growth medium containing basic fibroblast growth factor 
(bFGF; 20 ng/mL; PeproTech, Rocky Hill, NJ), epidermal growth factor (EGF; 20 
ng/mL; PeproTech), heparin (5 μg/mL; Sigma-Aldrich, St. Louis, MO), and 
serum-free supplement (B27; 1×; Gibco, Grand Island, NY) in a 3:1 mix of 
Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich) and Ham’s F-12 
Nutrient Mixture (F-12; Gibco). Successful gliomaspheres (1 to 4 weeks) were 
mechanically triturated with a flame-drawn glass Pasteur pipette and reseeded in 
fresh culture medium. Differentiation of gliomaspheres was carried out over 14 
days in DMEM/F12 without growth factors, supplemented with 5% Fetal Bovine 
Serum (FBS; Invitrogen).  All experiments were conducted with low-passage 
GPCs (within 20 passages) for which we previously demonstrated maintenance 
of the phenotypic, transcriptomic, and karyotypic features similar to the primary 




2.2 Lectin Screening 
Percentage differences of cells staining positive for the various lectins (Table 4.1) 
(Vector Laboratories) between the stem- and differentiated-states of GPCs were 
assessed using flow cytometric analysis. Lectin candidates that showed at least 
15% difference in lectin-positive staining between stem- and differentiated-states 
in at least 2 of 3 GPC lines tested were selected for subsequent analysis.  
2.3 Cell viability assay   
2.3.1 Cell viability assessment after small molecule inhibitor treatment 
Gliomaspheres were dissociated with AccutaseTM (eBioscience) and seeded in 
96-well plate format at 10,000 cells per well. A recovery period of 3-4 days was 
allowed before compounds were added, along with replenishment of growth 
factors. Viability was measured at day 7 post-treatment using alarmaBlue® 
(Serotec) according to manufacturer’s instructions. Briefly, cells were incubated 
with 10% volume of alarmaBlue® for approximately 16 hours before absorbance 
readings were measured at 570 and 650 nm.  
2.3.2 Cell viability assessment after lentiviral transduction 
Viability of lentiviral-transduced GPCs was assessed using CellTiter-Glo viability 
assay (Promega), where the measurement of intracellular ATP reflects the 
presence of metabolically active cells. Each well of a 96-well microtiter plate was 
seeded with 2,000 sorted cells and luminescence signals were quantitated using 




2.4 Gliomasphere formation assay 
Serial gliomasphere-forming ability, which approximates the bona fide GPC 
frequency within heterogeneous gliomaspheres, and sphere size, which reflects 
GPC proliferation, were assessed as described in our previous work (Chong et al, 
2009). Briefly, gliomaspheres were dissociated into single cells by AccutaseTM 
and 30 cells were subsequently flow-sorted into each well of 96-well plates. 
Gliomasphere number and size distribution were determined at days 7 and 14. A 
bona fide gliomasphere is defined as a single clonal sphere of diameter 
exceeding 20 μm. Scoring and diameter measurements were performed using 
Nikon Eclipse Ti Microscopy, accompanied with digital camera (DS-Qi1) and 
NIS-Element Imaging Software (Nikon Instruments Inc., New York, USA). 
 
2.5 Invasion assay 
Fifty thousand cells were added to the upper compartment of the BD BioCoat 
Matrigel invasion chamber (BD Bioscience) and 2% FBS was supplemented to 
the lower compartment as chemo-attractant. Cells were incubated for 24 hours 
before being wiped off from the upper surface of the filter with a cotton swab. The 
lower surface of the filter was subsequently stained with 0.005% crystal violet 
(Sigma-Aldrich). The number of cells having migrated to the bottom of the 




2.6 Lentiviral-mediated over-expression and knockdown 
ST3Gal1-Flag, FoxM1 and FoxM1-∆N∆KEN over-expression vectors were 
constructed using pCDH-CMV-MCS-EF1-GFP+Puro vector (System 
Biosciences). FLAG-tag was incorporated into the N-terminal of full length 
ST3GAL1 cDNA by PCR.  The amplified product was digested with BamHI and 
NheI, and subsequently ligated into the pCDH vector. FoxM1 vector was created 
using PCR-amplified full-length FoxM1 cDNA and mutant FoxM1-∆N∆KEN was 
created using specific primer to amplify cDNA encoding aa210-763 (Laoukili et al, 
2008). Both cDNA inserts were digested with EcoRI and BamHI, and 
subsequently ligated into pCDH vector. Lentiviral particles were generated using 
the Lenti-XTM HTX Packaging System (Clontech) according to the manufacturer’s 
protocol. Lentiviral-compatible pLKO.1-ST3Gal1 knockdown constructs 
[shST3GAL1 clone 1 (TRCN0000035551) and shST3GAL1 clone 2 
(TRCN0000035552)] were obtained from Open Biosystems. Lentiviral particles 
were generated as described above. 
 
2.7 Immunohistochemistry 
Patients’ tumor paraffin blocks with histological diagnosis were obtained with 
informed consent, as part of a study protocol approved by the SingHealth 
Centralised Institutional Review Board A.  Tissue sections were stained with the 
following antibodies: anti-ST3Gal1 antibody (1:50, OriGene, #TA307977) and 
anti-phospho-Smad2 antibody (Ser465/467; 1:50, Cell Signaling Technology, 
#3101). For quantitative analysis, the percentage of stained tumor cells and 
intensity of staining were evaluated under high-power fields (400x) on tissue 
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sections using optical microscopy. Immunopositivity for the ST3Gal1 and 
phospho-Smad2 protein expression were assessed by means of a 
semiquantitative scoring method (H-score). H-scores were then derived from 
both the staining intensity (scale of 0-3) and the percentage of positive cells (0-
100%), which, when multiplied, generated a score ranging from 0 to 300. Briefly, 
the percentage of weakly stained cells was multiplied by 1 plus moderately 
stained cells multiplied by 2 plus strongly stained cells multiplied by 3. At least 5 
random fields were counted and scoring was performed blinded to clinical data. 
 
2.8 In situ hybridization 
In situ hybridization analysis of ST3GAL1 mRNA was performed on brain tumor 
tissue array slides (Biomax, #GL803) containing 5 normal adjacent cererbral 
tissue (NAT) and 64 glioma specimens.  The digoxigenin-labeled anti-sense and 
sense riboprobes for human ST3GAL1 mRNA were synthesized. Deparaffinized 
sections mounted on Denhardt-coated glass slides were treated with Pepsin 
(0.25 mg/ml) for 25-30 minutes at 37 oC. The treated sections were then 
processed for in situ hybridization at 45-63 oC for 24 hours. The slides were 
counterstained by nuclear red fast. Staining was scored using a 0-3+ scale. 0 
means no staining; 0-1+ represents trace staining that is weaker than 1+ but 
stronger than 0. 1+, 2+ and 3+ indicate increased intensity of the staining. Sub-
regions excluding necrosis, macrophages and infiltrated neutrophils and 
lymphocytes were selected and scored. The intensity score for an array spot is 




2.9 Flow cytometric analysis and cell sorting 
For stemness analysis, gliomaspheres were dissociated with AccutaseTM and 
blocked with FcR blocking reagent (Miltenyi Biotec). Cells were stained according 
to manufacturer’s instructions with anti-CD133/2-allophycocyanin (Clone 293C, 
1:10; Miltenyi MACS, #130-090-854); anti-CD15-allophycocyanin (1:10, BD 
Biosciences, #347423), anti-Nestin (1:1000, Millipore, #MAB5326). Aldehyde 
dehydrogenase activity was determined using the AldeFluorTM kit (Stem Cell 
Technologies) according to manufacturer’s protocol. Dead cells were 
distinguished by 7-aminoactinomycin D (7-AAD; BD Pharmingen) staining. A total 
of 10,000 events was acquired on the FACSCalibur (BD Biosciences). Data were 
plotted using FlowJo software (Treestar Inc.). Biotinylated Peanut Agglutinin 
(PNA) (1:4000, Vector Laboratories, #B-1075) conjugated with Streptavidin-
Fluorescein Isothiocyanate (FITC) (1:250, BD Pharmingen, #554060)-stained 
single cells were analyzed and flow-sorted using the BD FACSAria II cytometer 
(BD Biosciences).  Dead cells were distinguished by 7-aminoactinomycin D (7-
AAD; BD Pharmingen). The top, middle and bottom 30% of PNA-stained cellular 
fractions were gated to represent the PNAhi, PNAmid and PNAlo populations 
respectively. 
 
2.10 Immunoblot analysis 
Cells were lysed in buffer containing 0.5% sodium deoxycholate, 1% NP-40 
detergent, 0.1% SDS, 0.15 M NaCl, 10 mM Tris-HCl (pH7.4), protease and 
phosphatase inhibitor cocktail tablets (Roche). Equal amounts of protein lysate 
were resolved by 10% SDS-PAGE (10% Acrylamide/Bis-Acrylamide, 0.375 M 
36 
 
Tris-HCl (pH8.8), 1% SDS, 1% Ammonium Persulfate, 0.1% N,N,N',N'-
Tetramethylethylenediamine) and electrotransferred onto polyvinylidene 
difluoride (PVDF) membranes. Membranes were processed according to 
standard procedure and proteins were detected using the imaging system, 
SYNGENE G:Box, iChemiXT. Antibodies used for immunoblot analysis included 
anti-Flag (1:1000, Sigma, #F3165),  anti-phospho-Smad2 (Ser465/467; 1:1000, 
Cell Signaling Technology, #3108), anti-Smad2 (1:1000, Cell Signaling, #3122), 
anti-phospho-PAX (Tyr31; 1:1000, Abcam, #AB32115), anti-PAX (1:1000, 
Millipore, #05-417), anti-FAK (1:1000, Cell Signaling, #AB28152), anti-FoxM1 
( 1:1000, Santa Cruz, #SC-502), anti-PLK1 (1:1000, Invitrogen, #377000), anti-
CDK1 (1:1000, Santa Cruz, #SC-54) , anti-p27 (1:1000, Santa Cruz, #SC-528), 
anti-cleaved PARP (1:1000, Cell Signaling, #9541), and anti-β-actin (AC-15, 
1:10000; Sigma-Aldrich, #A5441), anti-ubiquitin, Fk2 (1:2000, Enzo, #BML-
PW8810). 
 
2.11 Cell cycle analysis 
Cells were harvested and fixed in cold 70% ethanol before staining with a 
staining solution of 4 µg/mL Propidium Iodide (Sigma-Aldrich) and 100 µg/mL 
RNase A (Sigma-Aldrich). Data acquisition was performed using the 





2.12 Intracranial glioma mouse model 
Animal experimentation was performed according to protocols approved by the 
Institutional Animal Care and Use Committee of the National Neuroscience 
Institute of Singapore. Implantation was carried out as previously described 
(Chong et al, 2009; Ng et al, 2012), using NOD/SCID gamma mice (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ, The Jackson Laboratory). The following coordinates were 
used: antero-posterior=+1.0 mm; medio-lateral=+2.0 mm; dorso-ventral=-2.5 mm. 
Mice were euthanized by means of transcardiac perfusion with 4% 
paraformaldehyde upon presentation of neurological deficits with ataxia, 
cachexia, lethargy, or seizure. Animal survival was assessed using the log-rank 
test in GraphPad Prism software (GraphPad Software, Inc.). Hematoxylin and 
eosin staining was performed on 5-µm-thick paraffin sections. 
 
2.13 Small-molecule inhibitors and reagents 
The small molecule inhibitors targeting (p70S6, PKAlpha, Akt), (Androgen, 
glucocorticoid, progesterone receptors) and (mTOR, PI3Kalpha) were obtained 
from Eli Lilly pharmaceutical company. The TGFβ1 used at 200 pM, was 
obtained from R&D Systems. TGFβR1 inhibitor, SB431542 used at 2 or 4 µM, 
was obtained from TOCRIS Bioscience.  
 
2.14 Quantitative RT-PCR 
RNA was isolated using TRI Reagent® (Sigma-Aldrich) and reverse transcribed 
into cDNA using the Superscript® III First-Strand Synthesis System kit (Life 
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Technologies). Cycle parameters were: 38 cycles of 95 oC for 10 seconds, 55 oC 
for 10 seconds, and 72oC for 5 seconds. Each real-time PCR was done in 
triplicate, and the level of expression of each gene was determined relative to the 
normalizer gene, hypoxanthine phosphoribosyltransferase (HPRT). Real-time 
PCR was performed on Applied Biosystems 7900HT Fast Real-Time PCR 
System using SYBR® Select Master Mix (Life Technologies) with the following 
primers:  
ST3GAL1 Forward: 5’- CCTCCTTCTTCCTGAACTACTC -3’ 
ST3GAL1 Reverse: 5’- TGGTGTCATTCAAGTTATTGGG -3’ 
FOXM1 Forward: 5’- CCTTTGCGAGCAGAAACGGG -3’  
FOXM1 Reverse: 5’- CTTAACCTGTCGCTGCTCCAG -3’ 
HPRT Forward: 5’- CACTGGCAAAACAATGCAGACT -3’ 
HPRT Reverse: 5’- GTCTGGTTATATCCAACACTTCGT -3’ 
 
2.15 Co-immunoprecipitation assay 
Protein lysates were pre-cleared by incubating 1 mg of protein with sepharose 
beads (Protein A-Sepharose®; Zymed Laboratories Inc.). Subsequently, protein 
lysates were incubated overnight with agitation at 4oC using 5 µg anti-Flag 
(Sigma), anti-FoxM1 (Santa Cruz) or anti-PLK1 (Invitrogen) antibody. Fresh 
sepharose beads were then added to the protein-antibody mixture and incubated 
at 4oC with agitation. Sepharose beads were collected and washed 3 times with 
lysis buffer. The beads were subsequently resuspended and boiled in 2x SDS 
loading buffer (4% SDS, 20% Glycerol, 0.15 M Tris-HCl (pH6.8), 0.05% 
Bromophenol Blue, 20% β-mercapthoethanol) prior to gel loading. 
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2.16 Ubiquitination Assay 
HEK-293T cells were co-transfected with pCMX-CyclinB1-Myc (Addgene plasmid 
26060) and pLKO.1-ST3GAL1 knockdown constructs [shST3GAL1 clone 1 
(TRCN0000035551) and shST3GAL1 clone 2 (TRCN0000035552)]. Cells were 
lysed in buffer containing 1% NP-40 detergent, 10% glycerol, 0.15 M NaCl, 50 
mM Tris-HCl (pH 7.4), protease and phosphatase inhibitor cocktail tablets 
(Roche). Protein lysates were pre-cleared by incubating 1 mg of protein with 
sepharose beads (Protein A-Sepharose®; Zymed Laboratories Inc.). 
Subsequently, the beads were removed by centrifugation, and the lysates were 
immunoprecipitated by incubating overnight with agitation at 4oC with 5 µg anti-
Myc antibody (Sigma). Fresh sepharose beads were then added to the protein-
antibody mixture and incubated at 4oC with agitation. Sepharose beads were 
collected and washed 3 times with lysis buffer. The beads were subsequently 
resuspended and boiled in 2x SDS loading buffer prior to gel loading. The extent 
of ubiquitination was then analyzed via immunoblotting. 
 
2.17 Statistical analysis  
All grouped data were calculated as the mean ± standard error of the mean 
(S.E.M). Statistical significance was performed using paired Student’s t-test, 
unless otherwise indicated. Kaplan-Meier survival curves were analyzed using 
the log-rank test with Prism 5 (GraphPad Software, San Diego, CA). The 
statistical significance of correlation was evaluated using Spearman's rank 
correlation test. Unless otherwise stated, all the experiments were performed at 
least 3 times.  
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2.18 Bioinformatics analysis (with help from Edwin Sandanaraj, Senior 
Research Fellow in bioinformatics at NNI) 
2.18.1 Microarray data processing and analysis 
The PNA-sorted GPC profiles were hybridized on Illumina Human Ref-8v2 bead 
chips to study the impact of transcriptome pattern upon PNA affinity. The 
intensity value was measured using Genome studio software. The R/lumi 
packages were deployed to process the data and the data was normalized with 
variance stabilizing algorithm (Durbin et al, 2002). The non-exonic probes were 
trimmed off and the data was quantile-normalized using R/Biobase packages 
(Gentleman et al, 2004). The PNA-negative group included the expression 
profiles from both PNA-negative and lo profiles. Similarly the PNA-positive group 
combined the profiles from both PNA-positive and mid profiles. A linear model 
was fitted to detect the altered transcripts between PNA negative and positive 
using R/limma packages (Smyth, 2005). A false discovery rate (FDR) adjusted p-
value of <0.001 was considered to identify the transcripts that were significantly 
different between the experimental groups.  
The ST3GAL1 knockdown (KD) pellets of GPCs were profiled on Affymetrix 
GeneChip® Human Genome U133 Plus 2.0 Array using 3' IVT express kit. Raw 
cel files were summarized with mas5 algorithm and log2-scaled and gene 
expression dataset was created. Principal Component Analysis (PCA) was 
performed to assess for detectable batch effect or significant quality defect in our 
microarray datasets. All data pre-processing analysis was carried out by 
R/bioconductor packages. A linear model was regressed to assess the 
differentially expressed genes between KD clones and control profiles as 
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described in R/limma packages. FDR adjusted p-value of <0.05 with 1.5-log fold 
difference were considered as significantly perturbed genes upon ST3GAL1 KD. 
A subset of differential genes was extracted as ST3GAL1 KD gene signature by 
applying a stringent criterion of 2-log fold-change between KD clones and the 
control profiles. 
2.18.2 Predictive database analysis 
The combined list of genes including PNA-specific genes and ST3GAL1 KD gene 
signature was coined as ST3GAL1-associated gene signature. The ST3GAL1-
associated gene signature was applied on major glioma databases to predict the 
primary tumor samples having enriched transcriptome profile as in ST3GAL1-
associated gene signature using Connectivity Map approach as described 
previously (Koh et al, 2013; Ng et al, 2012; Yeo et al, 2012). The permutation-
based enrichment p-value of <0.1 was considered as significant to extract the 
enriched patients with identical/contrary signature profiles. Patients with positive 
and negative activation scores tended to have low sialylation (identical to 
ST3GAL1 KD signature) and high sialylation (contrary to ST3GAL1 KD signature), 
respectively. Kaplan-Meier survival curves were plotted to show the survival 
differences between patient groups. A log-rank test was adapted to estimate the 
survival difference between the high sialylation patient group and low sialylation 
patient group. Multivariate Cox Regression model was fitted to identify the 
significant clinical covariates associated with survival. A p-value of less than 0.05 
was defined as significant association of covariates for survival. 
42 
 
2.18.3 Pathway analysis 
Metacore from GeneGo Inc. was mined to identify the significantly enriched 
biological pathways for the differential genes identified. The pathways with 
significant enrichment p-values of less than 0.05 were reported as significantly 
enriched pathways or regulatory networks. The top 5 enriched pathways were 
considered for functional evaluation in our experiments. 
2.18.4 Functional gene module analysis 
To identify the functional gene modules of ST3GAL1, we performed preliminary 
analysis on public glioma databases. The mRNA expression of ST3GAL1 was 
ranked and categorized into 3 groups as high, intermediate and low according to 
their terciles. Gene Set Enrichment Analysis (GSEA) was performed on the 
genome-wide transcriptome profiles of high ST3GAL1 and low ST3GAL1 patient 
groups of REMBRANDT (Madhavan et al, 2009) and Gravendeel (Gravendeel et 
al, 2009) using the GSEA tool downloaded from Broad Institute portal 
(http://www.broadinstitute.org/gsea/index.jsp) (Subramanian et al, 2005). The top 
5 genesets with enrichment p-values of less than 0.05 were extracted from 2 
independent databases. The core gene markers were identified from the 
common signatures across the databases. Reactome pathway analysis was 
performed to identify the gene modules linked with Reactome clusters using 
ReactomePA package in R (Matthews et al, 2009; Yu, 2013). A significant p-




2.18.5 Interaction studies of sialylation status, tumor T2 volume and tumor 
grade 
MRI image files were obtained from The Cancer Imaging Archive 
(http://cancerimagingarchive.net/) sponsored by the Cancer Imaging Program, 
National Institute of Health, U.S.A. MRI data from REMBRANDT database were 
available for 43 patients belonging to the earlier sialylation cohorts. The volume 
of T2 hyperintensity surrounding tumor mass (T2 volume) for the sialylation 
cohort were calculated by subtracting the volume of entire lesion and volume of 
tumor alone. The T2 volume was dichotomized based on the median T2 volume 
value. Big and small invasion group patients were regarded as those having 
higher and lower T2 volume values than the median, respectively. To understand 
the interactions between T2 volume, sialylation status and tumor grade, a three-
way contingency analysis was performed using the log-linear model. A graphical 
representation was constructed using a mosaic plot to illustrate the interactions 
between these categorical variables as described (Friendly, 1994). Mosaic plots 
were generated using R statistical packages called "vcd" and "vcdExtra" (Achim 























CHAPTER 3 – GLIOMA-PROPAGATING CELLS REPRESENT A CLINICALLY 
RELEVANT CELLULAR PLATFORM TO STUDY GLIOMA DISEASE 
3.1 Introduction and Objectives 
Gliomas represent the most prevalent of primary adult malignant brain 
tumors and have a poor prognosis despite advanced surgical intervention and 
adjuvant radiotherapy and chemotherapy (Louis et al, 2007). Such devastating 
nature of the disease has been attributed to its highly aggressive and infiltrative 
features. Additionally, the highly recurrent and heterogeneous nature of the 
disease has prompted much research into the origin of gliomas.  In transgenic 
models, the glioma cell-of-origin has been demonstrated to be the 
oligodendrocyte progenitor cell (OPC) or neural stem cell (NSC) (Alcantara et al, 
2002; Liu et al, 2011; Zheng et al, 2008). In glioma xenograft models, significant 
enrichment of tumor formation has been shown to arise from implantations of 
flow-sorted cells expressing various markers such as CD133 and SSEA-1 (Singh 
et al, 2004; Son et al, 2009). These data provide strong evidence for the 
existence of cellular hierarchy within tumor mass.  
In recent years, stem-like GPCs have been prospectively isolated from 
human glioblastoma specimens and maintained as spheroid cultures 
(gliomaspheres) in serum-free medium supplemented with growth factors (Galli 
et al, 2004; Singh et al, 2004). Such cells may comprise a subpopulation of the 
bulk tumor, exhibiting extensive self-renewal, and are capable of initiating and 
sustaining tumor growth. The importance of studying GPCs is further highlighted 
by work from Lee et al. and Wakimoto et al. where they showed that patient-
derived GPCs contain phenotypic and karyotypic hallmarks of their parental 
primary tumors (Lee et al, 2006; Wakimoto et al, 2012). Moreover, our lab 
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demonstrated that patient-derived GPCs contain transcriptomic information that 
can dictate the primary tumor behavior (Ng et al, 2012). Essentially, we were 
able to determine signaling pathways governed by gene programs differentially 
expressed between 2 major brain tumor variants. We further validated the 
functionality of these predicted pathways in our primary tumors and GPCs. More 
importantly, xenografts established from GPCs are able to recapitulate the 
pathophysiology of the original tumor.  GPCs are thus important in vitro “replicas” 
of human tumors that can be prospectively tested with new candidate 
compounds, yet have retrospective clinical history, gene expression, and paraffin 
tissue blocks for mining prognostic indications.  
Furthermore, The Cancer Genome Atlas (TCGA) effort showed that 
histologically similar GBM tumors can be molecularly classified into 4 classes, 
each with distinct gene expression profile, karyotypic aberrations and clinical 
outcome (Verhaak et al, 2010). The 4 classes can also be distinguished by 
mutations in 3 major signaling pathways: Retinoblastoma (Rb), Receptor 
Tyrosine Kinase (RTKs) and TP53 tumor suppressor (Research, 2008). (Atlas, 
2008). In support, relying on TCGA data, Wiedemeyer et al. showed that the 
pattern of Rb pathway inactivation dictated response to a class of CDK4/6 (cell 
cycle-related) inhibitors in GBMs (Wiedemeyer et al, 2010). Thus, these findings 
indicate that histology-based grading of gliomas may be limited and highlights the 
necessity to molecularly subtype tumors for targeted therapy. Consequently, 
complementary approaches encompassing patient-derived GPCs and their 
corresponding xenograft tumors are needed to recapitulate the patient 
heterogeneity spectrum of brain tumors in research.  
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Recent literature implicates GPC subtypes that initiate tumor growth 
irrespective of CD133 status (Beier et al, 2007; Joo et al, 2008; Wang et al, 
2008b). Lottaz and colleagues demonstrated the utility of a 24-gene signature 
derived from GPCs that segregated these tumor-propagating cells into type I 
(Proneural) and type II (Mesenchymal) classes (Lottaz et al, 2010), each 
characterized by distinct signaling pathways. Importantly, these 2 classes of 
GPCs mapped to either adult or fetal normal neural stem cells, suggesting that 
GPCs develop differently and possibly arise from different cells-of-origin. 
Understanding the molecular profiles of GPCs can thus help to better understand 
the development of gliomas, the heterogeneity of these tumors, and the variable 
prognosis of GBM patients. This will lead to the development of more 
personalized and improved therapies targeting the tumor at its root, the GPCs. In 
this chapter, we will provide evidence that our GPCs are clinically relevant and 
present a useful cellular model to study glioma disease progression. 
 
3.2 GPCs form tumor xenografts that recapitulate the patient’s tumor 
pathophysiology 
We previously showed that GPCs can be isolated from human 
glioblastoma specimens and maintained as spheroid structures in serum-free 
medium containing growth factors (Chong et al, 2009). GPCs express stem cell-
like markers and are capable of differentiating into astrocytes, neurons and 
oligodendrocytes, thereby exhibiting multipotentiality. Importantly, when 
stereotaxically implanted into immune-compromised mice, GPCs formed tumors 
that recapitulated the actual human disease morphology (Figure 3.1A). These 
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xenografts were highly infiltrative and hemorrhagic, demonstrating features such 
as pseudopalisades, necrosis and increased vascularity. In contrast, xenografts 
formed from commercially procured American Type Culture Collection (ATCC) 
glioma cell line, U87MG (grown in serum-containing medium), displayed well-
delineated tumor margins and were spatially constrained, non-reflective of GBM 
pathophysiology (Figure 3.1B). Others have also shown that serum-grown 
glioma cells contain chromosomal aberrations not found in the original primary 
tumors, likely caused by in vitro passage artifacts (De Witt Hamer et al, 2008). 
These data highlight the importance of our GPCs as the representative model 
cellular system to study. 
 
Figure 3.1. Glioma-propagating cells are representative cell system to study glioma 
disease. A, Glioblastoma multiforme GPC intracranial xenograft exhibited extensive 
infiltration (black arrow head) and hemorrhaging, typically found in patients with invasive 
glioma. Scale bar = 100 µm. B, Intracranial xenograft established from serum-grown 
U87MG displayed spatially constrained, well-delineated tumor margins, non-reflective of 
human GBM disease pathology. Scale bar = 100 µm. 
 
3.3 GPC subclasses are distinguished by key signaling pathways 
Recent literature implicates GPC subtypes that initiate tumor growth irre-
spective of CD133 status (Beier et al, 2007; Joo et al, 2008; Wang et al, 2008b). 
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These subtypes were largely classified according to gliomaspheres that exhibited 
adherent or free-floating growth patterns. Notably, much of such GPC subtyping 
depended on mainly phenotypic characteristics, a rather subjective criterion. 
Recently, Beier et al. demonstrated the utility of a 24-gene signature derived from 
GPCs that segregated these cells into Type I (Proneural) or Type II 
(Mesenchymal) classes (Lottaz et al, 2010). Importantly, the authors were able to 
map GPC molecular profiles to the patients’ original tumor molecular profiles 
defined by major genomic efforts such as TCGA and the “Phillips” molecular 
classification scheme (Phillips et al, 2006). These findings are significant as they 
suggest that patient-specific GPCs dictate their respective primary tumor 
phenotype and molecular signaling pathways. We thus sought to utilize gene 
expression analyses to characterize our GPC collection with respect to 
international GPC collections by other investigators (Beier et al, 2007; Gunther et 
al, 2008; Lottaz et al, 2010; Pollard et al, 2009). This is an important approach 
because grouping our GPCs with international databases allows us to reliably 
connect the GPCs to their respective primary tumors and determine molecular 
pathways that might distinguish the molecular subtypes. As gene expression 
drives glioma disease progression and survival outcome (Verhaak et al, 2010), 
we analyzed the molecular patterns of our GPCs by 2 independent and 
complementary methods: Performing an unbiased hierarchical clustering (Figure 
3.2), as well as clustering based on the known 24-gene signature (Figure 3.3A) 
(Lottaz et al, 2010). Our data indicate that all our GPCs (except for NNI-9, 10, 
and 11 which are mesenchymal) are proneural, and importantly, our unbiased 
hierarchical clustering correctly segregated all published GPC lines according to 
their classes as previously defined (Figure 3.3B) (Gunther et al, 2008; Lottaz et 
al, 2010; Pollard et al, 2009).  
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Most importantly, we noted that proneural GPCs are upregulated in key 
genes such as ASCL1 and DLL3, previously documented as proneural genes in 
GBM tumor molecular classification by TCGA (Verhaak et al, 2010). In contrast, 
proneural GPCs are down-regulated in the transforming growth factor beta 
(TGFβ) signaling pathway. The mesenchymal GPCs demonstrate robust 
expression of TGFβ response genes such as TGFBI and COL1A2 (Lottaz et al, 
2010; Xu & Kapoun, 2009). These data suggest that our GPC collection contains 
biological and signaling pathways consistent with published literature. In addition, 
the ability to molecularly subtype our GPCs is important as it identifies signaling 
pathways potentially important in the therapeutic targeting of self-renewing GPCs 
within the heterogeneous tumor mass.  
 
 
Figure 3.2. Glioma-propagating cells can be grouped into 2 major subtypes – 
proneural or mesenchymal. An unbiased whole transcriptome hierarchical clustering 
based on a non-parametric rank-sorted binning (500 quantile bins) of each expression 
dataset, using a spearman rank correlation distance metric and complete linkage. 
Grouping of GPC samples into Type I (Proneural) represented as dark blue bar and Type 
II (Mesenchymal) represented as light blue bar, based on classification by Lottaz et al. 




Figure 3.3. GPC subtypes can be distinguished by key signaling pathways. A, 
Heatmap clustering of 4 GPC datasets based on a signature of 24-genes published by 
Lottaz et al. Clustering was based on spearman rank correlation distance of a non-
parametric rank-sorted binning (500 bins/sample) of gene level averaged expression data 
for each dataset. Notably, our GPC collection (underlined in red), along with several other 
groups’ GPCs, segregated into 2 distinct molecular subtypes: proneural and 
mesenchymal. B, 2D principal component analysis (PCA) of spearman rank correlation 
distance between the models in each of the GPC datasets. Distinct segregation of 
proneural (denoted by triangles) and mesenchymal (denoted by squares) groups from all 
4 GPC datasets was observed. 
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 Next we asked if the GPC molecular classification corresponds to the 
molecular subgroups of glioma patients. This is important as it validates the use 
of GPCs as a clinically relevant cellular platform. To address this, we interrogated 
the GPC mesenchymal gene signature (Figure 3.4A) derived from differentially 
expressed genes between mesenchymal and proneural GPCs, for patterns of 
association with individual patient gene expression data in the glioma databases, 
REMBRANDT (Madhavan et al, 2009) and Gravendeel (Gravendeel et al, 2009). 
We observed that the GPC mesenchymal gene signature stratified survival of 
glioma patients, with mesenchymal-like patients correlating with poorer prognosis 
(Figure 3.4B; REMRANDT p-value=9.6e-13; Gravendeel p-value=3.65e-11). 
More importantly, the GPC mesenchymal signature classes showed significant 
correlation with patient molecular subgroups predicted using the Phillips et al. 
classification scheme (Phillips et al, 2006), indicating the molecular signaling 









Figure 3.4. GPC mesenchymal gene signature stratifies survival in glioma patients. 
A, Heatmap clustering of 4 GPC datasets using GPC mesenchymal gene signature 
derived from comparing mesenchymal GPCs and proneural GPCs. B, GPC 
mesenchymal gene signature stratifies survival in REMBRANDT (hazard ratio, HR=2.62; 








Table 3.1. Contingency analysis of GPC mesenchymal signature classes and 
Phillips molecular classes 
 
 
3.4 GPCs possess common oncologic signaling pathways and 
represent a clinically relevant cellular platform for drug screening efforts 
(collaborative effort with Eli Lilly Singapore)  
Our initial Principal Component Analysis (PCA) indicated that GPCs 
possess a different transcriptomic expression profile from the primary tumor 
which is composed of a mix of relatively undifferentiated and more committed cell 
lineages. This highlights that conventional therapeutic approaches may not 
accurately target the GPC fraction. Traditional drug screening efforts typically 
involve the use of commercially procured cell lines grown in serum-containing 
media. Since serum is known to induce differentiation of GPCs, drug screening 
using cells grown under serum-conditions may not be the most ideal method. 
Furthermore, commercially procured glioma cell lines form tumor xenografts that 
are non-reflective of the original tumor profile, and they often contain additional in 
vitro passage-induced cytogenetic aberrations (Lee et al, 2006). It has been 
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shown that patient-derived GPCs contribute to tumor initiation and propagation 
by extensive stem-like self-renewal traits. Indeed, Piccirillo et al. demonstrated 
that GPCs exposed to the differentiative effects of bone morphogenetic proteins 
(BMPs) resulted in tumor growth cessation and subsequent involution (Piccirillo 
et al, 2006). In addition, a recently discovered proto-oncogene Pleiomorphic  
Adenoma Like 2 (PLAGL2) has been found to promote tumor growth by blocking 
differentiation, and sustaining GPC self-renewal via the Wnt signaling pathway 
(Zheng et al, 2010). These data strongly implicate GPCs as the culprits 
responsible for perpetuating tumor growth, and underscore the need to design 
better therapeutics aimed at eradicating this self-renewing population. To 
understand the signaling mechanisms regulating GPCs, we treated our cells with 
small molecules targeting common oncologic pathways. We observed that 
compounds targeted against recently published GPC signaling pathways 
reduced the viability of the cells significantly (Anido et al, 2010; Eyler et al, 2008; 
Fan et al, 2006). This validates that our repository of patient-derived GPCs 
shares common molecular profiles expected of various molecular subtypes, and 
more importantly, can be targeted by small molecules aimed at eradicating the 
small but relevant cellular population. 
Small molecule inhibitors (inhibitory concentrations ranging from 0.1 to 10 
µM) that were effective against GPCs included compounds targeting the 
phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway (Figure 3.4A-C, Table 
3.1). We observed that effective concentrations for our GPC lines corresponded 
to the low in vitro biochemical half maximal inhibitory concentration (IC50) values 
of the small molecule candidates, indicating preference for selective targeting 
over non-specific toxicity effects. Hyperactive PI3K-AKT signaling promotes 
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tumorigenic cell behavior in gliomas by increasing cell survival, proliferation, 
invasion and angiogenesis (Castellino & Durden, 2007; Hambardzumyan et al, 
2008; Knobbe et al, 2005). Eyler et al. demonstrated  that inhibition of the PI3K-
AKT pathway using small molecule inhibitors against PI3K, AKT or its 
downstream target mTOR (at approximately IC50 doses, Table 3.1) preferentially 
targeted the CD133-expressing GPC fraction, with concomitant apoptosis and 
reduction in GPC frequency and invasiveness, ultimately translating to prolonged 
survival of xenografted mice (Eyler et al, 2008). These data are consistent with 
an activated PI3K-AKT signaling in our GPCs. In addition, we observed that not 
all GPC lines were uniformly inhibited, suggesting the exciting notion that patient-
specific GPC subtypes may contribute to clinical heterogeneity in treatment 
response. In support, our recent work in the field of reactive oxygen species 
(ROS) discovered subtype-specific GPCs driving ROS-induced chemoresistance 
properties (Koh et al, 2013). 
 






In contrast, we observed no such reduction in viability (up to 10 µM) using 
small molecules targeting the androgen receptor (AR), glucocorticoid receptor 
(GR) and progesterone receptor (PR), common therapeutic targets in well-
established, hormone-driven breast and prostate cancers (Figure 3.4A). Indeed, 
these receptor types are present in a small collection of astrocytic neoplasms 
(Carroll et al, 1995). However, no effective clinical therapy has borne out to-date. 
In agreement, the high IC50 values for these compounds indicate that GPCs are 




Figure 3.5. GPC viabilities after treatment with small molecule inhibitors of key 
signaling pathways.  The design of this viability-based screen using gliomaspheres 
treated with candidate compounds was adapted from Diamandis et al. Viabilities were 
measured 7 days post compound treatment using standard AlarmaBlue® assay. At 10 
µM (A), GPC lines which demonstrated less than 20% viability were re-screened at 1 µM 





We provide evidence that our GPCs represent a clinically relevant cellular 
platform for investigative glioma studies. More importantly, we and others have 
found that GPC molecular subclasses can be distinguished by key signaling 
pathways such as TGFβ, Wnt and Notch (Ng et al, 2012). This is an important 
concept as we engage in further efforts to determine the GPC contribution to 
disease outcome, i.e. brain tumor patients should be treated according to their 
molecular profiles depicted by GPCs. Although the lengthy in vitro growth 
process of GPCs precludes their use as diagnostic tools, our findings point 
towards how mapping of the primary tumor-GPC relationship determines which 
signaling pathways must be targeted to eradicate the GPC subpopulation. In 
addition, we validated that our GPCs can be utilized for drug screening efforts 
and possess signaling mechanisms consistent with published literature. Taken 
together, our repository of patient-derived GPCs represents a valuable resource 
























CHAPTER 4 – HIGH SIALYLATION STATUS CORRELATES WITH GPC PRO-
SURVIVAL TRAITS AND PORTENDS POOR PROGNOSIS IN GLIOMA 
PATIENTS 
4.1 Introduction and Objectives 
Our earlier work demonstrated the significance and value of a patient-
derived GPC repository. GPCs are important because they recapitulate the 
primary tumor phenotype and molecular profile. Importantly, therapeutic targeting 
of GPC-like traits is likely to lead to long-lasting and curative treatment. For these 
reasons, much effort has been focused on identifying GPCs. Several markers 
have surfaced over the past decade (e.g. CD133 (Singh et al, 2003), CD15 (Son 
et al, 2009), aldehyde dehydrogenase (Rasper et al, 2010), Integrin α6 (Lathia et 
al, 2010), side population (Bleau et al, 2009)); however, many such markers are 
also present on normal cells. Consequently, there is a clear need to discover 
tumor-specific surface expression that marks GPCs. In our study, we initially 
focused our efforts on identifying novel GPC markers, relying on the complexity 
and unique presentation of cell surface carbohydrate moieties. 
Glycosylation represents one of the most prevalent post-translational 
modifications. Glycosylation, in general, can be divided into 2 types: O-
glycosylation, where the sugar moiety is bound to the hydroxyl group of a serine 
and/or threonine residue, and N-glycosylation, where the sugar is attached to the 
amide group of an asparagine residue (Kleene & Schachner, 2004). It is 
estimated that over half of all human proteins are glycosylated, with resultant 
carbohydrate side chains having complex oligosaccharide sequences and 
structure diversity, mainly arising from the abundant monosaccharide structures 
existing in nature. Such modifications are important for normal biological function 
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of the cells; for example, signal transduction, protein folding, cell-cell 
communication and interaction.  It has been demonstrated that a wide variety of 
human cancers has altered patterns of glycosylation and express aberrant 
glycosyl epitopes on their cell surface glycoconjugates. More importantly, these 
carbohydrates play key functional roles in oncogenic transformation, as well as in 
key events such as induction of invasion and metastasis.  (Hakomori, 2002).  
In the developing and adult nervous system, surface glycans have been 
shown to play important roles in neural cell interactions. Furthermore, the 
extensive structural diversity of glycan chains allows immense combination 
possibilities for involvement of diverse cell functions, such as neurite outgrowth, 
migration synapse formation and stabilization, modulation of synaptic efficacy 
and cell-matrix interactions (Kleene & Schachner, 2004). Clearly, 
glycoconjugates play important roles in biological processes in the brain. Given 
its diverse functions and structural combinations, one would anticipate unique 
presentation of cell surface glycans on malignant brain tumor cells as compared 
to normal neural cells. Indeed, previous literature highlights that brain tumors 
have altered expression of different glycotransferases, genes that control the 
biosynthetic machinery of glycoconjugates (Dawson et al, 2004; Kaneko et al, 
1996; Xu et al, 2001; Yamamoto et al, 1997; Yamamoto et al, 2000) and exhibit 
modified presentation of specific glycoconjugates (Comas et al, 1999; Hamasaki 
et al, 1999; Jennemann et al, 1994; Ladisch et al, 1997; Mennel & Lell, 2005; 
Traylor & Hogan, 1980; Wikstrand et al, 1991). 
Here, we ask whether GPCs can present unique cell surface patterning 
conferred by glycan molecules. We hypothesize that such glycosylation profiles 
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can mediate the tumorigenic process by facilitating interactions between key 
glioblastoma regulatory modules and stem cell-like processes. 
 
4.2 Screen for lectins that bind differentially between stem-state and 
differentiated GPCs 
 Lectins are carbohydrate-binding proteins that are highly specific for 
sugar moieties and have been widely used to study carbohydrate chemistry on 
the cell surface, as well as in the isolation and characterization of glycoproteins 
(Sharon & Lis, 2004).  We selected a panel of commercially available lectins that 
could possibly exhibit differential staining patterns between stem-state and 
differentiated GPCs (Table 4.1). Consistent with the role of carbohydrate 
changes in cell fate (Solter & Knowles, 1979), we hypothesize that certain lectin-
binding patterns will reveal unique glycobiology driving GPC profiles. 
Furthermore, novel lectin-binding patterns can potentially be utilized to identify 
and isolate GPCs. 




We analyzed the staining pattern of lectins in stem-state and 
differentiated GPC lines, using conditions previously validated in our lab (Figure 
4.1A). Briefly, stem-state gliomaspheres were maintained in serum-free medium 
supplemented with growth factors, while GPCs were induced to differentiate 
upon withdrawal of growth factors with addition of serum. Lectin binding was 
assessed by fluorescence-activated cell sorting (FACS) (Figure 4.1B). The 
percentage differences were computed by percentage positive stains in the stem-
state minus percentage positive stains in the differentiated-state.  We then 
filtered for lectins which demonstrated more than 15% difference in at least 2 of 
the GPC lines tested. We rationalized that this approach would winnow down the 
list to half, with expected “positive controls” such as Peanut Agglutinin (PNA) 
which has been shown to stain mouse normal hematopoietic and neural stem 
cells (Rietze et al, 2001; Salner et al, 1982). As such, 4 lectins (JAC, PNA, WFL 







Figure 4.1. Four lectin candidates demonstrate differential binding patterns 
between the stem- and differentiated-states of GPCs. A, Representative images of 
gliomaspheres cultured in serum-free defined growth media supplemented with growth 
factors or growth media containing 5% FBS for 2 weeks. Scale bar = 50 µm. B, 3D bar 
graph showing the percentage differences of cells staining positive for the various lectins 
between the stem- and differentiated-states using flow cytometric analysis. C, Four lectin 
candidates showed at least 15% difference in lectin-positive staining between stem- and 
differentiated-states in at least 2 of 3 lines tested.  
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Next, we assessed the ability of shortlisted lectins to enrich for GPC 
activity. The neurosphere assay, initially developed to measure neural stem cell 
frequency (Reynolds & Weiss, 1996), was utilized to test for GPC activity. 
Diamandis et al. have shown that the neurosphere assay can reliably determine 
GPC frequency in a small molecule drug screening effort (Diamandis et al, 2007). 
Here, gliomaspheres were dissociated into single cells and allowed to stain and 
flow-sort, according to staining intensities, into each well of 96-well pates at 
clonal densities. Seeding at clonal densities allows us to detect bona fide sphere 
formation from single self-renewing GPCs, as opposed to cellular aggregation 
(Singec et al, 2006).  
Interestingly, we observed that the cellular fraction staining most weakly 
for PNA (PNAlo) was significantly enriched in gliomasphere-forming capacity 
compared to all other lectins (Figure 4.2). PNAlo clearly enriched for GPC 
activity when compared to total unsorted cells (TP, total population), suggesting 





Figure 4.2. Low Peanut Agglutinin (PNA) cellular fraction of GPCs is enriched for 
gliomasphere-forming ability. NNI-2 GPC line was flow-sorted and plated into each 
well of a 96-well plate at clonal density (30 cells/cm2) according to their respective lectin 
staining intensity (The PNA histogram peak was divided into terciles with PNAlo defining 
the lowest tercile, PNAhi defining the highest tercile and PNAmid defining the remaining 
intermediate intensity). The number of reformed gliomaspheres was scored 2 weeks 
post-sorting. Note that the cellular fraction that has low PNA binding has higher 
gliomasphere-forming ability (Red box). TP, total unsorted population; **p<0.01; 
***p<0.001; n = 5. 
 
4.3  Peanut Agglutinin (PNA) staining reveals differential binding and 
function in GPCs 
 Our screening analysis revealed that the gliomasphere fraction staining 
weakly for PNA (PNAlo) is enriched for sphere-forming capacity and hence 
exhibits increased GPC frequency approximated by the neurosphere assay 
(Reynolds & Weiss, 1996). In support, the use of PNA in enriching for mouse 
normal neural stem cells has previously been implicated (Rietze et al, 2001). 
Rietze and colleagues demonstrated that isolation of pluripotent NSCs can be 
significantly enriched by flow-sorting for the PNAlo fraction of adult mouse brain 
68 
 
cells. Although the biological function mediated by the PNA stain is unclear, this 
finding may be relevant as patient-derived GPCs have been demonstrated to be 
phenotypically and transcriptomically similar to normal NSCs (Altaner, 2008). 
This notion is further supported by transgenic mouse models utilizing lineage-
tracing methodologies which implicate NSCs and OPCs as the tumor-initiating 
cells (Alcantara et al, 2002; Jacques et al, 2009; Persson et al, 2010; Zheng et al, 
2008).  
In recognizing that PNA is an exogenous protein isolated from Peanut, 
the screening results could easily be confounded if PNA staining by itself exerts a 
toxic effect on cell growth. Consequently, PNAhi cells with lower gliomasphere-
forming ability and proliferation could be interpreted as a result of excessive toxic 
PNA binding. Thus, a toxicity test was carried out to ensure that PNA has no 
significant effect at inhibiting cellular proliferation. Indeed, we observed no 
significant difference in proliferation of gliomaspheres stained with PNA when 
compared to the unstained cells (Figure 4.3). This further confirms that PNA is 
an inert marker and the functional behavior of the isolated cells is due solely to its 
intrinsic properties.  
Next, we confirmed our findings using additional patient-derived GPCs 
(NNI-2, NNI-4, NNI-8 and NNI-11). We observed that all GPC lines tested stained 
PNA with varying degrees, suggesting that isolation of different cellular fractions 
in each of the cell lines would be possible (Figure 4.4). Consistently, the 
neurosphere assay demonstrated that gliomasphere-forming capacity was 
significantly enriched in PNAlo cells (Figure 4.5A). Furthermore, PNAlo cells 
generally formed larger gliomaspheres, indicating increased GPC proliferation 
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(Figure 4.5B). PNAlo cells also displayed significantly higher invasive capacity, a 
feature consistent with GPCs (Figure 4.5C) (Qiu et al, 2012) . 
 
Figure 4.3. Peanut Agglutinin (PNA) staining does not affect GPC viability. The 
viability of unstained or PNA-stained GPCs was assessed using CellTiter-Glo® assay at 
days 0, 5 and 10. No significant difference in cell viability was observed. n.s., not 
significant (p>0.05, n = 3).  
 
 
Figure 4.4. Peanut Agglutinin (PNA) binding profile in GPCs. Four patient-derived 
GPC lines (NNI-2, NNI-4, NNI-8 & NNI-11) were stained with PNA and their respective 





Figure 4.5. PNAlo cellular fraction of GPCs enriches for in vitro self-renewal and 
invasive potential. A, Gliomasphere-forming ability was evaluated in unsorted total 
population (TP) and PNA-sorted, patient-derived GPC lines (i, NNI-2; ii, NNI-4; iii, NNI-8; 
iv, NNI-11). The PNA histogram peak was divided into terciles with PNAlo defining the 
lowest tercile, PNAhi defining the highest tercile and PNAmid defining the remaining 
intermediate intensity. **, p<0.01; ***p<0.001 (n=3). B, Gliomasphere size distribution 
was measured in TP and PNA-sorted cells of NNI-2, 4, 8 and 11 GPC lines. C, Invasive 
capacity was determined in TP and PNA-sorted GPCs of NNI-2, 4, 8 and 11 GPC lines. *, 




4.4  PNA binding is mediated by ST3Gal1 sialyltransferase 
As GPCs are mainly defined by their capacity to serially propagate tumors, 
we proceeded to determine the tumorigenic capacity of our cells in orthotopic 
mouse models. Mice implanted with different PNA cellular fractions died within 2 
weeks post-implantation (Supplementary Figure S1). Mice implanted with 
unstained GPCs continued to live till presentation of neurological deficits with 
development of tumors. Histological analysis of the mice that died prematurely 
showed signs of immunologic lesions in brains, consistent with the role of PNA at 
eliciting T cell lymphocyte response (Priatel et al, 2000).  Thus, we surmised that 
implanted GPCs stained with PNA triggered an immunological response that 
caused premature mouse death.  
While the identification of cancer stem cell markers has led to important 
advances in the field, each of these markers has limitations that have fueled 
debate, and the use of marker expression to identify CSCs has generated 
conflicting data such as in situations where mouse strains, the use of an 
extracellular matrix protein have confounded data interpretation (Quintana et al, 
2008). These findings suggest that cancer stem cells may simply be a result of 
modifying external conditions, rather than reflect bona fide tumor-initiating and 
sustaining capability. Indeed, brain tumor markers such as CD133 are debatable 
as tumors have also been shown to arise from CD133-negative cells in a subset 
of GBM tumors (Beier et al, 2007). In addition, CD133 expression changes with 
cell surface sialylation, disease state and progression, highlighting the limitations 
of relying solely on cell surface markers to define the GPC (Kemper et al, 2010; 




To determine the gene responsible for mediating differential PNA binding 
patterns, we flow-sorted PNA-lo, mid and hi GPCs, and subjected them to 
microarray gene expression analysis. We derived a gene signature that could 
stratify the various PNA-sorted fractions, as well as stratify patient survival in 2 
public clinical databases (Figure 4.6Ai). We rationalized that the latter approach 
would allow us to identify clinically relevant gene candidates, as well as offer 
greater statistical power than our limited collection of GPCs. ST3GAL1, a 
sialyltransferase, was identified as the most significant differentially regulated 
gene in the 6-gene signature, which could most likely account for the differential 
PNA binding pattern. Consistent with this, PNA is routinely used as a marker of 
intrathymic T cell development (Ball et al, 2010; Nyambura et al, 2011; Pereira et 
al, 1976). Immature cortical thymocytes express abundant non-sialylated core 1 
O-glycans, which are the preferred ligands of PNA, thus giving rise to the PNAhi 
phenotype. As these thymocytes mature and express increasing levels of 
ST3Gal1, the core 1 O-glycans become sialylated and non-recognizable by PNA, 
thus accounting for PNAlo staining (Didic et al, 2010; Felician & Ghaly, 2011; 
Prins et al, 2011; Zampetti et al, 2010). Importantly, the functional significance of 
this glycosylation change detected by PNA was demonstrated in ST3GAL1-null 
mice in which the T cells are constitutively PNAhi (Prins et al, 2011). We thus 
sought to verify the role of ST3Gal1 in our PNA-sorted, patient-derived GPCs. 
We observed that ST3GAL1 mRNA expression correlated inversely with PNA 
staining in all 4 of our GPC cell lines (Figure 4.6Aii). Furthermore, 
immunohistochemical staining of primary brain tumor samples revealed the 
mutually exclusive expression pattern of ST3Gal1 and PNA (Figure 4.6B). Using 
a lentiviral-mediated approach suitable for genetic manipulations in slowly-
dividing stem-like cells, we over-expressed ST3Gal1 (Figure 4.6Ci) and 
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analyzed its effect on the PNA binding pattern. As expected, over-expression of 
ST3Gal1 induced a PNAlo phenotype, resulting in the shift of the PNA peak to 
the left, almost back to the levels of the isotype controls (Figure 4.6Cii). Our data 





Figure 4.6. ST3Gal1 expression confers PNA binding intensity. Ai, Six most 
differentially expressed genes were identified in the gene expression analysis of PNA-
sorted GPCs (NNI-1, NNI-2, NNI-4 and NNI-8). ST3GAL1 (Red arrow) was the only 
glycosylation-related gene implicated in the analysis. Aii, ST3GAL1 mRNA expression 
was determined in PNAlo and hi expression groups of 4 GPC lines: NNI-1, 2, 4 and 8. p-
value=1.58e-6. B, Immunohistochemical staining of ST3Gal1 and PNA was carried out in 
primary brain tumors. Representative images show the mutually exclusive staining 
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pattern of ST3Gal1 and PNA.  Left panel scale bar = 50 µm; right panel insert scale bar = 
20 µm. Ci, Upper panel, FLAG-tagged ST3Gal1 protein was over-expressed in NNI-8 and 
11 GPC lines; lower panel, underwent puromycin selection. Efficient transduction 
efficiency was visualized through the green fluorescent protein (GFP) tag incorporated in 
the vectors. Scale bar = 50 µm. Cii, Flow histograms representing PNA fluorescence with 
defined controls. ST3Gal1 over-expression (black) resulted in shift of PNA fluorescence 
to the left, almost back to levels of isotype controls (orange, blue and red). 
 
4.5  ST3Gal1 expression increases with tumor grade and portends poor 
prognosis in glioma patients 
 Our earlier findings indicate that PNAlo cells possess higher self-renewal, 
proliferation and invasive potential. Importantly, ST3GAL1 is the sialyltransferase 
enzyme responsible for conferring the PNA binding profile. To determine the role 
of ST3Gal1 in the clinical context of glioma tumors, we sought to analyze its 
expression in patient tumors. Although elevated ST3GAL1 expression has been 
reported in several cancers (Burchell et al, 1999; Kudo et al, 1998; Videira et al, 
2009; Wang et al, 2005b), there has been no role ascribed to its expression in 
gliomas.  
As sialyltransferase enzymes are accurately reflected by their 
transcription profiles (Busigny et al, 2010; Llanes et al, 2010), we examined 
ST3GAL1 mRNA expression by in situ hybridization in a collection of 69 clinical 
specimens of which 64 were gliomas of varying grades I-IV, while the remaining 
5 were normal adjacent cerebral tissue. We observed that ST3GAL1 expression 
increased with higher tumor grades (Figure 4.7A). The results were further 
independently confirmed in 2 large clinical glioma databases with patient gene 
expression data, REMBRANDT (Madhavan et al, 2009) and Gravendeel 
(Gravendeel et al, 2009). Similarly, we observed increased ST3GAL1 expression 




Figure 4.7. ST3GAL1 mRNA expression increases with tumor grade. A, Upper panel, 
ST3GAL1 mRNA expression was evaluated in 5 normal adjacent cerebral tissue (NAT) 
specimens and 64 glioma specimens from Grades I-IV. Representative in situ 
hybridization images are shown with staining intensity increased with higher tumor grade. 
Lower panels, images of all clinical specimens were quantified. A greater number of 
patient tumors with high ST3GAL1 expression in higher grades were observed. Fisher 
test p-value=0.03475. B, ST3GAL1 mRNA expression was evaluated in 2 independent 
clinical glioma databases, REMBRANDT and Gravendeel. A greater proportion of 
patients with higher tumor grades correlated with high ST3GAL1 expression 









In addition, we divided patients into 3 groups according to ST3GAL1 
expression (high, intermediate and low), mimicking the tercile approach in PNA-
sorted GPCs. We observed that patients with high ST3GAL1 expression almost 
invariably fared worse than patients who demonstrated down-regulation of 
ST3GAL1 (Figure 4.8). Furthermore, patients with poor prognosis included other 
histologies besides GBM (Grade IV), indicating that ST3GAL1 detects molecular 
heterogeneity in gliomas that cannot be accounted for by histology alone, a 
current clinical indicator (Supplementary Table S2). This underscores the 
limitation of histology-based approaches to diagnose and subsequently treat 
patients. Taken together, we show for the first time that ST3GAL1 expression 





   
Figure 4.8. High ST3GAL1 expression portends poor prognosis in glioma patients. 
All glioma patients in both REMBRANDT (upper panel) and Gravendeel (lower panel) 
databases were grouped according to their ST3GAL1 expression level (low, intermediate 
and high). Patients with high ST3GAL1 expression displayed the worst prognosis. 




4.6  Summary 
Our findings identify ST3Gal1 as a prognostic indicator of glioma disease 
progression. Interestingly, we have unraveled the functional cause behind the 
PNA binding profile of patient-derived GPCs, drawing a parallel with PNA 
staining of mouse normal hematopoietic and neural stem cells. PNAlo enriches 
for GPC activity, and exhibits increased ST3GAL1 expression. Consistent with 
literature that GPCs contribute to tumorigenic growth in lineage-tracing mouse 
models, we now provide clinical correlation that increased ST3GAL1 expression 
portends poor prognosis in glioma patients. Our data suggests the exciting notion 
that tumor growth lies at the heart of sustenance of GPC traits. We will 































CHAPTER 5 – GENETIC KNOCKDOWN OF ST3GAL1 ABOLISHES IN VITRO 
AND IN VIVO TUMORIGENIC POTENTIAL & ST3GAL1 SIGNALING 
ACTIVATION PORTENDS POOR PROGNOSIS IN GLIOMA PATIENTS 
5.1 Introduction and Objectives 
 Earlier, we demonstrated that PNAlo cells display greater gliomasphere-
forming capacity and invasive potential. In addition, we showed that high 
ST3GAL1 expression mediates the PNAlo binding profile, and positively 
correlates with increasing glioma grade, and portends poor prognosis in glioma 
patients. This is the first report demonstrating the association of ST3GAL1 with 
glioma disease progression. 
 Although the ST3Gal1 protein and its role in transferring sialic acids to 
specific substrates have been well-characterized, the functional role of ST3Gal1 
in tumor biology is unclear. Most of the past studies examined ST3GAL1 
expression in various cancers (Burchell et al, 1999; Schneider et al, 2001; 
Videira et al, 2009). With the identification of essentially all of the human 
glycosyltransferase genes having been accomplished, it is probable that more 
reports on the differential expression of such genes will emerge. Nevertheless, it 
will be the functional studies showing a direct connection between altered 
glycoconjugate expression and cellular processes that will have the most impact 
and that are likely to lead to novel therapies 
To evaluate the role of ST3Gal1 in sustaining GPC growth and brain 
tumor formation, we adopted a 3-prong approach: First, we utilized lentiviral 
shRNA technology to knock down ST3GAL1 gene, and assessed its in vitro 
effect on GPC frequency and tumor cell invasiveness. Second, we implanted the 
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knocked down GPCs into immune-compromised mice and assessed the time to 
development of neurological deficits, indicative of tumor load. Lastly, to ascertain 
the role of ST3Gal1 in a clinical context, we relied on gene expression data 
derived from knocked down cells, for the reason that gene expression drives 
brain tumor disease progression (Verhaak et al, 2010), and that signaling 
activation programs are best demonstrated through multiple downstream target 
genes rather than single genes. We adapted the Connectivity Map (CMAP) to 
interrogate the ST3GAL1 KD gene signature for patterns of similarity with patient 
individual gene expression (Lamb et al, 2006). We will provide evidence that 
ST3Gal1 regulates GPC survival and contributes to brain tumor formation and 
patient prognosis. 
 
5.2 Lentiviral-mediated knockdown effectively diminishes ST3GAL1 
expression in GPCs 
To determine the role ST3Gal1 in GPC survival, we carried out lentiviral-
mediated knockdown of ST3GAL1, for the reason that our earlier data implicated 
a high sialylation status in GPCs. We selected the lentiviral approach as a 
genetic manipulation tool because of its effectiveness at transducing both 
dividing and slowly-dividing/quiescent cells, integrating into the host genome for 
sustained, prolonged expression of the gene construct (Uchida et al, 1998). This 
makes them ideal for genetic manipulations in stem-like GPCs with low 
proliferation rates. The lentiviral vector backbone, pLKO.1, has frequently been 
used as a genetic manipulation tool in the study of GPC survival (Figure 5.1A) 
(Guryanova et al, 2011; Hjelmeland et al, 2010; Lathia et al, 2010). Two different 
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shRNA sequences directed against ST3GAL1, and a control NT shRNA were 
used for the knockdown experiments. Both knockdown clones effectively 




Figure 5.1. pLKO.1-based lentiviral shRNAs targeting ST3GAL1 effectively knocks 
down ST3GAL1 expression in GPCs. A, Vector Map of pLKO.1-puro vector used in 
knockdown experiments. Abbreviations: U6, U6 promoter; cPPT, central polypurine tract; 
hPGK, human phosphoglycerate kinase eukaryotic promoter; puroR, puromycin 
resistance gene for mammalian selection; WPRE, Woodchuck Hepatitis Post-
Transcriptional Regulatory Element; SIN/3’LTR, 3’ self-inactivating long terminal repeat; 
F1 ori, F1 origin of replication; Amp R, Ampicillin resistance gene for bacterial selection; 
pUC ori, pUC origin of replication; 5’ LTR,  5’ long terminal repeat; Psi, RNA packaging 
signal; RRE, Rev response element. B, Quantitative real-time RT-PCR analyses of 
ST3GAL1 expression in NNI-11 and NNI-8 GPC lines expressing non-targeting (NT) 
control, shST3GAL1 clone 1 (C1) and shST3GAL1 clone 2 (C2) constructs. ***p<0.001 




5.3 ST3GAL1 depletion reduces GPC stemness marker expression and 
induces cellular differentiation  
Recent findings provide insight into the role of cell fate and tumorigenicity 
of GPCs (Piccirillo et al, 2006). The undifferentiated tumor stem cells retain 
tumor-initiating and propagating activity while the more lineage-committed, 
differentiated progenitors often exit mitosis and senesce, resulting in tumor 
growth cessation and involution. Induction of GPC differentiation has since been 
proposed as a viable therapeutic strategy. Since stem-like GPCs display high 
sialylation status, we examined the effects of ST3GAL1 knockdown on GPC 
stemness profile. We observed that ST3GAL1 knockdown resulted in down-
regulation of the stemness marker, Olig2 (Ligon et al, 2007); and significant up-
regulation of differentiation markers, glial fibrillary acidic protein (GFAP) (Jacque 
et al, 1978) and neuronal-specific class III β-tubulin (TuJ1) (Lee et al, 1990) 
(Figure 5.2A). Consistently, we also observed a decrease in at least 2 common 
GPC markers, CD15 (Son et al, 2009) and ALDH (Rasper et al, 2010) in 2 GPC 
lines tested, while CD133-expressing cells (Singh et al, 2004) were reduced in 
NNI-8 (Figure 5.2B). It should be noted that tumor growth can arise from CD133-
negative cells in a subset of brain tumors (Beier et al, 2007). Furthermore, Gene 
Set Enrichment Analysis (GSEA) revealed that the NT control samples were 
enriched in stem cell signaling modules, indicating the reduction of stemness 
properties in ST3GAL1 knockdown samples (Figure 5.3, Supplementary Table 
1). Collectively, our data demonstrate that ST3GAL1 depletion induces 
differentiation, with concomitant reduction of common GPC marker expression.  
We are currently testing if this reduction in stemness properties is a consequence 





Figure 5.2. Targeting ST3GAL1 expression reduces common GPC stemness 
expression and promotes cellular differentiation. A, NNI-11 and NNI-8 GPC lines 
were subjected to lentiviral-mediated ST3GAL1 knockdown and assessed for protein 
expression of stemness marker, Olig2, and differentiation markers, GFAP and TuJ1. β-
actin acted as the loading control. B, Flow cytometric analyses of common GPC 
stemness markers, CD133, CD15, ALDH and Nestin were determined in NNI-11 (left 
panel) and NNI-8 (right panel) ST3GAL1-depleted GPCs. *, p<0.05; ***, p<0.001 versus 






Figure  5.3. Targeting ST3GAL1 expression reduces GPC stemness programs.  
Gene Set Enrichment Analysis (GSEA) showed that NT control samples are positively 
enriched in the WONG_EMBRYONIC_STEM_CELL_CORE, 
KORKOLA_CORRELATED_WITH_POU5F1 and 






5.4  ST3GAL1 depletion reduces self-renewal capability, viability and 
invasiveness of GPCs  
Next, we assessed the effects of ST3GAL1 knockdown using the in vitro 
gliomasphere-forming, viability and invasiveness assays. GPCs were transduced 
with ST3GAL1-targeting shRNAs and dissociated into single cells, followed by 
flow-sorting into each well of 96-well plates at clonal densities. We observed that 
targeting ST3GAL1 expression significantly decreased the efficiency and ability 
of GPCs to form gliomaspheres, as indicated by the reduction of sphere size 
(Figure 5.4A) and sphere number (Figure 5.4B), both of which measure GPC 
proliferation and frequency respectively under prolonged serial sphere formation 
conditions (Rietze et al, 2001). Such a long-term assay is important to distinguish 
the bona fide slowly-dividing GPCs from faster growing transient progenitors in 
the cell mix. Consistently, targeting ST3GAL1 expression also resulted in 
significant decrease in GPC viability compared to the NT control, as determined 
by the short-term cell viability assay (Figure 5.4C). In addition, the invasiveness 
potential, one of the important features characterizing glioma biology, was also 
mitigated upon ST3GAL1 knockdown (Figure 5.4D, left panel). Consistent with 
this, we demonstrate that paxillin (PAX) and focal adhesion kinase (FAK) cell 
adhesion proteins were dramatically reduced upon gene knockdown (Figure 
5.4D, right panel). Collectively, our data implicate a prosurvival role for ST3Gal1 






Figure 5.4. Targeting ST3GAL1 expression in GPCs reduces gliomasphere-forming 
ability, viability and invasive potential. A, Representative images demonstrating 
reduced gliomasphere sizes and formation in ST3GAL1-depleted NNI-11 (left panel) and 
NNI-8 (right panel) GPCs compared to non-targeting (NT) control. Scale bar = 100 µm.  B, 
Targeting ST3GAL1 significantly attenuated the efficiency of GPCs to form 
gliomaspheres; ***p<0.001 compared to NT control (n=3). C, Targeting ST3GAL1 
decreased GPC viability. **p<0.01; ***p<0.001 compared to NT control (n=3). D, Left 
panel, targeting ST3GAL1 attenuated the invasive potential of GPCs measured by BD 
BioCoatTMMatrigel invasion chamber. ***p<0.001 compared to NT control of 
corresponding GPC line (n=3). Right panel, targeting ST3GAL1 in GPCs reduced the 
expression of cell adhesion proteins, p-PAX, PAX and FAK (n=3). 
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5.5  Targeting ST3GAL1 extends survival of mice bearing xenografts 
established from patient-derived GPCs 
To provide in vivo proof that ST3Gal1 is important for GPC survival as 
well as brain tumor formation, we stereotaxically implanted NNI-11 GPC line 
transduced with non-targeting (NT) control vector or ST3GAL-targeting 
constructs into the right frontal lobes of nonobese diabetic severe combined 
immunodeficient (NOD-SCID gamma or NSG) mice. We observed that all 
animals from the NT control group succumbed to tumor formation by 2 months 
post-implantation. In contrast, animals implanted with ST3GAL1 KD cells 
demonstrated prolonged survival for up to 150 days post-implantation (Figure 
5.5). Collectively our data supports that ST3Gal1 promotes tumorigenic growth in 
mice. 
 
Figure 5.5. Targeting ST3GAL1 decreases GPC tumorigenicity and prolongs the 
survival of mouse glioma model. Upper panel, representative H&E images of mice 
implanted with GPCs bearing non-targeting (NT) control, shST3GAL1(C1) or 
shST3GAL1(C2) vectors. Lower panel, Kaplan-Meier survival analyses demonstrate 
increased survival in mice (ST3GAL1 targeting in NSG mice injected with 500,000 GPCs). 
Scale bar = 500 µm. ***p<0.001 for shST3GAL1(C1) or (C2) groups versus NT group 
with log-rank analysis of survival curves (n=8).  
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5.6  ST3GAL1 signaling activation program portends poor prognosis and 
promotes greater invasive features in glioma patients 
Next, we asked if the activation of ST3Gal1 signaling cascade plays a 
role in the clinical context of glioma patients. To address this, we interrogated the 
differential gene signature derived from ST3GAL1 knockdown of NNI-2, 4, 8 and 
11 GPC lines, for patterns of association with individual patient gene expression 
data in 2 independent glioma databases, REMBRANDT (Madhavan et al, 2009) 
and Gravendeel (Gravendeel et al, 2009). The activation pathway, as defined by 
a set of genes, would be expected to be more representative of downstream 
events than single genes. We adapted the Connectivity Map which allows for 
comparison of data from multi-dimensional platforms (Lamb et al, 2006), as we 
have previously successfully demonstrated (Koh et al, 2013; Ng et al, 2012; Yeo 
et al, 2012).   
Our bioinformatical analyses demonstrated that: (i) The ST3GAL1 gene 
signature stratified survival of glioma patients, with activated ST3Gal1 signaling 
correlating with poorer prognosis (Figure 5.6A; (i) REMBRANDT p-value=2e-08; 
(ii) Gravendeel p-value<1.05e-11). (ii) This survival stratification is independent of 
current clinical indicators such as age and histology (Table 5.1), suggesting that 
ST3Gal1 activation contributes to the molecular heterogeneity of gliomas, 
thereby underscoring the limitation of relying solely on histology to diagnose and 
subsequently guide patient treatment regimens; (iii) ST3Gal1 activation 
correlates with higher grade gliomas of the mesenchymal molecular subtype, 
while down-regulation of the pathway is enriched with tumors of lower grades 
and the proneural molecular subtype (Figure 5.6B).  
91 
 
Since sialylation status has been associated with invasive potential in 
several cancers (Christie et al, 2008; Hsu et al, 2005; Matsushita et al, 1991), we 
hypothesized that ST3Gal1 signaling might predict the invasiveness of gliomas 
characterized by infiltration in the brain parenchyma. In addition, earlier, we 
showed that depletion of ST3Gal1 mitigated the invasive property of GPCs 
(Figure 5.4D). For this study, magnetic resonance imaging (MRI) scans of 
patients were downloaded from REMBRANDT database and their tumor volumes 
were measured. Specifically, we studied aspects of the T2 hyperintensity zone 
surrounding the solid tumor lesion (T2 volume), indicative of infiltrative tumors 
(Kelly et al, 1987). We demonstrate that ST3Gal1 signaling significantly 
correlates with increased tumor T2 volume and higher tumor grade (p=0.000146; 
Figure 5.7). 
Our data provide evidence that ST3Gal1 activation portends poor 
prognosis and promotes the invasive phenotype in glioma patients. Collectively, 
with our animal model, we implicate a prognostic role for ST3Gal1 and further 
suggest that ST3Gal1 may represent a novel target for therapeutic intervention of 











Table 5.1. Cox regression analysis of age, histology and ST3GAL1 knockdown 
signature performed on REMBRANDT and Gravendeel. High sialylation represents 




Figure 5.6. ST3GAL1 activation portends poor prognosis in glioma patients. A, The 
ST3GAL1-associated gene signature stratified survival in (i) REMBRANDT (hazard ratio, 
HR=2.47; p=2e-08) and (ii) Gravendeel (HR=2.89; p<1.05e-11) clinical glioma databases. 
High sialylation represents the patient cohort with up-regulated ST3GAL1-associated 
gene signature, and vice versa. B, The high and low sialylation patient cohorts were 
analyzed for the primary tumor molecular classification scheme specified by Phillips et al. 
(proneural, proliferative, mesenchymal) and histologies (astrocytoma, oligodendroglioma, 
mixed, GBM) in (i) REMBRANDT and (ii) Gravendeel databases. The corresponding 




Figure 5.7. High sialylation status correlates with increased T2 volume and higher 
tumor grade in glioma patients. Mosaic plot showing 3-way contingency analysis of 
sialylation status, T2 volume and tumor grade of patients in REMBRANDT database. 
Size of the box represents the proportion of patients in each category. Boxes colored in 
dark blue denotes >2.0 Pearson deviation from independence. The line colored in red 
denotes the separation between the proportions of high and low sialylation patients within 









Recent literature implicates the role of GPCs in sustaining glioma growth 
and how targeting them may eradicate the extensive self-renewal nature and 
recurrence of the disease (Rich & Eyler, 2008). Our interest lies in how ST3Gal1 
sialyltransferase, identified by our lectin screen of GPCs, promotes glioma 
progression. We demonstrate that ST3Gal1 promotes GPC function and survival, 
and contributes to brain tumor formation in mice. Most notably, the ST3GAL1 
signaling activation gene expression program portends poor prognosis in glioma 
patients, and promotes tumor cell invasiveness. High ST3GAL1 activation maps 
to patients with the mesenchymal molecular profile, previously shown to 
comprise patient cohorts with poor survival and increased recurrence rates. 
Importantly, the ST3GAL1 activation program contributes to the molecular 
heterogeneity of gliomas that cannot be accounted for by histology or age alone. 
This suggests the utility of the ST3GAL1 knockdown gene signature as a 
prognostic tool, and is likely able to identify patients most amenable to anti-































CHAPTER 6 – ST3GAL1 SIGNALING MECHANISM  
6.1 Introduction and Objectives 
Cell surface sialylation confers many roles in cancer biology including cell 
proliferation, invasiveness, metastasis and angiogenesis (Moskal et al, 2009). In 
previous chapters, we showed that ST3Gal1 sialyltransferase expression marks 
a self-renewing cellular fraction. Depletion of ST3GAL1 mitigates glioma cell 
growth and tumorigenicity. However, the mechanistic aspects of what triggers 
ST3Gal1 signaling, and its downstream targets, remain unclear. We will 
determine ST3Gal1-related events in this chapter. 
   To define the mechanism of ST3Gal1 in glioma disease, we recognized 
that our limited collection of patient-derived GPCs would not necessarily 
accurately identify the signaling events. We thus utilized the greater statistical 
power of bioinformatics interrogation in large, independent patient glioma 
databases with gene expression data. We then validated our in silico predictions 
in separate collections of patient tumors and GPC lines. Our approach enables 
us to identify patient cohorts most likely to benefit from anti-ST3Gal1 inhibition 
therapeutic strategies. We further show ST3Gal1 mediates the interaction 
between a key glioma regulatory pathway, TGFβ, and a stem cell module, FoxM1. 






6.2 TGFβ signaling pathway is enriched in patients with high ST3GAL1 
expression 
To determine the upstream mechanism triggering ST3Gal1 activation, we 
relied on a patient-centric bioinformatics approach for greater sample size and 
statistical power compared to our limited collection of GPCs, as well as for 
relevance in a clinical context. We asked which signaling pathways are enriched 
in the highly sialylated patient cohort, which is expected to correlate with poor 
prognosis. The mRNA expression of ST3GAL1 was ranked and categorized into 
3 groups as high, intermediate and low according to their terciles. Gene Set 
Enrichment Analysis (GSEA) was performed on the genome-wide transcriptome 
profiles of high and low ST3GAL1 patient groups in REMBRANDT and 
Gravendeel. The analysis identified the Dazard_Response_to_UV_NHEK_up 
module as the top-ranking module enriched in patients with high ST3GAL1 
expression (Figure 6.1, Supplementary Table S3).  
 
Figure 6.1. Gene Set Enrichment Analysis (GSEA) plot of Dazard_response_to_UV-
NHEK_up module. Patients with high ST3GAL1 expression are positively enriched in the 
Dazard_response_to_UV-NHEK_up module in both REMBRANDT (left panel) and 
Gravendeel (right panel) clinical databases. 
98 
 
The core gene markers from the module were subsequently investigated 
in Reactome pathway analysis to identify the functionally annotated events. The 
analysis demonstrated up-regulation of active TGFβ signaling in the high 
ST3GAL1 patient group (enrichment p-value<0.05, Table 6.1). This is interesting 
as activation of TGFβ signaling has previously been implicated in GPC survival 
and glioma tumor progression (Anido et al, 2010; Penuelas et al, 2009).  
Furthermore, Son et al. demonstrated that TGFβ activation induces ST3GAL1 
expression in porcine kidney cells (Son et al, 2011). Taken together, these 
studies implicate TGFβ signaling as a trigger for ST3Gal1 activation. 




6.3  TGFβ signaling positively correlates with ST3GAL1 expression in 
glioma patients 
To test our hypothesis that TGFβ1 may act as a trigger for ST3Gal1 
activation, we examined the correlation between TGFB1 and ST3GAL1 mRNA 
expression in REMBRANDT and Gravendeel databases. In both cases, we noted 
that there is a statistically significant linear relationship, ST3GAL1 expression 
increases with increasing TGFB1 (REMBRANDT cor=0.31, p<1.55e-11; 
Gravendeel cor=0.5, p<e-11; Figure 6.2A). We further verified this observation 
immunohistochemically by analyzing p-Smad2 staining (downstream effector of 
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TGFβ pathway) and ST3Gal1 staining patterns in a collection of 19 primary 
glioblastoma tumors. Similarly, we found that increasing pSmad2 staining 
correlated with increasing ST3Gal1 staining (cor=0.862, p<0.0001; Figure 6.2B). 
 
Figure 6.2. TGFβ signaling positively correlates with ST3Gal1 expression in glioma 
patients. A, TGFB1 and ST3GAL1 mRNA expression were evaluated in REMBRANDT 
(left panel) and Gravendeel (right panel) clinical databases. A linear correlation was 
observed (REMBRANDT, cor=0.31, p<1.55e-11; Gravendeel, cor=0.50, p<e-11). 
B, TGFβ (p-Smad2 staining) and ST3Gal1 activation were verified 
immunohistochemically in 19 patient GBM tumors. Left panel, representative images of 2 
patient tumors, GBM 26 and GBM 34 are shown. The pattern of ST3Gal1 staining largely 
correlated with p-Smad2 staining. Right panel, images were quantified using the H-score 
method (p<0.0001, cor=0.8621). Scale bar = 100 µm. 
 
When we examined closely for molecular features, ST3GAL1 mRNA 
expression is preferentially enriched in the mesenchymal cohort of glioma 
patients in 5 independent clinical databases tested: REMBRANDT (Madhavan et 
al, 2009), Gravendeel (Gravendeel et al, 2009), Phillips (Phillips et al, 2006), 
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TCGA (Verhaak et al, 2010) and Murat (Murat et al, 2008) (Figure 6.3). 
Consistent with our finding, the mesenchymal molecular profile has previously 
been associated with an enrichment of the TGFβ pathway genes in both patient-
derived GPCs and primary tumors (Lottaz et al, 2010). Our result is novel as we 
implicate a major glioblastoma regulatory module, TGFβ, with cell surface 
sialylation and activation.   
 
Figure 6.3. High ST3GAL1 expression is preferentially enriched in the 
mesenchymal molecular subtype of gliomas. High ST3GAL1 mRNA expression is 
preferentially enriched in the mesenchymal molecular glioma subtype in 5 clinical 





6.4  TGFβ signaling induces ST3GAL1 expression  
We further tested the relationship between TGFβ signaling and ST3Gal1 
activation in our patient-derived GPCs, which we previously showed contain 
transcriptomic information that dictates primary tumor phenotype (Ng et al, 2012). 
Exogenous addition of TGFβ1 protein resulted in an induction of ST3GAL1 
transcription in a time-dependent manner in both NNI-11 and NNI-8 GPC lines, 
which was mitigated upon addition of TGFβ pathway small molecule inhibitor, 
SB431542 (Figure 6.4B) (Anido et al, 2010). We further verified an active TGFβ 
signaling status by immunoblot analysis (Figure 6.4A). Cells treated with TGFβ1 
showed elevated p-Smad2 levels, which were diminished upon SB431542 
addition. Our findings provide evidence that TGFβ1 acts as a trigger for ST3Gal1 







Figure 6.4. TGFβ signaling induces ST3GAL1 expression. A, TGFβ1 treatment in 
NNI-11 (left panel) and NNI-8 (right panel) GPC lines resulted in elevated p-Smad2 
expression, verifying TGFβ pathway activation. In contrast, p-Smad2 levels were greatly 
diminished upon addition of TGFβ pathway small molecule inhibitor, SB431542 at 2 and 
4 µM concentrations. B, ST3GAL1 transcript expression was determined in the presence 
of TGFβ1 or SB431542 in NNI-11 (left panel) and NNI-8 (right panel) GPC lines. *, 
p<0.05; **, p<0.01; ***, p<0.001 versus vehicle control (n=3). 
 
6.5 ST3GAL1 knockdown reduces FoxM1-axis cell cycle protein 
expression and induces a G2/M cell cycle arrest with concomitant increase 
in apoptotic cells 
To identify possible downstream targets of ST3Gal1 activation, we 
established microarray gene expression data from GPCs transduced with non-
targeting vector control, and shST3GAL1 vectors. We examined the differential 
gene list and found that it is highly enriched for cell cycle gene modules, in 
particular processes involved with mitotic progression (Figure 6.5). Of note, 
FOXM1 emerged as a significantly modulated gene upstream of the cell cycle 
processes (Figure 6.6). We focused our efforts on FoxM1 since its over-
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expression has been shown to induce hyperplasia of human epithelial cells, 
through a mechanism involving expansion of the stem cell/progenitor pool 
(Batista et al, 2010). Furthermore, FoxM1 was recently implicated in a GPC 
prosurvival role in glioblastoma (Zhang et al, 2011). 
 
 
Figure 6.5. GeneGo process network. Top 10 ranking processes derived from 





Figure 6.6. GeneGo map analysis. FOXM1 was identified as a significant modulated 
gene upstream of the cell cycle processes (left with blue thermometer, indicates down-
regulation upon ST3GAL1 knockdown). 
 
To verify our bioinformatical predictions, we evaluated the cell cycle 
profile of ST3GAL1-knockdown GPCs, NNI-11 and NNI-8. We observed that the 
gene knockdown resulted in a G2/M cell cycle arrest, with concomitant increase 
in the level of sub-G0 apoptotic cells (Figure 6.7A, B). Importantly, the Forkhead 
family of transcription factors, FoxM1 was reduced, accompanied by a similar 
reduction in levels of its transcriptional targets, polo-like kinase 1 (PLK1) and 
cyclin-dependent kinase 1 (CDK1) (Figure 6.7C) (Laoukili et al, 2005). In 
contrast, the cyclin-dependent kinase inhibitor (CDKI), p27Kip1 which is normally 
reduced as cells exit G1, was elevated upon ST3GAL1 knockdown, consistent 
with a G2/M arrest. Similar to our earlier data, we also observed increased levels 
of cleaved poly (ADP-ribose) polymerase (PARP) by immunoblot analysis upon 
105 
 
ST3GAL1 knockdown, indicating increased apoptosis (Figure 6.7D). Collectively, 
these data demonstrate a role for ST3Gal1 in mitotic progression, most likely 
mediated by FoxM1.  
 
Figure 6.7. ST3Gal1 depletion reduces FoxM1-axis cell cycle proteins and induces 
G2/M cell cycle arrest with concomitant increase in apoptotic cells. A,    Cell cycle 
profile was (i) evaluated and (ii) quantified upon ST3GAL1 knockdown in NNI-11 GPC 
line.  *, p<0.05; **, p<0.01; versus NT control at each corresponding cell cycle phase 
(n=3). B,    Cell cycle profile was (i) evaluated and (ii) quantified 
upon ST3GAL1 knockdown in NNI-8 GPC line. *, p<0.05; **, p<0.01; versus NT control at 
each corresponding cell cycle phase (n=3). C,    Cell cycle proteins were assessed in NNI-
11 (left panel) and NNI-8 (right panel) GPC lines after ST3GAL1 knockdown compared to 
the loading control, β-actin. D,    Extent of apoptosis, defined by PARP level, and FoxM1 
protein level were determined upon ST3GAL1 knockdown over 4-6 days in NNI-11 (upper 
panel) and NNI-8 (lower panel) GPC lines. 
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6.6 ST3GAL1 knockdown induces FoxM1 protein degradation  
 FoxM1 is a proliferation-associated transcription factor essential for cell 
cycle progression and it has been shown to be over-expressed in many cancers. 
FoxM1 expression peaks at S and G2/M cell cycle phases and its timely 
expression is required to activate expression of other cell cycle genes essential 
for mitotic progression. FoxM1 is degraded in late mitosis and early G1 phase by 
an E3 ubiquitin ligase, the anaphase-promoting complex/cyclosome (APC/C) and 
its adapter protein, Cdh1 (Laoukili et al, 2008).  
As we observed depletion of FoxM1 upon ST3GAL1 knockdown earlier, 
and direct binding between ST3Gal1 and FoxM1 was absent (Figure S2), we 
asked if the process was mediated through ubiquitin-mediated proteasomal 
degradation, a role associated with the APC/C-Cdh1 complex (Laoukili et al, 
2008). We treated ST3GAL1-knocked down GPCs with the proteasome inhibitor 
MG132, which blocks the proteolytic activity of the 26S proteasome complex (Lee 
& Goldberg, 1998). Consequently, we expect to see the accumulation of 
ubiquitinated FoxM1. Consistently, we observed that FoxM1 degradation was 
mitigated upon MG132 inhibitor treatment, resulting in the elevation of 
ubiquitinated proteins, thereby implicating the role of the proteasome complex in 










Figure 6.8. ST3Gal1 depletion induces proteasomal degradation of FoxM1 protein. 
FoxM1 protein expression and the extent of ubiquitination were assessed upon ST3GAL1 
knockdown or in the presence of increasing concentrations of MG132 (0.1 µM and 1.0 












Since FoxM1 ubiquitination and degradation are mediated by APC/C-
Cdh1, we investigated specifically the activity of the APC/C-Cdh1 complex in 
ST3Gal1-depleted cells.  We assessed the ubiquitination status of cyclin B1, an 
established substrate of APC/C-Cdh1 (King et al, 1995) after ST3GAL1 
knockdown. Consistently, we observed that the depletion of ST3Gal1 leads to 
enrichment of ubiquitinated cyclin B1, implicating an elevated APC/C-Cdh1 
activity.  
 
Figure 6.9. ST3Gal1 depletion induces APC/C-Cdh1 activity. HEK-293T cells were 
cotransfected with cyclinB1-Myc and shST3Gal1 knockdown vectors and treated with 
proteasome inhibitor MG132 (1 µM) for 16 hours before harvesting. Cell lysates were 







The (D)-box and KEN sequence degradation motifs present in the N-
terminal region of FoxM1 are crucial for the binding of the APC/C complex 
(Laoukili et al, 2008).  To confirm that ST3GAL1 targeting mediates FoxM1 
protein degradation via the ubiquitin-associated proteasomal process, we created 
a stable mutant of FoxM1 lacking its destruction (D)-box and KEN sequence 
elements (FoxM1-ΔNΔKEN) (Laoukili et al, 2008) (Figure 6.10A). The 
expression of full-length FoxM1 and FoxM1-truncated stable mutant constructs 
was verified in HEK-293T cells (Figure 6.10B).  
 
 
Figure 6.10. Construction of full-length and N-terminal-deleted FOXM1 (FoxM1-
ΔNΔKEN) vectors. A, Schematic representation of the FoxM1 protein depicting 2 
destruction boxes: (D-box) sequence and a KEN Box sequence, and the amino acid 
position of these sequences. Abbreviations: DBD, DNA binding domain; TAD, C-terminal 
transcriptional activation domain. B, Immunoblot analysis of HEK-293T cells transfected 
with full-length FOXM1 (110 kDa) and N-terminal-deleted FOXM1 (FoxM1-ΔNΔKEN; 
62kDa) vectors.  
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Upon ST3GAL1 knockdown, we observed the expected degradation of 
endogenous FoxM1 (110 kDa); in contrast, the FoxM1-ΔNΔKEN mutant protein 
(62 kDa) was stable (Figure 6.11A). We confirmed that this degradation was 
mediated at the protein level and not at the mRNA level. The depletion of FoxM1 
protein was observed at 48 hours post-transduction, while significant reduction of 
FOXM1 mRNA only occurred after that, i.e. 60 hours (Figure 6.11B), thus ruling 
out transcription-initiated FoxM1 degradation. This is an important distinction to 
make as FoxM1 also auto-regulates itself via a positive feedback loop mediated 
by its own transcript level (Halasi & Gartel, 2009). Collectively, our data 
implicates ST3Gal1-mediated FoxM1 protein depletion by the ubiquitin-
associated proteasomal degradation machinery of APC/C-Chd1 complex.  
 
 
Figure 6.11. FoxM1 protein degradation mediated by ST3Gal1 depletion requires 
KEN sequence and (D)-box element. A, GPCs were transduced with vector control or 
FoxM1-ΔNΔKEN over-expression constructs; followed by ST3GAL1 knockdown (C1 and 
C2) or NT control. FoxM1 protein level was assessed and compared to β-actin loading 
control. B, NNI-8 GPC line was subjected to ST3GAL1 knockdown and FoxM1 protein 
and mRNA changes were assessed. Data indicate that ST3Gal1 regulates FoxM1 at the 





6.7 Over-expression of FoxM1 rescues the ST3GAL1 knockdown 
phenotype 
We next assessed the ability of over-expressed FoxM1 or its stable 
mutant FoxM1-ΔNΔKEN to rescue the ST3GAL1-knocked down phenotype in 
our collection of patient-derived GPCs. Consistently, endogenous and wild-type, 
over-expressed FoxM1 protein was degraded upon ST3GAL1 knockdown; in 
contrast, the FoxM1-ΔNΔKEN mutant was stable (Figure 6.12A). We however 
observed no depletion of full-length, over-expressed FoxM1 in NNI-11 GPCs. 
Since FoxM1 mediates ST3Gal1 signaling, we rationalized that ST3GAL1 
knockdown was most likely more effective at causing cell death in lower FoxM1-
expressing clones, thus cells containing higher expression of FoxM1 were 
selectively propagated in culture. This paradox was further confirmed by the 
enrichment of FoxM1-ΔNΔKEN expression in ST3GAL1-knocked down GPCs 
(NNI-11 & NNI-8). Next, we assessed the ability of over-expressed FoxM1 to 
rescue the ST3GAL1-knocked down phenotype of GPCs. Consistent with our 
hypothesis, FoxM1 or FoxM1-ΔNΔKEN over-expression rescued the 
gliomasphere-forming ability, viability and invasive potential of ST3GAL1-
knocked down GPCs (Figure 6.12B, C, D). In summary, our data provide 
evidence that ST3Gal1 regulates GPC survival through control of FoxM1 protein 







Figure 6.12. FoxM1 over-expression rescues ST3GAL1-knockdown phenotype. A, 
NNI-11 and NNI-8 GPCs were transduced with vector control, FoxM1 or FoxM1-ΔNΔKEN 
over-expression constructs; followed by ST3GAL1 knockdown (C1 and C2) or NT control. 
FoxM1 protein level was assessed and compared to β-actin loading control. B, The ability 
of FoxM1 and FoxM1-ΔNΔKEN over-expression constructs to rescue gliomasphere 
formation after ST3GAL1 knockdown in NNI-11 and NNI-8 GPC lines was evaluated. *, 
p<0.05; **, p<0.01; ***, p<0.001; versus NT control (n=3). C, The ability of FoxM1 and 
FoxM1-ΔNΔKEN over-expression constructs to rescue viability after ST3GAL1 
knockdown in NNI-11 and NNI-8 GPC lines was evaluated. *, p<0.05; **, p<0.01; ***, 
p<0.001; versus NT control (n=3). D, The ability of FoxM1 and FoxM1-ΔNΔKEN over-
expression constructs to rescue invasive potential after ST3GAL1 knockdown in NNI-11 




6.8 Summary  
Taken together, our results show that TGFβ induces ST3GAL1 
expression and correlates with the pattern of ST3Gal1 activation in patient 
tumors of the mesenchymal molecular subtype, frequently associated with highly 
aggressive and recurrent tumors. To delineate the downstream events of 
ST3Gal1 signaling, we utilized a bioinformatical approach that leveraged on the 
greater statistical power of large patient databases, and subsequently verified our 
predictions in patient-derived glioma cells. We identify FoxM1, a major stem cell 
regulatory gene, as a downstream effector, and show that ST3Gal1 mediates the 
glioma phenotype through control of FoxM1 protein degradation via the APC/C-
Cdh1 machinery.  
Our work is unique because we show for the first time how cell surface 
sialylation, a well-known cancer invasiveness factor, is triggered by a key glioma 
pathway, TGFβ. Furthermore, we are now able to link this upstream activation to 
a stem cell-related pathway, FoxM1, highlighting that promoting glioma stem-like 
cell survival is at the heart of sustenance of tumor growth. We demonstrate that 
ST3Gal1 activation portends poor prognosis in patient glioma databases. Our 
results illustrate an important interplay between stem cell mediators and 
sialylation status during glioma tumorigenesis, and further suggest that the 
inhibition of ST3Gal1 could be an attractive avenue for the therapeutic 
























CHAPTER 7 – GENERAL DISCUSSION 
7.1 Discussion 
 In our initial effort to study glioma-propagating cells (GPCs), we have 
decided to validate the use of these patient-derived GPCs as a reliable means to 
study gliomas.  We sought to align our collection of patient-derived GPCs with 
that of other investigators to demonstrate that the common oncologic signaling 
pathways are present in our cells, consistent with published literature. It is 
noteworthy to highlight that our collection of GPCs can be molecularly classified 
into distinct GPC subtypes – Proneural and Mesenchymal, each with unique 
signaling pathways that can be potentially targeted. This finding is an extension 
of our earlier work published in Stem Cells where we demonstrated the 
preservation of important biological characteristics such as marker expression, 
self-renewing potential, karyotypic and transcriptomic profiles of these cells 
(Chong et al, 2009). More importantly, the tumor xenograft generated from GPCs 
recapitulates the pathophysiology of the original patient tumor. In addition, we 
demonstrated proof-of-concept for the utility of our GPCs by carrying out a small 
scale inhibitor treatment and verified the presence of common signaling 
mechanisms in glioma. GPCs thus provide a versatile and sustainable source to 
probe for the biology of glioma disease.  
Malignant gliomas are devastating, in part due to the highly infiltrative and 
recurrent nature of the disease. Sialylation, the addition of 9-carbon sugars at the 
non-reducing ends of cell surface glycoproteins, has been shown to play major 
roles in tumor cell invasiveness (Fuster & Esko, 2005). ST3Gal1 sialylation for 
instance, has been implicated in cancers of the breast, colorectum and bladder 
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(Burchell et al, 1999; Schneider et al, 2001; Videira et al, 2009). In these studies, 
while α2,3-sialylation has been demonstrated to correlate with disease 
progression, no functional role has been ascribed. Furthermore, it remains 
unclear mechanistically how such cell surface carbohydrate moieties regulate 
tumorigenicity and invasiveness. Our findings here are unique because we show 
for the first time how ST3Gal1 sialyltransferase is triggered by the TGFβ signaling 
pathway in the mesenchymal patient cohort, and regulates brain tumor formation 
through APC/C-Cdh1-targeted control of Forkhead box protein M1 (FoxM1) 
protein degradation (Figure 7.1). Our work further highlights the role that GPCs 
play in the sustenance of brain tumor progression, and we provide evidence that 
the ST3Gal1 gene expression-based activation program in GPCs prognosticates 
survival in patient databases, suggesting that targeting ST3Gal1-linked 
processes may provide viable therapeutic strategies. We recognize that ST3Gal1 
may play important roles in the functioning of normal stem cells, such as in 
mouse hematopoietic and neural stem cells where PNAlo enriches for stem cell 
activity, and that specificity/toxicity issues of such therapies will warrant further 
investigations. Nevertheless, we had observed a markedly higher intensity of 





Figure 7.1. ST3Gal1 contributes to tumorigenicity, invasion and prognosis in 
glioma. Glioma patients classified under the Mesenchymal molecular subtype possess 
an activate TGFβ pathway that stimulates ST3Gal1 signaling, leading to survival and 
maintenance of gliomas. Targeting ST3Gal1 signaling promotes the degradation of 
FoxM1 protein, which in turns mitigates self-renewal, invasiveness and tumorigenicity. 
 
The true definition of a GPC lies in its ability to display stem cell-like 
activity in vitro and in vivo, the latter through serial transplantations of sustainable 
xenograft tumors (Rich & Eyler, 2008). We noted that we were not able to 
determine the tumorigenic potential of PNA-stained and –sorted cells due to 
immunologic response to PNA, resulting in premature death of mice. Ideally, 
antibodies raised against the extracellular domain of ST3Gal1 could conceivably 
aid in the isolation and validation of long-term self-renewal of these cells in vivo. 
Currently, as such antibodies are not available, we will have to examine our 
options in greater depth in future work. 
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  We unraveled the role of ST3Gal1 by evaluating its co-expressed gene 
module for the ability to stratify PNA-sorted cellular fractions, and more 
importantly, for its ability to stratify patient survival groups. This patient-centric 
approach is advantageous as it offers greater statistical power in a clinical 
context to guide our lab decisions that is otherwise impossible with our limited 
collection of patient-derived GPCs, as with any such studies. Consistent with this, 
gene signatures derived from cancer stem-like cells have been demonstrated to 
contribute to patient prognostic outcome in several cancer types (Liu et al, 2007; 
Shats et al, 2011; Yan et al, 2011). This ability of GPCs to mirror the signaling 
pathways in primary tumors lends credence to the utility of such cells as a 
clinically relevant study platform. Moreover, orthotopic glioma models established 
from such cells have been shown to recapitulate the molecular heterogeneity 
spectrum of patients (Verhaak et al, 2010). Furthermore, our study has identified 
the functional cause behind the frequently observed stem cell-related PNA 
staining (Rietze et al, 2001; Salner et al, 1982). In support, the ST3GAL1 copy 
number has been shown to be amplified in an analysis of oligoneural 
glioblastoma tumors from The Cancer Genome Atlas (TCGA) effort, in particular, 
linked with major cell cycle processes that have been found relevant in our study 
(Kim et al, 2011). Our findings emphasize the important contribution of stem-like 
GPCs to the primary tumor phenotype, and underscore the value of targeting 
ST3Gal1-linked processes as a therapeutic strategy.  
 We further identified the mesenchymal molecular subtype of glioma 
patients with association between TGFβ and ST3Gal1 signaling. Consistent with 
our finding, the mesenchymal molecular profile has previously been associated 
with an enrichment of the TGFβ pathway in both patient-derived GPCs and 
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primary tumors (Lottaz et al, 2010). The finding that TGFβ1 triggers ST3GAL1 
transcription and activity is important because a major glioma regulatory module 
is implicated in sialylation-mediated tumor cell invasiveness and tumorigenicity. 
Our ability to further stratify patient cohorts with ranked patterns of similarity 
between the ST3GAL1 gene module and individual patient gene expression 
profiles demonstrates that sialylation, conferred by ST3Gal1, contributes to the 
molecular heterogeneity of the disease that cannot be accounted for by current 
clinical indicators of age and histology. This is significant as histology remains 
the current guide to diagnose and subsequently treat patients. Our bioinformatic 
analyses suggest that a closer examination of the ST3GAL1 gene signature may 
reveal prognostic and therapeutic candidates for further validation. This presents 
a novel paradigm to clinical management of the disease as now, histologically 
identical tumors can be molecularly distinct and their response to specific 
pathway inhibitors may be predicted by the signaling modules implicated by their 
molecular profiles. We thus provide a means to identify patient subgroups most 
likely to benefit from ST3Gal1 inhibition therapeutic approaches. 
 FoxM1 has many roles in cancer biology including regulation of 
tumorigenicity through expansion of the stem/progenitor cell pool (Gemenetzidis 
et al, 2010; Halasi & Gartel, 2009; Zhang et al, 2011). Our study has revealed the 
role of ST3Gal1-mediated FoxM1 degradation through the APC/C-Cdh1 complex. 
Conceivably, ST3Gal1 depletion elevates the activity of the APC/C-Cdh1 
complex as cells enter mitosis, which then targets the N-terminal of FoxM1 
protein for subsequent degradation, thus arresting GPCs at the G2/M phase. 
Consequently, this arrest becomes a signal for cell fates such as apoptosis and 
cellular differentiation, as our findings have shown. Zhang et al. have implicated 
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a role for FoxM1 in the maintenance of the GPC state (Zhang et al, 2011). In the 
authors’ study, FoxM1 binds to β-catenin and regulates its nuclear localization 
and transcriptional activity, both of which are crucial to promote the self-renewal 
of GPCs and their tumorigenic potential. Genetic knockdown of FOXM1 disrupts 
β-catenin nuclear localization and thus induces cellular differentiation. Our work 
provides another key mechanism through which ST3Gal1, a major invasiveness 
factor, impacts on tumorigenic growth by regulating the stem cell/progenitor pool. 
Additionally, while the precise action of ST3Gal1 on the APC/C-Cdh1 complex 
remains to be further explored, we propose from our study (Figure 6.7C), that 
the cyclin-dependent kinase 1 (CDK1), which acts as a negative inhibitor of 
ACP/C-Cdh1, is down-regulated upon ST3GAL1 knockdown, consequently 
promoting Cdh1 recognition and binding of APC/C (ngListovsky et al, 2000; 
Zachariae et al, 1998). 
 Collectively, our study provides novel and significant insight into the role 
of TGFβ pathway-mediated sialylation in promoting GPC survival and 
tumorigenicity. We further implicate FoxM1 regulation through the cell cycle 
machinery. Our work emphasizes that promoting GPC survival is at the heart of 
sustenance of tumor growth. 
 
7.2 Future Directions 
Our results illustrate an important interplay between stem cell mediators 
and sialylation status during glioma tumorigenesis. To further implicate ST3Gal1 
signaling as a potential avenue for the therapeutic intervention of malignant 
glioma progression, we will perform the following experiments: 
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1. We will determine if mesenchymal GPC lines have increased ST3Gal1 
signaling program compared to the proneural subtype. This hypothesis is 
supported by an observation that TGFβ signaling (upstream trigger of 
ST3GAL1) is increased in mesenchymal GPCs (Figure 3.3A). Thus, we 
expect an increase of ST3Gal1 signaling in mesenchymal GPCs due to 
its inherent activate TGFβ signaling. The verification of GPC lines with 
different ST3Gal1 activation status according to its molecular 
classification is important for future drug screening efforts as these cell 
lines can be reflective of the cohorts of patients who are more likely to 
receive treatment benefit from this class of inhibitors.  
 
2. We are in the process of determining if FoxM1 or FoxM1-ΔNΔKEN stable 
mutant over-expression will rescue the ST3GAL1 knockdown phenotype 
in the animal model, resulting in an expected increase in survival rate 
compared to the (vector control + ST3GAL1 KD) group. This will provide 
conclusive evidence that FoxM1 mediates ST3Gal1 signaling in vivo. 
 
3. Next, we will examine the “ST3GAL1-associated gene signature” and 
employ 3 criteria to winnow down the gene list to likely mechanistic 
targets: (1) Most highly variable; (2) Differentially regulated in normal 
brain tissue; and (3) Survival-related. We will focus on the up-regulated 
genes in the ST3Gal1 activation program, as these likely represent 
biomarkers in glioma progression and hence therapeutic targets. We had 
utilized this strategy in our recent collaboration and manuscript with 
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A/Professor Shu Wang to identify genes responsible for miR-376a* 
regulation of glioblastoma growth (Choudhury et al, 2012). 
 
4. In addition, we will identify small molecule inhibitors that selectively target 
the ST3Gal1 activation program by utilizing the Connectivity Map 
(CMAP), developed by the Broad Institute, an adaptation of which was 
used in our previous sections. The original CMAP is a collection of 
genome-wide transcriptional expression data from cultured human cells 
treated with bioactive small molecules and simple pattern-matching 
algorithms that enable the discovery of functional connections between 
drugs, genes and diseases through common gene expression changes 
(Lamb et al, 2006).  It allows researchers to screen compounds against 
genome-wide disease signatures, rather than a pre-selected set of target 
genes. In this case, we will map the “ST3Gal1-associated gene signature” 
(derived from ST3GAL1 knockdown clone) into the database and rank the 
patterns of association. Small molecule inhibitors which display high 
enrichment and specificity scores to our query signature will be selected 
and tested for their efficacy. Additionally, these well-characterized small 
molecule inhibitors will likely provide insightful information on the 
mechanism of ST3Gal1 signaling.  
 
5. While our work provides evidence that ST3Gal1 confers tumorigenic 
growth and glioma disease progression through APC/C-Cdh1-targeted 
control of FoxM1 protein degradation, direct mechanism of ST3Gal1 on 
the APC/C-Cdh1 complex remains to be elucidated. A negative regulator 
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of APC/C-Cdh1 complex, CDK1 which was down-regulated upon 
ST3GAL1 knockdown remains an exciting avenue for further analysis. 
Zachariae et al. demonstrated that CDK1 is essential for mammalian 
APC/C complex regulation by inhibiting the binding of co-activator Cdh1 
(Zachariae et al, 1998). Depletion of ST3Gal1 down-regulates CDK1 
expression, thus implicating CDK1 as potential mediator for the cross-talk 
between ST3Gal1 signaling and cell cycle processes.  
 
7.3 Conclusion 
Cell surface sialylation confers various roles in cancer including 
proliferation, invasiveness and metastasis. However, the molecular mechanisms 
of ST3Gal1 sialyltransferase mediating malignant glioma progression remain 
poorly defined. We demonstrate that ST3Gal1 sialyltransferase marks the self-
renewing fraction and depleting its expression abrogates tumorigenicity.  Active 
TGFβ signaling induces ST3GAL1 expression and correlates with ST3Gal1 
activation in patient tumors with mesenchymal features. A bioinformatics 
approach was utilized to delineate downstream events of ST3Gal1 signaling and 
a major stem cell regulatory gene, FoxM1, emerged as a downstream effector. 
Importantly, we show that ST3Gal1 mediates the glioma phenotype through 
FoxM1 protein degradation, which in turn is regulated by the APC/C-Cdh1 
complex. These data suggest that ST3Gal1 represents an amenable target for 
the development of efficacious therapeutics that target the relevant self-renewing 
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Supplementary Figure S1. Intracranial implantation of PNA-stained GPCs induces 
pre-mature death in NOD/SCID gamma (NSG) mice. A, H&E staining of NSG mice 
implanted with PNA-stained GPCs died 4-weeks post-implantation before tumor 
formation B, H&E staining of NSG mice implanted with unstained GPCs succumbed to 













Supplementary Figure S2. Co-immunoprecipitation assay indicates absence of 
direct binding between ST3Gal1 and FoxM1. FoxM1 (left panel) or Flag-ST3Gal1 (right 
panel) were over-expressed in HEK-293T cells and subsequently immunoprecipitated to 
assess physical interaction. PLK1 was probed as a positive control for FoxM1 binding in 




Supplementary Table S1: Stem cell-related genesets significantly enriched in non-targeting (NT) control samples 
NAME Description Class association Size NES NOM p-val 
WONG_EMBRYONIC_
STEM_CELL_CORE 
The 'core ESC-like gene module': genes 
coordinately up-regulated in a  
compendium of  mouse embryonic stem 
cells (ESC) which are shared with the 
human ESC-like module 
The transcriptome pattern of NT 
control samples positively enriched 
with the genesets 
296 1.43 0.13 
KORKOLA_CORRELAT
ED_WITH_POU5F1 
Genes whose expression pattern in 
adult male germ cell tumors (GCT) 
correlates with POU5F1 
The transcriptome pattern of NT 
control samples positively enriched 
with the genesets 
21 1.42 0.035 
BHATTACHARYA_EMB
RYONIC_STEM_CELL 
The 'stemnes' signature: genes up-
regulated and common to 6 human 
embryonic stem cell lines tested 
The transcriptome pattern of NT 
control samples positively enriched 
with the genesets 











Supplementary Table S2: Cox regression analysis of age, histology and ST3GAL1 expression performed on REMBRANDT 
and Gravendeel. 
REMBRANDT 
        Covariates coef HR L.95% U.95% se(coef) z Pr(>|z|)   
ST3GAL1 - High expression 0.21199 1.2361 0.8794 1.738 0.1737 1.22 0.223   
ST3GAL1 - Intermediate expression 0.47467 1.6074 1.1499 2.247 0.17093 2.777 0.0055 ** 
Histology - GBM 0.960439 2.612845 1.8611 3.668 0.173102 5.548 2.88E-08 *** 
Histology - MIXED -0.02611 0.974224 0.3869 2.453 0.471175 -0.055 0.9558   
Histology - OLIGODENDROGLIOMA -0.00424 0.995768 0.6211 1.596 0.240827 -0.018 0.98595   
AGE 0.014806 1.014916 1.0053 1.025 0.004841 3.058 0.00223 ** 
 
Gravendeel 
        Covariates coef HR L.95% U.95% se(coef) z Pr(>|z|)   
ST3GAL1 - High expression 0.38464 1.46909 1.0591 2.0377 0.16694 2.304 0.02122 * 
ST3GAL1 - Intermediate expression 0.26124 1.29854 0.9415 1.7909 0.16403 1.593 0.11123   
Histology - GBM 0.49986 1.64848 1.0424 2.6069 0.23383 2.138 0.03254 * 
Histology - MIXED -0.5191 0.59506 0.3305 1.0715 0.30009 -1.73 0.08366   
Histology - OLIGODENDROGLIOMA -0.84313 0.43036 0.2531 0.7317 0.27082 -3.113 0.00185 ** 







Supplementary Table S3: Top 5 stem cell-related genesets significantly enriched with high ST3GAL1 patient groups 
REMBRANDT 
NAME Description ST3GAL1 class association Size NES NOM p-val 
DAZARD_RESPONSE
_TO_UV_NHEK_UP 
Activated signaling genes responsible for 
resistance to UVB-induced apoptotic 
pathwayin normal human epidermal 
keratinocytes (N=45) 
The transcriptome pattern of 
Rembrandt patients with high 
ST3GAL1 expression positively 
enriched with resistance pathway 
genes 
134 1.74514 0.00415 
KANG_IMMORTALIZE
D_BY_TERT_DN 
Down-regulated genes in the signature 
of adipose stromal cells immortalized by 
forced expression of telomerase (N=102) 
The transcriptome pattern of 
Rembrandt patients with high 
ST3GAL1 expression positively 
enriched with pathway related to 
proliferative and multilineage potential 




Genes down-regulated in hematopoietic 
stem cells (HSC, CD34+) cultured in a 
three-dimentional collagen gel compared 
to the cells grown in suspension (N=275) 
The transcriptome pattern of 
Rembrandt patients with high 
ST3GAL1 expression positively 
enriched with growth factors, cytokines 
and chemokines related pathway 




Genes up-regulated in hematopoietic 
stem cells (HSC, CD34+) cultured in a 
three-dimentional collagen gel compared 
to the cells grown in suspension (N=233) 
The transcriptome pattern of 
Rembrandt patients with high 
ST3GAL1 expression positively 
enriched with growth factors, cytokines 
and chemokines related pathway 




Activated signaling genes responsible for 
pluripotency and self-renewal in 
embryonic stem cells (N=185) 
The transcriptome pattern of 
Rembrandt patients with high 
ST3GAL1 expression positively 
enriched with pluripotency and self-
renewal in embryonic stem cells 






NAME Description ST3GAL1 class association Size NES NOM p-val 
DAZARD_RESPONSE
_TO_UV_NHEK_UP 
Activated signaling genes responsible for 
resistance to UVB-induced apoptotic 
pathway in normal human epidermal 
keratinocytes (N=45) 
The transcriptome pattern of 
Rembrandt patients with high 
ST3GAL1 expression positively 
enriched with resistance pathway 
genes 




Genes commonly down-regulated in 
human alveolar rhabdomyosarcoma 
(ARMS) and its mouse model 
overexpressing PAX3-FOXO1 (N=408) 
The transcriptome pattern of 
Gravendeel patients with high 
ST3GAL1 expression positively 
enriched with mesenchymal stem cells 
pattern causing human alveolar 
rhabdomyosarcoma 




Activated signaling genes responsible for 
pluripotency and self-renewal in 
embryonic stem cells (N=185) 
The transcriptome pattern of 
Gravendeel patients with high 
ST3GAL1 expression positively 
enriched with pluripotency and self-
renewal in embryonic stem cells 
130 1.697 0 
BENPORATH_MYC_T
ARGETS_WITH_EBOX 
Targets of c-Myc identified by ChIP on 
chip in cultured cell lines, focusing on E-
box-containing genes; high affinity bound 
subset (N=230) 
The transcriptome pattern of 
Gravendeel patients with high 
ST3GAL1 expression positively 
enriched with pluripotency and self-
renewal in embryonic stem cells 




Genes down-regulated in bone marrow 
hematopoietic stem cells (HSC, CD34+) 
from patients with low risk of 
myelodysplastic syndrom (N=23) 
The transcriptome pattern of 
Gravendeel patients with high 
ST3GAL1 expression positively 
enriched with genes, resulting low risk 
patients susceptible to cell damage 






Supplementary Table S4. Probesets in the ST3GAL1-associated gene signature (“sialylation signature”) 
Probe ID Entrez Gene ID 
Gene 
Symbol Description Fold difference p-value 
219978_s_at 51203 NUSAP1 nucleolar and spindle associated protein 1 -2.177714426 6.85E-08 
218039_at 51203 NUSAP1 nucleolar and spindle associated protein 1 -2.007982986 0.000000766 
239688_at 8243 SMC1A structural maintenance of chromosomes 1A -2.003761092 0.0000101 
226096_at 252995 FNDC5 fibronectin type III domain containing 5 2.003113721 0.000796047 
1554242_a_at 1690 COCH coagulation factor C homolog, cochlin (Limulus polyphemus) -2.228266121 0.000311317 
227296_at 113655 MFSD3 major facilitator superfamily domain containing 3 -2.395267474 0.0000185 
200660_at 6282 S100A11 S100 calcium binding protein A11 -2.107375026 0.00000564 
210448_s_at 5026 P2RX5 purinergic receptor P2X, ligand-gated ion channel, 5 -2.186276641 0.00000022 
219804_at 79933 SYNPO2L synaptopodin 2-like -2.294332313 0.0000296 
200644_at 65108 MARCKSL1 MARCKS-like 1 -2.466089962 2.75E-13 
223082_at 30011 SH3KBP1 SH3-domain kinase binding protein 1 -2.531857696 8.22E-18 
1554168_a_at 30011 SH3KBP1 SH3-domain kinase binding protein 1 -2.484612902 8.91E-17 
1556429_a_at 93594 WDR67 WD repeat domain 67 -3.073323832 0.0000344 
1560648_s_at 7259 TSPYL1 TSPY-like 1 -2.026634956 0.0000689 
203379_at 6195 RPS6KA1 ribosomal protein S6 kinase, 90kDa, polypeptide 1 -2.200484707 0.0000437 
208657_s_at 10801 SEPT9 septin 9 -2.173909145 2.84E-10 
222403_at 23788 MTCH2 mitochondrial carrier 2 -2.270425345 2.81E-15 
217489_s_at 3570 IL6R interleukin 6 receptor -2.161828421 0.000521351 
200791_s_at 8826 IQGAP1 IQ motif containing GTPase activating protein 1 -2.380959603 6.1E-16 
210815_s_at 10203 CALCRL calcitonin receptor-like 2.058585096 0.002594357 
225368_at 28996 HIPK2 homeodomain interacting protein kinase 2 -2.189628681 7.87E-17 
225115_at 28996 HIPK2 homeodomain interacting protein kinase 2 -2.060568931 1.19E-13 




202094_at 332 BIRC5 baculoviral IAP repeat containing 5 -2.294950079 9.42E-10 
202095_s_at 332 BIRC5 baculoviral IAP repeat containing 5 -2.337122641 1.67E-08 
205046_at 1062 CENPE centromere protein E, 312kDa -2.044329728 0.00000119 
231120_x_at 5570 PKIB protein kinase (cAMP-dependent, catalytic) inhibitor beta -2.256508251 0.000499343 
218585_s_at 51514 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) -2.082768483 0.00000162 
207742_s_at 2649 NR6A1 nuclear receptor subfamily 6, group A, member 1 2.480700174 0.00000647 
232124_at 729085 FAM198A family with sequence similarity 198, member A -2.114271662 0.000973513 
212005_at 26099 C1orf144 chromosome 1 open reading frame 144 -2.817589577 1.73E-09 
239002_at 259266 ASPM asp (abnormal spindle) homolog, microcephaly associated (Drosophila) -2.131487348 0.000000475 
1552843_at 10861 SLC26A1 solute carrier family 26 (sulfate transporter), member 1 -2.309321574 0.0000841 










jumonji domain containing 7 /// JMJD7-PLA2G4B 
readthrough /// phospholipase A2, group IVB (cytosolic) -2.011103199 0.000435507 
224846_at 92799 SHKBP1 SH3KBP1 binding protein 1 -2.098552179 0.000245101 
228846_at 4084 MXD1 MAX dimerization protein 1 2.125647316 2.27E-12 
201890_at 6241 RRM2 ribonucleotide reductase M2 -2.670953205 3.71E-08 
209773_s_at 6241 RRM2 ribonucleotide reductase M2 -2.883428925 6.51E-08 
226408_at 8463 TEAD2 TEA domain family member 2 -2.076577442 0.000095 
1555950_a_at 1604 CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group) -2.217281189 0.001130212 
212155_at 149603 RNF187 ring finger protein 187 -2.247915535 1.19E-11 
211122_s_at 6373 CXCL11 chemokine (C-X-C motif) ligand 11 2.152057463 0.000648739 
225972_at 169200 TMEM64 transmembrane protein 64 -2.123370452 8.39E-12 
225033_at 6482 ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 -2.003735274 0.0000995 
203154_s_at 10298 PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 -2.061839981 2.47E-08 




203213_at 983 CDK1 cyclin-dependent kinase 1 -2.36049823 0.0000367 
216396_s_at 9538 EI24 etoposide induced 2.4 mRNA -2.270142678 2.73E-14 
205565_s_at 2395 FXN frataxin -2.099188154 4.7E-13 
225836_s_at 83695 C12orf32 chromosome 12 open reading frame 32 -2.142160412 2.7E-12 
225837_at 83695 C12orf32 chromosome 12 open reading frame 32 -2.004532791 6.5E-17 
212739_s_at 4833 NME4 NME/NM23 nucleoside diphosphate kinase 4 -2.003772672 2.2E-11 
228205_at 7086 TKT transketolase -3.166063173 0.000000184 
1553601_a_at 259236 TMIE transmembrane inner ear -2.44646536 0.0000187 
1556357_s_at 157697 ERICH1 glutamate-rich 1 -2.083513335 0.001994122 
236481_at 2184 FAH fumarylacetoacetate hydrolase (fumarylacetoacetase) -2.270313781 0.00000529 
1554140_at 79819 WDR78 WD repeat domain 78 2.523671185 0.00000173 
208561_at 10060 ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 -2.133033278 0.003617928 
231358_at 83876 MRO maestro -2.77234051 0.000000161 
206023_at 10874 NMU neuromedin U -2.134620771 4.59E-10 
209408_at 11004 KIF2C kinesin family member 2C -2.176346114 0.000000175 
1559265_at 387640 SKIDA1 SKI/DACH domain containing 1 -2.235697819 0.001454108 
228403_at 375704 ENHO energy homeostasis associated -2.111839202 3.58E-10 
206884_s_at 8796 SCEL sciellin 2.412696597 0.000124406 
230830_at 123264 OSTBETA organic solute transporter beta 2.135063983 0.000230338 
201710_at 4605 MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 -2.797889586 0.000000366 
221795_at 4915 NTRK2 neurotrophic tyrosine kinase, receptor, type 2 -2.038133651 6.69E-08 
221796_at 4915 NTRK2 neurotrophic tyrosine kinase, receptor, type 2 -2.417451927 2.26E-09 
1556368_at 5261 PHKG2 phosphorylase kinase, gamma 2 (testis) 2.063100377 0.001278693 
1556369_a_at 5261 PHKG2 phosphorylase kinase, gamma 2 (testis) 2.03737102 0.000371413 
201517_at 22916 NCBP2 nuclear cap binding protein subunit 2, 20kDa -2.109448252 9.15E-19 




204709_s_at 9493 KIF23 kinesin family member 23 -2.104645707 0.0000032 
208998_at 7351 UCP2 uncoupling protein 2 (mitochondrial, proton carrier) -2.480232219 4.08E-12 
230521_at 84904 C9orf100 chromosome 9 open reading frame 100 -2.115559793 0.000322873 
209680_s_at 3833 KIFC1 kinesin family member C1 -2.588998537 0.000011 
241436_at 6340 SCNN1G sodium channel, non-voltage-gated 1, gamma subunit -2.075630137 0.004234596 
225113_at 8540 AGPS alkylglycerone phosphate synthase -2.099418996 2.5E-11 
230974_at 11269 DDX19B DEAD (Asp-Glu-Ala-Asp) box polypeptide 19B -2.414390152 0.000000167 
1555801_s_at 151126 ZNF385B zinc finger protein 385B -2.002903124 0.007422343 
210121_at 8707 B3GALT2 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 2.108308508 0.0000168 
208396_s_at 5136 PDE1A phosphodiesterase 1A, calmodulin-dependent 2.21724295 0.00000747 
200606_at 1832 DSP desmoplakin -2.019964763 0.000852256 



















small nucleolar RNA, C/D box 116-17 /// small nucleolar 
RNA, C/D box 116-19 /// small nucleolar RNA, C/D box 
116-20 /// small nucleolar RNA, C/D box 116-21 /// small 
nucleolar RNA, C/D box 116 cluster 
2.137869981 0.0000218 
208322_s_at 6482 ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 -0.55883947 1.49718E-09 
215874_at 6482 ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 -0.55883947 1.49718E-09 
225033_at.1 6482 ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 -0.55883947 1.49718E-09 
225034_at 6482 ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 -0.55883947 1.49718E-09 
1559452_a_at 6482 ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 -0.55883947 1.49718E-09 
220116_at 3781 KCNN2 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 0.338191913 5.32125E-07 




201492_s_at 6171 RPL41 ribosomal protein L41 -0.316788815 6.90269E-07 
212104_s_at 23543 RBFOX2 RNA binding protein, fox-1 homolog (C. elegans) 2 -0.316788815 6.90269E-07 
216215_s_at 23543 RBFOX2 RNA binding protein, fox-1 homolog (C. elegans) 2 -0.316788815 6.90269E-07 
203159_at 2744 GLS glutaminase -0.219833202 8.94926E-08 
244796_at 2744 GLS glutaminase -0.219833202 8.94926E-08 
203157_s_at 2744 GLS glutaminase -0.219833202 8.94926E-08 
221510_s_at 2744 GLS glutaminase -0.219833202 8.94926E-08 
203158_s_at 2744 GLS glutaminase -0.219833202 8.94926E-08 
223079_s_at 2744 GLS glutaminase -0.219833202 8.94926E-08 
211414_at 2744 GLS glutaminase -0.219833202 8.94926E-08 
226757_at 3433 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 0.760032374 1.38847E-07 
217502_at 3433 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 0.760032374 1.38847E-07 
224783_at 283991 FAM100B family with sequence similarity 100, member B -0.284297141 1.6872E-06 












Supplementary Table S5. Activation scores, associated p-value and metadata of REMBRANDT samples identified as low or 
high sialylation status based on sialylation signature.  
Samples Activation score 
Normalized 
score p-value Class 
Survival 
(mths) Status Histology Grade Age 
E10462 0.603038794 1 0.1014 Low Sialylation 35.9 1 GBM IV 45 
HF1511 0.591000816 0.980037804 0.0305 Low Sialylation 56.6 1 ASTROCYTOMA II 25 
HF1235 0.587359072 0.973998816 2.00E-04 Low Sialylation 98.4 0 ASTROCYTOMA II 35 
HF1381 0.585582474 0.97105274 0 Low Sialylation 136.2 0 ASTROCYTOMA II 25 
HF0048 0.575897678 0.954992753 0.0136 Low Sialylation 59 1 GBM IV 40 
E09278B 0.573669454 0.95129776 4.00E-04 Low Sialylation 36.6 0 GBM IV 55 
HF0802 0.5593023 0.927473167 5.00E-04 Low Sialylation 88 0 ASTROCYTOMA II 30 
HF1677 0.547530051 0.907951622 0.0139 Low Sialylation 63.5 0 ASTROCYTOMA II 50 
HF0152 0.54468593 0.903235307 0.0032 Low Sialylation 131.5 0 ASTROCYTOMA III 30 
E09430 0.534235353 0.885905447 0.0519 Low Sialylation 32 1 GBM IV 45 
HF1606 0.53336127 0.884455984 0.0301 Low Sialylation 73.6 0 ASTROCYTOMA II 60 
HF1551 0.532827708 0.883571195 0.0047 Low Sialylation 70.9 0 ASTROCYTOMA II 30 
E09867 0.527955137 0.875491166 0.0377 Low Sialylation 38.7 0 OLIGODENDROGLIOMA II 75 
E09860 0.527419448 0.874602849 0.0046 Low Sialylation 36.8 0 OLIGODENDROGLIOMA II 40 
HF0962 0.52358494 0.868244208 0.0025 Low Sialylation 116.5 0 OLIGODENDROGLIOMA II 45 
HF0087 0.522218336 0.865978011 0.0042 Low Sialylation 78.8 1 ASTROCYTOMA III 60 
HF0305 0.510353888 0.846303576 0.1023 Low Sialylation 49.2 1 ASTROCYTOMA II 30 
E09394 0.508921316 0.843927988 0.0658 Low Sialylation 51.7 1 MIXED III 30 
HF1489 0.505064058 0.837531621 0.0095 Low Sialylation 68.3 1 ASTROCYTOMA II 50 
HF0726 0.504558723 0.836693639 0.0058 Low Sialylation 89.4 0 ASTROCYTOMA II 35 
HF0899 0.504094283 0.835923473 0.0053 Low Sialylation 66.7 1 ASTROCYTOMA II 55 
HF1568 0.495029627 0.820891844 3.00E-04 Low Sialylation 42.6 1 ASTROCYTOMA II 30 
HF1409 0.494579899 0.820146073 2.00E-04 Low Sialylation 12.7 1 ASTROCYTOMA III 50 
E10097 0.487706537 0.808748197 0.0191 Low Sialylation 36.6 0 OLIGODENDROGLIOMA II/III 60 




E09262 0.483033161 0.800998486 0.1033 Low Sialylation 13.6 1 MIXED II/III 50 
HF1156 0.47832532 0.793191624 0.0019 Low Sialylation 105.3 0 ASTROCYTOMA II 30 
E09804 0.476643206 0.790402227 0.0088 Low Sialylation 42.4 0 OLIGODENDROGLIOMA II 70 
HF0434 0.476309938 0.78984958 3.00E-04 Low Sialylation 6.1 1 ASTROCYTOMA II 60 
HF0022 0.466535531 0.773640992 0.0061 Low Sialylation 133.9 0 ASTROCYTOMA II 20 
HF0835 0.466272836 0.773205373 0.0296 Low Sialylation 45.3 1 OLIGODENDROGLIOMA II 20 
HF0017 0.465723172 0.772293883 0.0028 Low Sialylation 133.2 0 ASTROCYTOMA III 45 
HF0914 0.460455682 0.763558972 0.0041 Low Sialylation 146.9 0 ASTROCYTOMA II 40 
HF1587 0.457643898 0.75889628 0.0018 Low Sialylation 75.3 0 ASTROCYTOMA III 30 
HF0931 0.457328521 0.758373301 0.0035 Low Sialylation 119 0 ASTROCYTOMA II 35 
E10433 0.453746168 0.752432799 0.0345 Low Sialylation 10.7 1 GBM IV 45 
HF1613 0.451659621 0.748972744 0.1053 Low Sialylation 66.8 1 ASTROCYTOMA III 35 
HF0975 0.45082601 0.747590394 0 Low Sialylation 36.5 1 ASTROCYTOMA III 60 
E09956 0.447563772 0.742180729 0.0445 Low Sialylation 21 1 GBM IV 70 
E10138 0.441688739 0.732438349 0.0036 Low Sialylation 46.9 0 ASTROCYTOMA II/III 25 
E09670 0.440542036 0.730536809 0.0034 Low Sialylation 14.2 1 GBM IV 75 
HF0960 0.438710895 0.727500285 1.00E-04 Low Sialylation 88.7 1 OLIGODENDROGLIOMA II 45 
E10144 0.435725484 0.722549673 0.037 Low Sialylation 25.9 1 GBM IV 50 
HF0435 0.432704363 0.717539845 0.1024 Low Sialylation 110.5 0 ASTROCYTOMA III 40 
E09688 0.432530712 0.717251885 0.0448 Low Sialylation 50.8 1 MIXED II 55 
E09997 0.430855089 0.714473253 0.0025 Low Sialylation 46.9 0 ASTROCYTOMA II/III 35 
E09673 0.429268329 0.711841979 0.0169 Low Sialylation 213.8 0 ASTROCYTOMA II 45 
E10258 0.423042233 0.701517444 0.1433 Low Sialylation 20.6 1 GBM IV 50 
E10026 0.42298092 0.701415771 0.1842 Low Sialylation 15.4 1 GBM IV 65 
HF1442 0.422958726 0.701378966 0.0187 Low Sialylation 47.2 1 ASTROCYTOMA II 35 
E09358 0.419479185 0.695608955 7.00E-04 Low Sialylation 127.1 0 MIXED II 55 
HF1640 0.419345196 0.695386765 9.00E-04 Low Sialylation 5.5 1 GBM IV 50 
HF1325 0.418828703 0.694530281 0.0187 Low Sialylation 84.5 0 ASTROCYTOMA II 35 




E09278 0.418134654 0.693379362 0.1896 Low Sialylation 36.6 0 GBM IV 40 
E10102 0.417615611 0.692518648 0.0117 Low Sialylation 38.8 0 GBM IV 45 
HF0757 0.41414012 0.686755352 0.0639 Low Sialylation 74.9 1 ASTROCYTOMA II 40 
HF0654 0.412931077 0.684750435 0.7602 Low Sialylation 14.6 1 GBM IV 20 
E09818 0.410644985 0.680959482 0.0828 Low Sialylation 38.1 0 ASTROCYTOMA II/III 30 
HF1588 0.407097676 0.675077093 0.0021 Low Sialylation 75.2 0 ASTROCYTOMA II 40 
E09890 0.405851715 0.673010955 0.0682 Low Sialylation 1.8 NA OLIGODENDROGLIOMA II 35 
HF0026 0.405397199 0.672257247 0.0014 Low Sialylation 57.1 1 ASTROCYTOMA II 60 
HF0252 0.405397199 0.672257247 9.00E-04 Low Sialylation 123.1 0 ASTROCYTOMA II 35 
HF1058 0.404073134 0.670061592 0.0027 Low Sialylation 18 1 GBM IV 40 
E10158 0.403306131 0.668789695 0.0248 Low Sialylation 40.6 0 GBM IV 70 
E10193 0.40234437 0.667194838 0.226 Low Sialylation 34.2 NA GBM IV 50 
E09661 0.402317304 0.667149955 0.0073 Low Sialylation 48.5 0 OLIGODENDROGLIOMA II 65 
HF1345 0.395242343 0.655417772 0.2086 Low Sialylation 83.5 0 ASTROCYTOMA II 15 
E10483 0.39517837 0.655311688 0.4957 Low Sialylation 66.4 1 ASTROCYTOMA II 25 
HF1492 0.392361231 0.650640116 0.0211 Low Sialylation 2.2 1 GBM IV 30 
HF0505 0.392322995 0.65057671 0 Low Sialylation 3.2 1 GBM IV 35 
E09858 0.391074568 0.648506483 0.0102 Low Sialylation 129.5 0 OLIGODENDROGLIOMA II/III 65 
E09192 0.388900464 0.644901236 0.024 Low Sialylation 13.4 1 GBM IV 75 
HF1708 0.385743432 0.639666031 2.00E-04 Low Sialylation 67.8 0 ASTROCYTOMA II 20 
E09801 0.383412262 0.635800326 0.0045 Low Sialylation 42.5 1 ASTROCYTOMA III 30 
E09531 0.381730486 0.633011491 0.0104 Low Sialylation 19.3 1 ASTROCYTOMA II/III 55 
E09786 0.379106606 0.628660394 0.0069 Low Sialylation 46.3 1 GBM IV 50 
HF0285 0.374980693 0.621818524 0.0334 Low Sialylation 14.4 1 OLIGODENDROGLIOMA II 80 
HF0608 0.374024155 0.620232327 0.0749 Low Sialylation 10.6 1 ASTROCYTOMA II 50 
E09454 0.373934942 0.620084388 1.00E-04 Low Sialylation 18 1 GBM IV 55 
HF1509 0.371986626 0.616853559 0.0156 Low Sialylation 2.7 1 GBM IV 40 
HF1097 0.36702616 0.608627777 0.0259 Low Sialylation 9 1 GBM IV 45 




HF0050 0.364792811 0.604924284 0.0376 Low Sialylation 26.2 1 GBM IV 35 
E10072 0.363330369 0.602499163 0.0516 Low Sialylation 37.2 0 OLIGODENDROGLIOMA II/III 65 
HF1186 0.362953486 0.60187419 0.2154 Low Sialylation 20.1 1 ASTROCYTOMA III 30 
E10077 0.361977738 0.600256139 0.017 Low Sialylation 25.8 1 GBM IV 55 
E10318 0.35782916 0.593376684 0.0923 Low Sialylation 26.4 NA GBM IV 70 
HF0268 0.356401315 0.591008934 0.3975 Low Sialylation 21.9 1 GBM IV 45 
E09606 0.349042395 0.578805871 0.0036 Low Sialylation 13.3 1 GBM IV 30 
E10211 0.348719632 0.578270644 0.0457 Low Sialylation 28.4 1 GBM IV 85 
E09513 0.342671225 0.568240764 0.72 Low Sialylation 13.4 1 OLIGODENDROGLIOMA II/III 55 
E09471 0.340215508 0.564168526 0.1311 Low Sialylation 27.2 1 ASTROCYTOMA II 70 
HF0450 0.33800017 0.560494902 0.103 Low Sialylation 29.5 1 ASTROCYTOMA II 30 
E09759 0.334645926 0.554932667 0.1457 Low Sialylation 20.1 1 GBM IV 45 
HF1581 0.329072163 0.545689872 0.0155 Low Sialylation 0.2 1 ASTROCYTOMA III 65 
HF1000 0.327243802 0.54265796 0.6251 Low Sialylation 40.3 1 ASTROCYTOMA II 30 
HF0291 0.325852392 0.540350629 0.1461 Low Sialylation 94.5 1 OLIGODENDROGLIOMA II 35 
E10041 0.324019087 0.537310517 0.1369 Low Sialylation 8.2 1 GBM IV 35 
HF1502 0.320900375 0.532138858 0.0526 Low Sialylation 6.4 1 OLIGODENDROGLIOMA III 70 
HF1220 0.320130955 0.530862952 0.3617 Low Sialylation 10.4 1 GBM IV 35 
E09852 0.315605662 0.523358805 0.2751 Low Sialylation 48.3 1 GBM IV 50 
E09690 0.303729634 0.503665165 0.1317 Low Sialylation 62.3 0 GBM IV 75 
HF1469 0.299722503 0.497020267 0.4152 Low Sialylation 22.2 1 GBM IV 25 
E09664 0.284566139 0.471886953 0.505 Low Sialylation 27.1 1 OLIGODENDROGLIOMA II/III 40 
E09602 0.251576778 0.417181748 0.1983 Low Sialylation 4.1 1 GBM IV 60 
E09832 -0.235820922 -0.381247878 0.7765 High Sialylation 5.6 1 GBM IV 50 
HF0583 -0.278760712 -0.450667942 0.1547 High Sialylation 15.8 1 GBM IV 25 
E09334 -0.288230078 -0.465976914 0.3741 High Sialylation 85.2 1 MIXED III 50 
HF0855 -0.305467923 -0.49384506 0.0293 High Sialylation 13.7 1 ASTROCYTOMA II 55 
E09802 -0.310455588 -0.501908538 0.0314 High Sialylation 32.2 1 GBM IV 80 




HF1517 -0.320029423 -0.517386403 0.0695 High Sialylation 8.3 1 GBM IV 55 
E10300 -0.321343975 -0.519511617 0.3326 High Sialylation 9.4 1 GBM IV 60 
E09647 -0.324297751 -0.524286938 0.0344 High Sialylation 19.3 1 GBM IV 55 
E10250 -0.325230124 -0.525794292 0.0636 High Sialylation 6 NA GBM IV 35 
HF1286 -0.335766409 -0.542828133 0.066 High Sialylation 13.2 1 ASTROCYTOMA III 75 
HF1334 -0.340477115 -0.550443855 0.4063 High Sialylation 115.7 1 ASTROCYTOMA II 20 
E10226 -0.343783355 -0.555789 0.5231 High Sialylation 18.7 1 GBM IV 65 
HF0180 -0.346118417 -0.559564058 0.0106 High Sialylation 0.3 1 GBM IV 35 
HF0996 -0.348429725 -0.563300712 0.0071 High Sialylation 120.5 0 GBM IV 50 
E10444 -0.348461168 -0.563351545 0.0103 High Sialylation 17 1 GBM IV 60 
HF0894 -0.352127512 -0.569278864 0.0454 High Sialylation 14.1 1 GBM IV 40 
HF1585 -0.355842682 -0.575285119 0.0136 High Sialylation 19.9 1 GBM IV 25 
HF1292 -0.35814803 -0.579012139 0.0125 High Sialylation 57.7 1 GBM IV 35 
E09730 -0.35991422 -0.581867509 0.4837 High Sialylation 61.7 1 GBM IV 40 
HF0790 -0.364910915 -0.589945586 0.4153 High Sialylation 7.5 1 GBM IV 45 
E09782 -0.366327107 -0.59223512 0.0039 High Sialylation 17.3 0 GBM IV 50 
E09698 -0.36752637 -0.59417395 0.368 High Sialylation 4.1 NA GBM IV 50 
HF0543 -0.368949005 -0.5964739 0.0029 High Sialylation 67.6 0 GBM IV 30 
HF1493 -0.377304767 -0.609982526 0.7768 High Sialylation 41.9 1 OLIGODENDROGLIOMA III 65 
HF1057 -0.379128534 -0.612930981 0.1048 High Sialylation 24.5 1 OLIGODENDROGLIOMA III 55 
E10488 -0.380511023 -0.615166028 0.0093 High Sialylation 21.9 1 GBM IV 55 
E09139 -0.383085522 -0.61932818 0.0132 High Sialylation 36.5 1 GBM IV 45 
HF0510 -0.383924464 -0.620684483 0.3174 High Sialylation 19.6 1 OLIGODENDROGLIOMA II 45 
HF1397 -0.386496473 -0.624842608 0.0108 High Sialylation 30 1 GBM IV 20 
HF0460 -0.39068064 -0.631607084 0.1268 High Sialylation 10.7 1 OLIGODENDROGLIOMA III 45 
HF0891 -0.396297608 -0.640687945 5.00E-04 High Sialylation 28.8 1 GBM IV 35 
E10105 -0.397839774 -0.64318114 0.0042 High Sialylation 1.1 NA ASTROCYTOMA III 40 
E10001 -0.404176092 -0.653424963 0 High Sialylation 8.7 1 OLIGODENDROGLIOMA III 50 




HF0142 -0.405650115 -0.655807992 0.0154 High Sialylation 0.3 1 GBM IV 25 
E09740 -0.408641981 -0.660644895 3.00E-04 High Sialylation 16.8 1 GBM IV 50 
HF1139 -0.409409142 -0.66188515 0.2682 High Sialylation 15.8 1 GBM IV 40 
E09833B -0.413402564 -0.668341252 0.0378 High Sialylation 20.8 1 GBM IV 45 
E50123 -0.41350881 -0.668513018 0.0149 High Sialylation 17.5 1 GBM IV 30 
E09938 -0.414668206 -0.670387394 0.0179 High Sialylation 25.2 1 GBM IV 45 
E09744 -0.417952432 -0.67569695 0.0542 High Sialylation 46.8 1 GBM IV 70 
E10110 -0.4207849 -0.680276155 0.0515 High Sialylation 23.1 1 GBM IV 50 
HF1618 -0.423913439 -0.685334014 0.0854 High Sialylation 2.4 1 GBM IV 50 
HF1540 -0.424031121 -0.685524268 0.0351 High Sialylation 10.2 1 GBM IV 55 
E10284 -0.433644413 -0.701065922 0.1248 High Sialylation 4.8 1 GBM IV 55 
HF1382 -0.434957574 -0.703188888 1.00E-04 High Sialylation 48.3 1 GBM IV 35 
E09988 -0.435691164 -0.704374872 0.0235 High Sialylation 64.6 1 OLIGODENDROGLIOMA III 70 
E10031 -0.438088374 -0.708250401 0.0045 High Sialylation 27.5 1 GBM IV 55 
E10290 -0.439545195 -0.71060562 0.0049 High Sialylation 6.9 1 GBM IV 30 
E10292 -0.4401432 -0.711572407 1.00E-04 High Sialylation 5.5 1 GBM IV 60 
HF1137 -0.443440676 -0.716903383 0.1569 High Sialylation 18.3 1 GBM IV 35 
E10002 -0.448336336 -0.724818117 0.0178 High Sialylation 8.4 1 GBM IV 55 
E09451 -0.448613489 -0.725266185 0.0014 High Sialylation 5.3 1 GBM IV 60 
HF1078 -0.458721357 -0.741607413 0.0053 High Sialylation 22.8 1 GBM IV 50 
E10013 -0.458744035 -0.741644077 4.00E-04 High Sialylation 4.9 1 GBM IV 55 
E10262 -0.462458117 -0.747648572 7.00E-04 High Sialylation 18 1 GBM IV 50 
HF1608 -0.462943253 -0.748432883 0.0015 High Sialylation 7.9 1 GBM IV 60 
HF0066 -0.470638161 -0.760873117 0.0192 High Sialylation 9.1 1 GBM IV 50 
HF1136 -0.477059002 -0.771253587 2.00E-04 High Sialylation 45.3 1 ASTROCYTOMA III 35 
E10162 -0.477950009 -0.772694063 0.0065 High Sialylation 15.4 NA ASTROCYTOMA III 55 
HF0108 -0.478331425 -0.773310693 0.0371 High Sialylation 132 0 ASTROCYTOMA III 35 
E08021 -0.479365584 -0.774982601 0.0066 High Sialylation 81.5 1 OLIGODENDROGLIOMA III 40 




HF0702 -0.482270316 -0.779678635 0.0011 High Sialylation 8.5 1 ASTROCYTOMA III 50 
HF0408 -0.489265977 -0.790988407 0.1076 High Sialylation 15.8 1 GBM IV 30 
HF1458 -0.490585243 -0.793121243 0.0063 High Sialylation 8.8 1 OLIGODENDROGLIOMA III 75 
HF0327 -0.497993896 -0.805098692 0.1287 High Sialylation 19.6 1 OLIGODENDROGLIOMA II 75 
E10551 -0.503166636 -0.813461378 0.0063 High Sialylation 12.3 1 GBM IV 65 
HF0244 -0.505349649 -0.81699062 0.0479 High Sialylation 7.5 1 ASTROCYTOMA III 60 
HF0992 -0.507082052 -0.819791367 0.0192 High Sialylation 20 1 GBM IV 30 
E10267 -0.510804015 -0.825808605 0.0846 High Sialylation 12 1 GBM IV 75 
HF1191 -0.512751375 -0.828956871 0.0219 High Sialylation 0.3 1 GBM IV 25 
E09917 -0.521644156 -0.843333687 0.0044 High Sialylation 6.1 1 GBM IV 50 
HF1297 -0.523365196 -0.846116063 0.0137 High Sialylation 17.2 1 GBM IV 60 
E09951 -0.524718914 -0.848304597 0.0014 High Sialylation 22.6 1 GBM IV 45 
HF1628 -0.555249886 -0.897663527 2.00E-04 High Sialylation 14.6 1 GBM IV 70 
HF0251 -0.562176207 -0.908861199 0 High Sialylation 22.7 1 OLIGODENDROGLIOMA III 65 
E09448 -0.613354972 -0.991601081 0.0021 High Sialylation 229.1 1 OLIGODENDROGLIOMA III 60 












Supplementary Table S6. Activation scores, associated p-value and metadata of Gravendeel samples identified as low or 
high sialylation status based on sialylation signature.  
Samples Activation score 
Normalized 
score p-value Class 
Survival 
(Yrs) Status Histology Grade Age 
GSM405429 0.667611238 1 0 Low Sialylation 18.72 1 MIXED III 43.93 
GSM405258 0.644496715 0.965377272 0 Low Sialylation 1.85 1 ASTROCYTOMA II 59.35 
GSM405211 0.547162609 0.819582683 0.0192 Low Sialylation 1.83 1 OLIGODENDROGLIOMA III 34.93 
GSM405340 0.532091313 0.797007724 1.00E-04 Low Sialylation 5.56 0 GBM IV 52.88 
GSM405311 0.529988882 0.793858539 0 Low Sialylation 7.48 0 ASTROCYTOMA II 43 
GSM405356 0.522437403 0.782547348 1.00E-04 Low Sialylation 0.18 1 GBM IV 43.21 
GSM405319 0.514222339 0.770242187 0 Low Sialylation 5.62 1 OLIGODENDROGLIOMA III 53.65 
GSM405325 0.50469571 0.75597246 9.00E-04 Low Sialylation 3.65 1 MIXED III 42.98 
GSM405331 0.500412731 0.749557082 0 Low Sialylation 8.23 0 OLIGODENDROGLIOMA III 59.56 
GSM405327 0.498383206 0.746517101 0.0167 Low Sialylation 3.3 1 OLIGODENDROGLIOMA III 66.86 
GSM405217 0.493371606 0.739010337 0.0028 Low Sialylation 6.77 0 GBM IV 33.2 
GSM405318 0.482029888 0.722021831 0.0347 Low Sialylation 6.21 0 OLIGODENDROGLIOMA III 62.46 
GSM405365 0.475483085 0.71221552 0.0848 Low Sialylation 2.66 1 GBM IV 64.29 
GSM405287 0.474649946 0.71096758 0.0016 Low Sialylation 6.87 1 OLIGODENDROGLIOMA III 43.57 
GSM405433 0.472734391 0.708098312 0.0189 Low Sialylation 4.91 0 ASTROCYTOMA II 43.85 
GSM405343 0.468925293 0.70239275 0.1936 Low Sialylation NA 0 GBM IV 66.8 
GSM405381 0.464317062 0.695490183 0.02 Low Sialylation 15.82 1 OLIGODENDROGLIOMA III 38.37 
GSM405248 0.459474966 0.688237316 0.0425 Low Sialylation 0.84 1 GBM IV 55.2 
GSM405338 0.448016293 0.671073624 7.00E-04 Low Sialylation 7.96 1 OLIGODENDROGLIOMA II 50.23 
GSM405394 0.447055294 0.669634165 0.0049 Low Sialylation 0.86 0 ASTROCYTOMA II 31.77 
GSM405252 0.446588533 0.668935014 0.0859 Low Sialylation 0.37 1 GBM IV 68.04 
GSM405286 0.444584925 0.665933855 0.7153 Low Sialylation 3.16 1 MIXED III 62.2 




GSM405222 0.442328136 0.66255346 0.0485 Low Sialylation 1.3 1 GBM IV 54.06 
GSM405408 0.441343975 0.661079308 0 Low Sialylation 1.78 1 OLIGODENDROGLIOMA II 63.1 
GSM405313 0.439609239 0.658480886 0.009 Low Sialylation 3.31 1 GBM IV 32.5 
GSM405249 0.439174344 0.657829466 0.6213 Low Sialylation 0.04 1 GBM IV 23.02 
GSM405202 0.433728669 0.649672512 0.0548 Low Sialylation 11.67 1 OLIGODENDROGLIOMA III 28.69 
GSM405244 0.433020997 0.648612504 0.0152 Low Sialylation 2.05 1 GBM IV 29.55 
GSM405295 0.42659752 0.638990922 0.0033 Low Sialylation 1.99 1 ASTROCYTOMA III 41.77 
GSM405281 0.421136264 0.630810628 0.1557 Low Sialylation 3.32 1 ASTROCYTOMA III 37.12 
GSM405227 0.419135328 0.62781347 0.0061 Low Sialylation 4.77 1 OLIGODENDROGLIOMA III 48.1 
GSM405469 0.41683386 0.624366152 3.00E-04 Low Sialylation 5.56 0 OLIGODENDROGLIOMA III 46.86 
GSM405275 0.416504871 0.623873368 0.132 Low Sialylation 3.46 1 GBM IV 60.39 
GSM405203 0.415631671 0.62256542 0.1024 Low Sialylation 8.92 1 OLIGODENDROGLIOMA III 38.58 
GSM405395 0.415202167 0.621922075 8.00E-04 Low Sialylation 3.76 1 MIXED II 55.42 
GSM405406 0.410102767 0.614283799 1.00E-04 Low Sialylation 1.69 1 OLIGODENDROGLIOMA III 78.82 
GSM405439 0.408636844 0.612088025 2.00E-04 Low Sialylation 3.7 0 MIXED II 32.92 
GSM405299 0.407678492 0.610652531 1.00E-04 Low Sialylation 1.75 1 GBM IV 54.94 
GSM405251 0.40494683 0.606560836 0.2296 Low Sialylation 3.21 1 GBM IV 26.17 
GSM405335 0.402557394 0.602981752 0 Low Sialylation 7.44 1 OLIGODENDROGLIOMA III 65.59 
GSM405437 0.400772527 0.600308241 0.013 Low Sialylation 3.44 0 OLIGODENDROGLIOMA II 51.63 
GSM405334 0.399984067 0.599127224 0.0015 Low Sialylation 1.47 1 OLIGODENDROGLIOMA III 57.01 
GSM405425 0.398613389 0.597074115 3.00E-04 Low Sialylation 16.05 1 OLIGODENDROGLIOMA II 32.98 
GSM405212 0.388914716 0.582546689 4.00E-04 Low Sialylation 17.49 1 OLIGODENDROGLIOMA III 23.33 
GSM405350 0.384197156 0.575480361 0.1787 Low Sialylation 0.61 1 GBM IV 40.74 
GSM405483 0.383155865 0.573920635 0.0056 Low Sialylation 0.19 0 MIXED I 32.35 
GSM405256 0.376560817 0.564042059 0.0304 Low Sialylation 4.79 1 ASTROCYTOMA II 38.05 
GSM405250 0.372884548 0.558535457 0.1146 Low Sialylation 1.48 1 ASTROCYTOMA II 30.69 




GSM405447 0.368645269 0.552185537 0.1462 Low Sialylation 2.79 1 GBM IV 59.03 
GSM405387 0.366741392 0.549333761 0 Low Sialylation 11.41 1 MIXED III 37.11 
GSM405344 0.365668175 0.547726213 0.0016 Low Sialylation 1.19 1 OLIGODENDROGLIOMA II 34.71 
GSM405265 0.360023536 0.539271235 0.0141 Low Sialylation 1.81 1 ASTROCYTOMA III 32.14 
GSM405255 0.35755515 0.535573894 0.0973 Low Sialylation 1.08 1 GBM IV 47.93 
GSM405320 0.35129893 0.526202841 0.1199 Low Sialylation 0.6 1 GBM IV 70.28 
GSM405462 0.350645607 0.525224244 0.0024 Low Sialylation 7.52 1 ASTROCYTOMA II 49.83 
GSM405423 0.348095297 0.521404191 0.0136 Low Sialylation 6.12 1 ASTROCYTOMA III 35.67 
GSM405245 0.342271507 0.512680865 0.1547 Low Sialylation 1.4 1 GBM IV 37.98 
GSM405207 0.341812688 0.511993611 0.0438 Low Sialylation 8.12 1 OLIGODENDROGLIOMA III 44.41 
GSM405278 0.340471627 0.509984865 0.0029 Low Sialylation 0.73 1 GBM IV 58.23 
GSM405478 0.3401353 0.509481089 0.0125 Low Sialylation 6.06 1 OLIGODENDROGLIOMA III 26.66 
GSM405298 0.339106847 0.507940592 0.2774 Low Sialylation 1.96 1 MIXED III 42.56 
GSM405442 0.338522224 0.507064897 0.1255 Low Sialylation 0.3 1 GBM IV 63.61 
GSM405473 0.335470144 0.502493256 0.4336 Low Sialylation 1.12 1 GBM IV 47.29 
GSM405277 0.334072497 0.50039975 0.4602 Low Sialylation 2.76 1 ASTROCYTOMA III 43.89 
GSM405420 0.33316297 0.499037391 0.0128 Low Sialylation 3 1 OLIGODENDROGLIOMA III 49.94 
GSM405283 0.331894017 0.497136654 0.226 Low Sialylation 4.07 1 MIXED III 38.07 
GSM405261 0.331717488 0.496872236 0.4546 Low Sialylation 0.98 1 OLIGODENDROGLIOMA III 60.46 
GSM405404 0.322193748 0.482606837 0.0554 Low Sialylation 0.04 1 OLIGODENDROGLIOMA III 54.35 
GSM405450 0.321129851 0.48101325 0.0373 Low Sialylation 13.3 0 MIXED III 36.66 
GSM405451 0.320265608 0.47971872 9.00E-04 Low Sialylation 3.69 1 MIXED II 28.55 
GSM405329 0.316257124 0.4737145 0.2577 Low Sialylation 5.02 1 OLIGODENDROGLIOMA III 60.33 
GSM405427 0.314814881 0.471554197 0.3113 Low Sialylation 1.53 1 GBM IV 50.83 
GSM405378 0.307646065 0.460816186 0.3479 Low Sialylation 0 1 OLIGODENDROGLIOMA II 57.22 
GSM405259 0.306156399 0.45858485 0.5178 Low Sialylation 0.41 1 ASTROCYTOMA III 64.01 




GSM405418 0.300580967 0.450233534 0.2349 Low Sialylation 5.17 1 GBM IV 46.61 
GSM405307 0.300471977 0.450070281 0.5535 Low Sialylation 0.33 1 GBM IV 72.22 
GSM405413 0.299537947 0.448671218 0.028 Low Sialylation 1.2 1 ASTROCYTOMA III 46.47 
GSM405412 0.294205663 0.440684109 0.1419 Low Sialylation 0.65 1 GBM IV 55.71 
GSM405333 0.291210581 0.436197842 0.3502 Low Sialylation 9.11 1 OLIGODENDROGLIOMA III 57.64 
GSM405445 0.284360635 0.42593746 0.1196 Low Sialylation 3.33 0 OLIGODENDROGLIOMA III 56.15 
GSM405468 0.283610411 0.424813716 0.3122 Low Sialylation 7.04 0 MIXED I 33.48 
GSM405257 0.26073026 0.390542048 0.0495 Low Sialylation 10.86 0 OLIGODENDROGLIOMA III 46.04 
GSM405471 0.256063448 0.383551734 0.4143 Low Sialylation 0.15 1 GBM IV 78.12 
GSM405376 0.251807028 0.377176137 0.5128 Low Sialylation 1.85 1 GBM IV 52.98 
GSM405225 0.231270437 0.346414836 0.1296 Low Sialylation 3.47 1 MIXED III 31.56 
GSM405389 -0.243140337 -0.392552781 0.0962 High Sialylation 5.56 0 GBM IV 52.88 
GSM405339 -0.25380684 -0.409773967 0.4398 High Sialylation NA 0 GBM IV 78.08 
GSM405456 -0.262799327 -0.424292438 0.4 High Sialylation NA 0 GBM IV 52.5 
GSM405436 -0.266205744 -0.429792137 0.3042 High Sialylation 0.48 1 GBM IV 79.06 
GSM405330 -0.268753746 -0.433905913 0.0312 High Sialylation 0.71 1 GBM IV 33.12 
GSM405377 -0.27037873 -0.436529468 0.0774 High Sialylation 0.6 1 OLIGODENDROGLIOMA III 41.98 
GSM405464 -0.27311866 -0.440953116 0.0815 High Sialylation 0.56 1 GBM IV 54.72 
GSM405454 -0.277528833 -0.44807339 0.2608 High Sialylation 3.32 1 GBM IV 22.52 
GSM405305 -0.303643334 -0.490235541 0.1196 High Sialylation 1.06 1 GBM IV 52.69 
GSM405229 -0.308686799 -0.498378273 0.0166 High Sialylation 0.66 1 GBM IV 54.18 
GSM405241 -0.312312998 -0.50423281 0.0184 High Sialylation 0.16 1 GBM IV 55.98 
GSM405363 -0.315746844 -0.509776793 0.2707 High Sialylation 9.79 1 GBM IV 48.84 
GSM405271 -0.324894946 -0.524546507 0.1324 High Sialylation 0.3 1 GBM IV 69.89 
GSM405366 -0.326576529 -0.52726144 0.0652 High Sialylation 2.21 1 OLIGODENDROGLIOMA III 75.13 
GSM405214 -0.330479251 -0.533562429 0.0107 High Sialylation 1.5 1 GBM IV 37.84 




GSM405361 -0.333694526 -0.538753525 0.1893 High Sialylation 1.64 1 OLIGODENDROGLIOMA III 79.19 
GSM405470 -0.334028301 -0.539292409 0.136 High Sialylation 1.92 1 GBM IV 31.72 
GSM405453 -0.334052563 -0.53933158 0.0307 High Sialylation 0.21 1 GBM IV 70.23 
GSM405215 -0.334408085 -0.539905575 0.0719 High Sialylation 2.3 1 GBM IV 51.44 
GSM405303 -0.346897351 -0.560069634 0.0491 High Sialylation 0.55 1 GBM IV 56.64 
GSM405236 -0.348174767 -0.562132036 0.0085 High Sialylation 1.03 1 GBM IV 52.2 
GSM405475 -0.351389884 -0.567322878 0.1428 High Sialylation 1.05 1 GBM IV 33.74 
GSM405273 -0.351766368 -0.567930716 0.0294 High Sialylation 0.54 1 MIXED III 56.42 
GSM405382 -0.352783071 -0.569572194 0.0689 High Sialylation 4.86 1 MIXED III 44.15 
GSM405414 -0.352900825 -0.569762309 0.0368 High Sialylation 5.33 1 OLIGODENDROGLIOMA III 35.23 
GSM405449 -0.358414292 -0.578663862 4.00E-04 High Sialylation 2.02 1 OLIGODENDROGLIOMA III 45.39 
GSM405374 -0.359038699 -0.579671974 0.0185 High Sialylation 1.21 1 GBM IV 58.58 
GSM405337 -0.362792999 -0.585733334 0.0403 High Sialylation 0.28 1 GBM IV 15.02 
GSM405232 -0.36656577 -0.591824515 5.00E-04 High Sialylation 0.98 1 GBM IV 35.7 
GSM405234 -0.373761991 -0.603442895 0.008 High Sialylation 0.62 1 GBM IV 57.68 
GSM405383 -0.379247872 -0.61229991 0.2362 High Sialylation 1.32 1 ASTROCYTOMA II 37.6 
GSM405292 -0.381032593 -0.615181362 0.1008 High Sialylation 1.11 1 GBM IV 65.52 
GSM405289 -0.382895503 -0.618189051 0.0679 High Sialylation 0.19 1 ASTROCYTOMA III 37.44 
GSM405388 -0.385069269 -0.621698619 0.0149 High Sialylation 0.53 1 MIXED III 78.52 
GSM405262 -0.385069692 -0.621699302 0.0224 High Sialylation 2.89 1 GBM IV 43.26 
GSM405448 -0.385363744 -0.622174054 0.0935 High Sialylation 0.48 1 GBM IV 58.71 
GSM405426 -0.386955787 -0.624744425 0.3234 High Sialylation 0.05 1 GBM IV 67.1 
GSM405384 -0.389559806 -0.628948643 0.0321 High Sialylation 0.02 0 GBM IV 70.3 
GSM405239 -0.391443025 -0.63198912 0 High Sialylation 0.59 1 GBM IV 73.65 
GSM405391 -0.398081677 -0.642707297 0.1164 High Sialylation 1.05 1 GBM IV 55.55 
GSM405440 -0.399260909 -0.644611181 0.0263 High Sialylation 0.53 1 GBM IV 69.88 




GSM405392 -0.411892034 -0.665004273 0.0036 High Sialylation 0.47 1 GBM IV 48.35 
GSM405226 -0.412279349 -0.665629598 0.0107 High Sialylation 0.28 1 MIXED III 48.6 
GSM405463 -0.414714553 -0.669561261 0 High Sialylation 2.22 1 GBM IV 65.53 
GSM405285 -0.416429499 -0.672330061 0.0783 High Sialylation 1.27 1 MIXED III 36.61 
GSM405280 -0.425112074 -0.686348174 0.0102 High Sialylation 2.46 1 GBM IV 30.43 
GSM405312 -0.425372436 -0.686768532 0.0557 High Sialylation 1.02 1 GBM IV 61.31 
GSM405247 -0.425825936 -0.687500712 0.0014 High Sialylation 1.59 1 GBM IV 39.36 
GSM405349 -0.429204284 -0.692955093 0.0021 High Sialylation 2.41 1 GBM IV 24.42 
GSM405399 -0.431504761 -0.696669238 0.0034 High Sialylation 1.18 1 MIXED III 52.07 
GSM405467 -0.431906304 -0.697317535 0 High Sialylation 1.34 1 OLIGODENDROGLIOMA III 43.9 
GSM405352 -0.433837176 -0.700434948 0.0174 High Sialylation 0.4 1 GBM IV 69.95 
GSM405254 -0.444001486 -0.71684534 0 High Sialylation 0.59 1 GBM IV 40.58 
GSM405347 -0.446442056 -0.720785668 0.0159 High Sialylation 0.19 1 MIXED III 43.11 
GSM405460 -0.450509122 -0.727351991 0.002 High Sialylation 0.48 1 OLIGODENDROGLIOMA III 52.52 
GSM405375 -0.470941413 -0.760340152 0.0927 High Sialylation 0.06 1 GBM IV 67.03 
GSM405351 -0.476444278 -0.769224588 0 High Sialylation 1.22 1 GBM IV 42.7 
GSM405474 -0.479231462 -0.773724528 0.129 High Sialylation 0.29 1 GBM IV 61.28 
GSM405263 -0.488048158 -0.787959183 0.0614 High Sialylation 1.55 1 GBM IV 61.74 
GSM405221 -0.524625216 -0.847013249 0.0622 High Sialylation 0.69 1 GBM IV 55.52 
GSM405431 -0.531166893 -0.857574861 0.0085 High Sialylation 0.92 1 GBM IV 80.65 
GSM405279 -0.532982646 -0.860506413 1.00E-04 High Sialylation 0.71 1 MIXED III 46.15 
GSM405465 -0.544087912 -0.878435989 1.00E-04 High Sialylation 0.63 1 GBM IV 69.38 
GSM405417 -0.600648221 -0.969753238 5.00E-04 High Sialylation 0.02 1 GBM IV 77.31 
GSM405220 -0.607418287 -0.980683584 6.00E-04 High Sialylation 1.27 1 GBM IV 54.12 






Supplementary Table S7. Contingency tables for classification of low and high sialylation status patients based on Phillips 
molecular subtypes.  
 
REMBRANDT     
Class Mesenchymal Proliferative Proneural Total 
Low Sialylation 20 (18.87%) 1 (0.94%) 85 (80.19%) 106 (100%) 
High Sialylation 35 (43.75%) 40 (50%) 5 (6.25%) 80 (100%) 
X-squared = 110.8308, df = 2, p-value < 2.2e-16     
     
Gravendeel 
    
Class Mesenchymal Proliferative Proneural Total 
Low Sialylation 16 (18.18%) 16 (18.18%) 56 (63.64%) 88 (100%) 
High Sialylation 15 (22.06%) 53 (77.94%) 0 (0%) 68 (100%) 
X-squared = 74.5338, df = 2, p-value < 2.2e-16     
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